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The active form of vitamin D, 1,25(OH)2D3, plays well-established roles in 
calcium regulation and bone formation.  1,25(OH)2D3 is also thought to exert 
immunoregulatory effects upon cells of the innate (dendritic cell) and adaptive (T cell) 
immune systems, that may impact health and disease.  In recent years, the role of 
1,25(OH)2D3 has been implicated in autoimmune diseases such as rheumatoid 
arthritis (RA).  1,25(OH)2D3 brings about genetic and epigenetic changes within 
immune cells, the latter which may include effects of microRNAs (miRNAs); small 
non-coding RNAs with an important regulatory role.   
To study the role of 1,25(OH)2D3 on miRNAs in RA, we utilised n=20 (RA) and 
n=7 (reactive arthritis, ReA) matched patient serum and synovial fluid (SF) samples 
to derive measurements of vitamin D metabolite concentrations by LC-MS/MS, 
vitamin D binding protein abundance by ELISA, and circulating miRNA expression by 
qPCR.  To study the role of 1,25(OH)2D3 on miRNAs in healthy immune cells, we 
also generated in vitro models of dendritic cells (DC) and CD4+ T cells, treated with 
1,25(OH)2D3 or vehicle at different stages of development. An unbiased array 
approach was then used to screen 372 miRNAs closely related to inflammation in the 
DC and T cell models.  Bioinformatic analyses were used to identify predicted gene 
targets of significantly regulated miRNAs in both DC and T cells.   
Results showed that 1,25(OH)2D3 in SF was low or undetectable in 13/20 RA 
and 4/7 ReA samples.  MiR-146a and miR-155 was up-regulated in RA SF compared 
to serum, but did not significantly correlate with RA disease markers.  In DC, miR-155 
but not miR-146a was up-regulated by LPS-induced cell maturation in the presence 
 
or absence of 1,25(OH)2D3.  Global down-regulation of miRNAs was observed after 
either short or long-term treatment of DC with 1,25(OH)2D3.  This was due, in part, to 
suppression of expression for miRNA processing genes. In contrast to DC, global 
miRNA down-regulation was not observed in T cells treated with 1,25(OH)2D3. 
Notably, MiR-155 was up-regulated by cell activation but not 1,25(OH)2D3, and miR-
212-3p was up-regulated by activation and 1,25(OH)2D3.      
Together, these results suggest that any 1,25(OH)2D3 generated within the 
synovial microenvironment may be restricted to the cells involved in 
immunoregulation within   this tissue.  The role of miR-146a and miR-155 in immune 
cells is still unclear; it is unlikely that these miRNAs are actively mediating gene 
silencing to cause inflammation within the local environment, but rather they are 
maintained as a reserve of miRNAs not associated with their target gene.  Global 
down-regulation of miRNAs following 1,25(OH)2D3 in DC, but not T cells, suggests a 
role for 1,25(OH)2D3-mediated miRNA down-regulation as opposed to decreased 
miRNA synthesis.  Coupled with bioinformatic tools and gene ontology analysis, 
there is potential to identify novel roles for 1,25(OH)2D3-responsive miRNAs in the 
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2.1 Vitamin D metabolism, signalling and endocrine regulation 
 
Vitamin D is a fat-soluble secosteroid and an essential vitamin with important 
physiological roles in the human body including the regulation of mineral 
homeostasis and bone metabolism.   The discovery of vitamin D and its link to rickets 
in 1924 was a key advance in medical history [1], and to this day vitamin D continues 
to be well studied with respect to its classical effects on the skeleton, but also in 
relation to many other diseases.  Vitamin D can be found in two main forms; 
ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), both of which are able to 
fulfil the actions of vitamin D.  Vitamin D3 can be obtained as dietary intake from 
foods such as oily fish, or from de novo epidermal synthesis from the conversion of 7-
dehydrocholesterol to vitamin D3 by UV irradiation [2].  Epidermal production of 
vitamin D3 by UV light varies depending on the season of the year, geographic 
location and social patterns of an individual [3]. Conversely, vitamin D2, which is 
produced by irradiation of the molecule ergosterol in plant sources, can be used to 
fortify food as a ‘vegetarian’ source of vitamin D.  The chemical structure of vitamin 
D2 was characterised in 1931 [4], followed by vitamin D3 in 1937 [5].  
Both vitamin D2 and D3 are inactive forms of vitamin D, and are required to 
undergo metabolic conversion to become active; this process is mediated by 
cytochrome P450 (CYP) mixed-function oxidase enzymes located in the endoplasmic 
reticulum (ER) or mitochondria [6]. Prior to these metabolic steps, parental vitamin D 
is first bound to vitamin D binding protein (DBP) and transported via the bloodstream 
to the liver, where it undergoes hydroxylation at carbon position 25 to form 25-
hydroxyvitamin D3 (25(OH)D3/calcidiol). This reaction appears to be mediated by the 
13 
 
enzyme CYP2R1, located in the ER and in which mutations in the CYP2R1 gene 
have been linked to low circulating levels of 25(OH)D3 [7].  However, other enzymes 
such as CYP27A1 may also participate in 25-hydroxylase activity [8].  25(OH)D3 is 
the major circulating vitamin D metabolite and has a half-life of 14-20 days [9], thus 
circulating concentrations of 25(OH)D3 are routinely used to measure vitamin D 
status. After 25-hydroxylation, 25(OH)D3 is then transported to the kidneys via DBP, 
where the endocytic receptors megalin and cubilin present in proximal tubule cells 
aid reabsorption of the DBP-25(OH)D3 complex from the glomerular filtrate, and 
subsequent conversion of 25(OH)D3 to the hormonally active 1,25-dihydroxyvitamin 
D₃ (1,25(OH)₂D3/calcitriol) by hydroxylation of 25(OH)D3 at the carbon 1 position 
[10].  This conversion is mediated by the enzyme 25-hydroxyvitamin D-1α-
hydroxylase (1α-hydroxylase), also known as CYP27B1 [11]. Mutations in the 
CYP27B1 gene are associated with low serum concentrations of 1,25(OH)₂D3 and 
the genetic disease hereditary vitamin D resistant rickets type 1 [12].  The vitamin D 






Figure 2.1. The vitamin D metabolic pathway  
Vitamin D can be obtained from fortified dietary intake, or direct conversion of 7-
dehydrocholesterol mediated by UVB.  The molecule undergoes several hydroxylation 
reactions to become the active form, 1,25-dihydroxy D3 responsible for the reported effects 
of vitamin D.   
 
The active form of vitamin D, 1,25(OH)₂D3, functions as a steroid hormone 
and  exerts its biological effects by binding to the intracellular vitamin D receptor 
(VDR) located in the nuclei of target cells [13].  VDR is a member of the steroid 
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hormone receptor superfamily of transcription regulatory proteins [14]. Upon binding 
1,25(OH)₂D3, the VDR conventionally forms a heterodimer with the retinoid X 
receptor (RXR) and this dimer complex binds to hormone response element DNA 
sequences within target genes (see Figure 2.2) [13]. These vitamin D response 
element (VDRE) sequences targeted by VDR-1,25(OH)₂D3 are frequently located 
within proximal gene promoter regions, but may also be found in more distal regions 
of genes [15]. The process of interaction between the VDR and VDRE involves 
alteration in chromatin structure [16] and recruitment of accessory proteins (co-
activators and co-repressors) that facilitate function of the VDR-RXR heterodimer [17, 
18], which  acts as a transcription factor that can then modulate target gene 
expression [13, 15]. Mutations in the VDR gene are associated with elevated serum 
concentrations of 1,25(OH)₂D3, due to impaired VDR-mediated feedback regulation 





Figure 2.2. The endocrine and intracrine systems for vitamin D 
Active 1,25(OH)₂D3 (1,25D) exerts intracrine effects on cells of the immune system.  
Circulating 25(OH)D3 (25D) is mostly bound to DBP, which aids conversion to 1,25(OH)2D3 
(1,25D3) in renal proximal tubules to generate systemic 1,25(OH)2D3 which acts on distal 
target tissues (endocrine action). In other cells such as macrophages, 25(OH)D3 is 
internalized and converted to 1,25(OH)2D3 locally before acting on VDR within the same cell 
(intracrine action).   
 
The VDR is almost ubiquitously expressed throughout the body and thus, 
1,25(OH)₂D3 potentially has diverse actions in a wide range of biological processes 
beyond its classical roles in mineral homeostasis and bone metabolism.  To maintain 
homeostasis in the setting of potent VDR-1,25(OH)₂D3 activity, the vitamin D 
pathway is tightly regulated. This occurs primarily via altered expression of CYP 
enzymes that catabolise 1,25(OH)₂D3 (and other vitamin D metabolites) to less 
active catabolites [20, 21].  The most well characterised catabolic pathway for vitamin 
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D involves the enzyme vitamin D-24-hydroxylase (24-hydroxylase) also known as 
CYP24A1, which catalyses conversion of 1,25(OH)₂D3 to various intermediates 
leading to the catabolic end product calcitroic acid [22].  These reactions act as a 
negative feedback loop which regulates vitamin D metabolite concentrations and 
limits potential toxicity to 1,25(OH)₂D3; mutations in the CYP24A1 gene are 
associated with idiopathic infantile hypercalcemia due to impaired catabolism of 
serum 1,25(OH)₂D3 and inappropriate serum elevation of this metabolite [23]. 
The metabolism and function of vitamin D is regulated by well characterised 
endocrine mechanisms, involving the interplay of positive and negative feedback 
regulation by parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23).  
Osteocytes in bone synthesise and secrete FGF23; this process is under positive 
regulation by 1,25(OH)₂D3 and serum phosphorus levels. The negative regulatory 
mechanism of FGF23 is not as well understood but is thought to involve dentin matrix 
protein 1 (DMP1) and phosphate-regulating gene with homologies to endopeptidases 
on the X chromosome (PHEX).  Conversely, FGF23 can also inhibit the synthesis of 
1,25(OH)₂D3 and the secretion of PTH, which is produced by the parathyroid glands 
[24].   
The main action of PTH besides bone remodelling includes increasing calcium 
reabsorption in renal tubules both directly and indirectly via stimulating renal 
1,25(OH)₂D3 production [25].  The parathyroid glands act as a ‘calciostat’ to increase 
or inhibit the production of PTH depending on the extracellular concentration of 
calcium [26].  Additionally, the parathyroid glands closely regulate serum phosphate 
levels, where elevated serum phosphate stimulates the secretion of PTH in a 
feedback fashion [27, 28].  Phosphate is taken up from circulation by cells via 
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sodium-phosphate cotransporters, where it is used for a variety of functions including 
DNA synthesis, intracellular signalling and, more recently established, vitamin D 
regulation. Serum phosphate levels are dependent on the balance between dietary 
intestinal absorption and urinary excretion, with around 30% of intestinal phosphate 
absorption occurring in a 1,25(OH)₂D3-regulated manner [29].  1,25(OH)₂D3 is able 
to increase the efficiency of phosphorus absorption by up to 80% [30].  Renal 
phosphate reabsorption plays a key role in maintaining phosphate homeostasis, and 
is under tight control by PTH and FGF23 regulation [31].  As a result of this tightly 
regulated process, serum PTH levels in healthy vitamin D-sufficient adults have the 
capacity to act as a biological readout of serum 25(OH)D activity independent of DBP 
concentrations [32].  This bone-parathyroid-kidney axis ultimately acts to regulate the 
production of renal 1,25(OH)₂D3 to ensure homeostasis. The relationship between 




Figure 2.3. The relationship between PTH, FGF23 and vitamin D control  
PTH is secreted by the parathyroid glands and is up-regulated by increased serum 
phosphate, and down-regulated by increased calcium and 1,25(OH)₂D3 (vitamin D) and high 
FGF23. FGF23 expression is up-regulated by increased 1,25(OH)₂D3 levels and down-
regulated by DMP1 and PHEX.  High FGF23 expression in turn down-regulates PTH 
secretion. 1,25(OH)₂D3 production is up-regulated by PTH and down-regulated by high 
FGF23.       
 
Over the past decade the generation of genomic datasets, in particular 
chromatin immunoprecipitation sequencing (ChIPseq) data, have been very 
informative in detailing the role of the VDR in genetic regulation.  Key studies have 
shown the vast number of VDR binding sites and target genes thought to be within 
the genome, providing an appreciation for considerable range and complexity of 
vitamin D effects that may be mediated through effects on the transcriptome [33-35].  
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ChIPseq in human cell models have demonstrated between 1,000 and 10,000 
genomic VDR binding sites, providing great potential for genome-wide effects of VDR 
targeting by 1,25(OH)₂D3 [36].  Of particular interest, recent ChIPseq data revealed 
the occurrence of VDR binding sites was linked to the development of different 
immune phenotypes [37].  Results from this study suggest that due to enriched 
numbers of VDR binding sites within genes involved in immune regulation, the 
immunomodulatory functions of vitamin D may be amongst its most important 
actions.        
 
2.2 Vitamin D transport and bioavailability 
 
In circulation, the majority of vitamin D metabolites including 25(OH)D3 and 
1,25(OH)₂D3 are bound to DBP, with smaller proportions of these metabolites bound 
to other abundant serum carrier proteins such as albumin [38]. In the kidney, binding 
to DBP facilitates the bioavailability of 25(OH)D3 for proximal tubule uptake and renal 
conversion to 1,25(OH)₂D3 [10]. A similar mode of uptake for vitamin D may also 
occur in several extra-renal tissues that express megalin [39]. However, in cells that 
do not express megalin or cubilin, it is unclear how vitamin D metabolites such as 
25(OH)D3 or 1,25(OH)₂D3 are taken up by these tissues. This process may involve 
megalin-independent receptor-mediated uptake of DBP, but may also occur via non-
receptor uptake of vitamin D metabolites not associated with DBP or other binding 
proteins – the so-called free hormone hypothesis [40].  Uptake of non DBP-bound or 
free 25(OH)D3 may be particularly important for immunomodulatory actions of 
vitamin D where because DBP binds 25(OH)D3 more strongly than 1,25(OH)₂D3, 
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uptake of 25(OH)D3 is central to the production of 1,25(OH)₂D3 that occurs in 
immune cells such as monocytes, macrophages and dendritic cells [41].  The amount 
of free or bioavailable 25(OH)D is dependent on the amount of DBP and other 
binding proteins in circulation, and has been postulated as a more physiologically 
relevant marker of vitamin D status [42].  However, in some studies free or 
bioavailable 25(OH)D3 does not appear to have any advantages over conventional 
total serum 25(OH)D3 [43]. Expression of DBP and albumin remains stable despite 
seasonal variations in the amount of DBP-bound 25(OH)D and free 25(OH)D, which 
also correlates with variations in total 25(OH)D levels [44].  However, DBP 
expression has also been reported to vary according to sex [45] and race [46]. In the 
latter study, decreased serum concentrations of DBP in African and African-American 
subjects were associated with increased free or bioavailable 25(OH)D3 [46], although 
this observation has not been confirmed in subsequent studies [47]. Altered DBP and 
free/bioavailable 25(OH)D3 in different racial groups has been proposed to be due to 
single nucleotide polymorphic variations in the DBP gene (Gc) that may affect the 
level of DBP [46], and/or the affinity of 25(OH)D3 binding [48].  
Around 90% of 25(OH)D is bound to DBP in circulation, with another 10-15% 
bound to albumin, leaving <1% of 25(OH)D that is unbound and ‘free’ in circulation 
[40].  Nevertheless, due to the lipophilic nature of 25(OH)D3 it is suggested that 
some of its biological actions are exerted through the small fraction of 25(OH)D3 that 
is not bound to DBP or albumin and is therefore able to diffuse across cell 
membranes [49, 50]. It is unclear whether this mode of action for 25(OH)D3 is 
common to most cell types, and whether a similar mechanism is observed for other 
vitamin D metabolites such as 1,25(OH)₂D3, which has lower binding affinity for DBP 
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compared to 25(OH)D3 [51].  The ‘free hormone’ hypothesis is not unique to the 
actions of vitamin D; this mechanism has been described for the uptake of other 
steroid hormones [52]. Extra-renal actions of vitamin D are highly dependent on the 
availability of 25(OH)D for cell-specific conversion to 1,25(OH)₂D3, thus seasonal 
variations in 25(OH)D may result in differential effects on immune cells at different 
times of the year.  Since DBP binds 25(OH)D3 with higher affinity than it binds 
1,25(OH)₂D3, it is important to consider the impact of bound versus free 25(OH)D3 in 
extra-renal vitamin D-mediated responses.  An alternative name has been proposed 
for free 25(OH)D3, termed ‘bioavailable’ 25(OH)D3 which includes 25(OH)D3 in 
circulation that is not bound to DBP but is associated with albumin. This component 
of circulating 25(OH)D3, which makes up around 10% of all serum 25(OH)D3, has 
gained popularity in clinical studies as an alternative to free 25(OH)D although, unlike 
free 25(OH)D3, bioavailable 25(OH)D3 cannot be measured directly in serum [53]. 
Studies have shown that the 25(OH)D2 form of 25(OH)D has a lower affinity for DBP 
compared to 25(OH)D3, as a result of structural differences at carbon position 24.  
Lower binding affinity for 25(OH)D2 results in faster clearance of this metabolite from 
circulation, thereby reducing levels available for conversion to 1,25(OH)2D [54, 55]. 
Because of this it has been suggested that supplementation with vitamin D2 is less 
effective than vitamin D3 in maintaining serum levels of 25(OH)D.        
 
2.3 Vitamin D-sufficiency and -deficiency 
 
The vitamin D ‘status’ of any given individual is normally referred to by serum 
or plasma levels of 25(OH)D3, even though this is not the active form of vitamin D.  In 
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contrast to 1,25(OH)₂D3, measurement of 25(OH)D3 is relatively straightforward, 
with this analysis being common to many core assay services at hospitals around the 
world. Despite this, the question still remains as to what is the optimal serum 
concentration of 25(OH)D3?  In 2011, the Institute of Medicine (now the National 
Academy of Medicine) in North America carried out a consultation that resulted in a 
recommended serum 25(OH)D3 concentration of 20 ng/mL (50 nmol/L), although 
they emphasized that this only related to the calcium and bone effects of vitamin D 
[56]. Other organisations have proposed alternative targets for optimal 25(OH)D3 
status. In the USA, the Endocrine Society recommended an optimal 25(OH)D3 serum 
level of 30 ng/mL (75 nmol/L), with levels between 50-75 nmol/L being classed as 
vitamin D ‘insufficient’ [57]. In the UK, the Science Advisory Council on Nutrition 
(SACN) recommended serum 25(OH)D3 greater than 10 ng/mL (25 nmol/L) but 
again, this was purely for calcium and bone effects of vitamin D [58].   Overall the cut-
off value for vitamin D deficiency has been the topic of much debate, although 
current accepted consensus by medical experts define vitamin D deficiency as a 
serum 25(OH)D3 concentration of below 20 ng/mL [59]. A normal serum 25(OH)D3 
range can be between 20-100 ng/mL, however 25(OH)D3 levels <30 ng/mL are 
classed as sub-optimal for general health [60].   
 
2.4 Vitamin D status and human health 
 
The importance of vitamin D as a regulator of calcium homeostasis and bone 
metabolism is well established [61-63], but in recent years there has been growing 
interest in the extra-skeletal effects of vitamin D [64], particularly with regard to 
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human disease.  There have been many association studies that have reported the 
link between vitamin D status and a variety of disease manifestations including 
cancers [65-68] and autoimmune diseases such as rheumatoid arthritis [69-73].  
However other studies have questioned whether low vitamin D levels are a 
consequence, as opposed to the cause of, these diseases [61].  Despite this, the 
overarching proposal is that deficiency of vitamin D is very likely to be a leading 
factor in the onset and progression of multiple diseases.  A list of well-published 
extra-skeletal diseases with regard to their links with vitamin D status is summarised 












associated with vitamin D 
deficiency 
Role of vitamin D in disease manifestation 
Breast cancer, prostate 
cancer 




Vitamin D down-regulates genes encoding pro-
inflammatory markers [75-77].   
Low serum 1,25(OH)₂D3  is associate with vascular 
dysfunction, a leading predictor of CVD [78, 79]. 
Muscle myopathies Vitamin D reduces muscle inflammation [80].   
Low serum 1,25(OH)₂D3 raises PTH excessively [81, 82].  
Alzheimer’s Disease Vitamin D is associated with neuroprotective functions and 
reduced cognitive decline [83-85]. 
Type 1 Diabetes (T1D) Polymorphisms in genes encoding CYP2R1[86], VDBP 
[87], VDR [88] and CYP27B1 [89, 90] is associated with 
increased susceptibility to T1D.  
Multiple sclerosis (MS) Higher vitamin D status is correlated with reduced brain 
lesions and severity of MS symptoms [91-95]. 
Systemic lupus 
erythematosus (SLE) 
Low vitamin D status is associated with loss of tolerance of 
immune response leading to worsened SLE symptoms 
[96-98]. 
Pre-eclampsia Vitamin D exerts effects on molecular pathways implicated 
in the development of pre-eclampsia. Maternal deficiencies 
lead to increased risk of pre-eclampsia [99-103]. 
Rheumatoid arthritis (RA) Vitamin D levels are inversely associated with RA disease 
progress and activity [69-73, 104]. 
Inflammatory bowel disease 
(IBD) 
Low vitamin D status is associated with worsened IDB 
severity and disease duration [105-108].   
VDR gene polymorphisms are associated with greater 
susceptibility to IBD [109]. 
26 
 
Vitamin D status has also been implicated in pregnancy outcomes, with 
maternal serum 25(OH)D3 levels positively correlated with a reduced risk of the 
hypertensive disease pre-eclampsia [101, 110]. Target serum levels for 25(OH)D3 
and 1,25(OH)₂D3 vary at different stages of life.  Circulating levels of 1,25(OH)₂D3 in 
pregnant women averages 130 pg/mL and can be as high as 300-400 pg/mL 
compared to a range of 16-56 pg/mL in healthy non-pregnant women [111].  This 
dramatic increase in 1,25(OH)₂D3 occurs very early in pregnancy, and the function of 
this is still unclear as most skeletal development within the foetus takes place much 
later in gestation, but is thought to relate to hormonal changes [112].   
Whilst some published studies have suggested that high dose vitamin D 
supplementation has limited benefits to general health [113-115] and disease 
outcomes [116-119], with one study suggesting that a serum 25(OH)D concentration 
of >50 ng/mL has no additional benefits compared to levels between 30-50 ng/mL 
[80], there have been some notable examples of successful vitamin D 
supplementation trials in improving disease outcomes [96, 120-124].  For example, 
vitamin D supplementation in patients with multiple sclerosis significantly improved 
cognitive function and decreased mental decline compared to non-supplemented 
control patients [121].  Vitamin D supplementation also decreased the rate of 
recurrence of rheumatic disease [122].  Despite the controversy in literature 
regarding the effectiveness of vitamin D supplementation in disease outcomes, none 
of these trials have associated vitamin D supplementation with an increased risk of 
disease, and research is mostly positive regarding the benefits of vitamin D 
supplementation.   
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The upper normal limit of serum 25(OH)D3 has also been debated, with 
previous studies suggesting a serum concentration of over 55 ng/mL as potentially 
dangerous [125-127], with very high levels of supplementation causing 
hypercalcaemia. However later studies dispelled this limit and showed that vitamin D 
toxicity did not occur unless serum 25(OH)D3 levels were above 150 ng/mL, after 
which symptoms of hypercalcemia manifested [128].  Based on the current literature, 
vitamin D intoxication is defined as being above a total 25(OH)D3 serum 
concentration of 150 ng/mL [128, 129].  In contrast to the uncertainties concerning 
circulating concentrations of 25(OH)D3, the range for serum levels of 1,25(OH)₂D3 
are clearer.  1,25(OH)₂D3 concentrations are subject to much tighter regulation, with 
a normal reference range between 39-59 pg/mL in healthy individuals [130].  The 
current paradigm of these strict limits lies in the tight regulation of renal CYP27B1 
activity amongst other regulatory factors [131].  Excessive serum 1,25(OH)₂D3 in 
sarcoidosis patients has been linked to worsened disease severity, perhaps due to 
the overall burden of the disease triggering further 1,25(OH)₂D3 production [132].     
Despite the biological activity of 1,25(OH)₂D3, this form of vitamin D is not 
routinely used to measure vitamin D status. This is due, in part, to the secondary 
hyperparathyroidism associated with vitamin D deficiency, which elevates circulating 
levels of 1,25(OH)₂D3 [133]. However, serum concentrations of 1,25(OH)₂D3  are an 
important indicator of diseases including hereditary vitamin D-resistant rickets types 1 
and 2 (where 1,25(OH)₂D3  is respectively suppressed or elevated), and chronic 




2.5 Quantification of vitamin D metabolites 
 
Methods of quantifying 25(OH)D levels in patients have come a long way 
since the first assay to quantify 25(OH)D was performed using DBP as a competitive 
binder [134].  The major limitation of this assay was the detection of not only 
25(OH)D in serum, but also other metabolites including 24,25(OH)₂D3. Since then 
more advanced methods of analysing 25(OH)D metabolite concentrations have been 
developed, notably the development of radioimmunoassays (Diasorinᵀᴹ) in 1985 
[135] and high-performance liquid chromatography (HPLC) [136], both of which are 
now also known to have limitations affecting their detection accuracy.  The major 
limitation of the Diasorin method was, like the DBP assay method, the detection of 
other metabolites, which meant that levels of 25(OH)D were usually overestimated by 
around 15%.  Such an overestimation can be crucial for defining the line between 
vitamin D sufficiency and deficiency.  The HPLC method for quantification of vitamin 
D removed assay interference by separating out 25(OH)D from other vitamin D 
metabolites, but it was a long and expensive procedure requiring large sample 
volumes and was therefore not suitable for large-throughput analysis in clinical 
settings.  The current gold standard for measuring vitamin D status uses liquid 
chromatography-tandem mass spectrometry (LC/MS-MS) which combines the 
separation capabilities of HPLC with the detection specificity of mass spectrometry, 
to accurately measure 25(OH)D3 and other vitamin D metabolites in patient serum 
[137, 138]. This technique is more accurate, and requires relatively small volumes of 
serum or plasma. Recent developments in analytical chemistry mean that it is now 
possible to accurately differentiate between 25(OH)D2 and 25(OH)D3 in serum, as 
well as other metabolites including 1,25(OH)₂D3 [139, 140].    
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2.6 Vitamin D and the immune system 
 
Perhaps the best example of an extra-skeletal role for vitamin D is its potent 
ability to regulate the function of immune cells.  A link between vitamin D and the 
immune system was first proposed based on two key observations: 1) activated cells 
from both the innate and adaptive immune systems express VDR and respond to 
1,25(OH)₂D3; 2) activated innate immune cells such as macrophages and DC 
express CYP27B1 and are able to synthesise 1,25(OH)₂D3 (see Figure 2.4).  Initially 
these observations were considered to be either pathological features or potential 
mechanisms for therapeutic targeting.  For example, over-active macrophage 
production of 1,25(OH)₂D3 in granulomatous diseases such as sarcoidosis was 
linked to the pathological hypercalcemia that is occasionally observed for this type of 
disorder [141, 142]. In a similar fashion, the expression of VDR in cells of the immune 
system suggested potential therapeutic use of 1,25(OH)₂D3 as treatment for 
diseases such as leukaemia [143]. In the case of the latter, this led to the 
development of analogues of 1,25(OH)₂D3 that retained ability to regulate monocyte 
function, whilst minimising the established hypercalcaemic effects of 1,25(OH)₂D3  
[144]. However, in more recent years it has become clear that vitamin D may have an 
important role in regulating normal immune responses, by modulating cells from both 
the innate and adaptive immune systems. The remainder of this section of the thesis 
introduction will detail the mechanisms associated with immunoregulation by vitamin 
D.  However, specific details on the effects of vitamin D on DC and T cells are 
provided in the thesis chapters dedicated to these cell types (Chapters 5 and 6 
respectively). The interactions between vitamin D and the innate and adaptive 




Figure 2.4. Expression of VDR and CYP27B1 in cells from the innate and adaptive 
immune systems 
Immune cells including macrophages and dendritic cells of the innate immune system 
express VDR and CYP27B1, hence are able to activate 25(OH)D3 (25D) to 1,25(OH)2D3 
(1,25D).  VDR has also been found in cells of the adaptive immune system including T cell 
subsets and B cells, meaning these cells are all capable of responding to 1,25(OH)2D3 in a 




Monocytes and macrophages constitute key members of the innate immune 
response with the ability to recognise foreign pathogen-associated molecular 
patterns (PAMPs) via pattern recognition receptor (PRR) such as toll-like receptors 
(TLRs), thus providing the first line of defence against pathogens and enhancing the 
antimicrobial properties of these immune cells.  Effects of 1,25(OH)₂D3 on 
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Further research found that monocytes and macrophages also express the enzyme 
CYP27B1, thus are able to produce 1,25(OH)₂D3 within immune-active tissues 
independent of renal CYP27B1 [11, 146, 147].  Macrophage CYP27B1 behaves 
differently to renal CYP27B1; CYP27B1 produced by macrophages can be up-
regulated by the presence of immune stimuli such as IFN-γ and Lipopolysaccharide 
(LPS). Conversely, 1,25(OH)₂D3 produced by monocytes and macrophages is not 
subject to the same regulatory mechanisms as renal CYP27B1 in that elevated 
calcium or 1,25(OH)₂D3 levels do not suppress CYP27B1 production [148, 149].  
Instead, IFN-У and LPS stimulate up-regulation of CYP27B1, via the JAK/STAT or 
MAPK signalling pathways [148, 150].  
1,25(OH)2D3 promotes antibacterial activity responses following activation of 
TLRs as part of innate immune responses to infection.  Liu et al. [145] showed that 
activation of the TLR-2 pathway in macrophages resulted in up-regulation of 
CYP27B1 and VDR expression, leading to intracrine synthesis of 1,25(OH)2D3,  
1,25(OH)₂D3-VDR-RXR heterodimer binding to VDRE and subsequent transcription 
of antimicrobial genes such as cathelicidin.  Wang et al. [151] showed that in addition 
to this, 1,25(OH)₂D3 induced expression of CD14, a TLR co-receptor and monocyte 
marker.  
 
Dendritic cells (DC) 
In contrast to stimulatory effects on innate immune function, 1,25(OH)₂D3 
tends to inhibit the adaptive immune system, but some of these effects can be 
mediated via cells from the innate immune system such as the antigen presenting 
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dendritic cells (DC). In antigen presenting cells (APC) such as DC, 1,25(OH)2D3 
decreases cell maturation and thereby changes antigen presentation to T cells [152, 
153].  In DC, 1,25(OH)₂D3 down-regulates expression of the maturation marker 
CD80/CD86 [154-156] and CD83 [157], indicating that 1,25(OH)2D3 promotes DC 
differentiation way from an antigen presentation phenotype. 1,25(OH)₂D3 also 
induces maintenance of tolerogenic DC [158-160]. DC stimulated with 1,25(OH)₂D3 
show up-regulated IL-10 production and inhibition of pro-inflammatory cytokine 
release, such as TNF-α, IFN-γ and IL-12 [154, 161, 162].  Thus 1,25(OH)₂D3  is able 
to maintain an immature-like DC phenotype [163], thereby further reducing 
stimulation of T cells. The role of vitamin D in DC immunomodulation is described in 
further detail in Chapter 5 of this thesis.   
 
Neutrophils 
Neutrophils are granulocyte cells that also constitute part of the innate immune 
system, and they have been shown to express functional VDR at a level similar to 
that found in monocytes [164]. However neutrophils lack the CYP27B1 required to 
convert 25(OH)D to 1,25(OH)₂D3 and subsequent intracrine stimulation of 
cathelicidin expression.  It has been demonstrated that CD14 cell surface marker is 
augmented in neutrophils in the presence of 1,25(OH)₂D3, with this mechanism likely 
to involve 1,25(OH)₂D3-mediated modulation of the target genes trappin-
2/elafin/SKALP [164].  The anti-microbial activity of neutrophils is driven by the 
presence of granules containing anti-microbial agents; neutrophil development and 
granulopoiesis requires the down-regulation of RXRα [165, 166].  The exact 
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mechanism of this action and the role of 1,25(OH)₂D3 in this response is not well 
understood, although studies suggest that 1,25(OH)₂D3 may alter the neutrophil 
inflammatory process in a VDR-dependent manner [167].  1,25(OH)₂D3 up-regulates 
the production of IL-8 in neutrophils following LPS stimulus [168] and suppresses 
neutrophil activation [169].  
   
Eosinophils/Basophils 
Eosinophils and basophils, along with mast cells, are involved in the 
pathogenesis of allergic disease in individuals with allergen-specific immunoglobulin 
E (IgE).  Upon activation, these cells release or synthesise a host of 
immunomodulatory mediators such as histamines, cytokines and chemokines [170].  
Eosinophils make up around 5% of circulating leukocytes in blood, with the majority 
found residing in bone marrow, thymus and lymph organs.  Basophils make up less 
than 1% of leukocytes in healthy blood, and are rapidly recruited to sites of 
inflammation.  Eosinophils and basophils both express VDR, and serum 25(OH)D3 
levels have been reported to be inversely correlated with blood eosinophil counts in 
human [171-173] and mouse [174] models of allergic disease, leading to excessive 
eosinophil activation, overproduction of IgE and exacerbated allergic reactions. The 
precise molecule mechanism of 1,25(OH)₂D3 in eosinophils and basophils is still 
unknown.  Epidemiological studies have suggested that vitamin D is protective 
against allergic diseases by prolonging eosinophil survival at non-inflamed sites 





The activation of mast cells forms the acute phase of an allergic reaction.  
Mast cells express TLR-2 and their activation is triggered by the crosslinking of IgE 
with specific allergens, and primarily leads to the release of histamines and TNF-α 
cytokine, followed by the release of prostaglandins [170, 177].  The expression of 
VDR in these cells provides potential for 1,25(OH)₂D3 to dampen mast cell activation 
by suppressing IgE and reducing inflammatory cytokine release [178].  Mast cells can 
actively convert 25(OH)D3 to 1,25(OH)₂D3 via intrinsic CYP27B1 activity [179], and 
exposure to 1,25(OH)₂D3 in culture up-regulates mast cell expression of VDR [180].  
Furthermore, it has been demonstrated that 1,25(OH)₂D3 is required to maintain 
mast cell stability as shown by excessive mast cell activation under vitamin D-
deficient conditions.  In mast cells of Vdr knockout mice, 1,25(OH)₂D3 can induce IL-
10 secretion and suppress inflammation, demonstrating that 1,25(OH)₂D3 can act 
upon mast cells in a VDR-independent fashion [181].  These studies highlight the 
wide range of potential anti-inflammatory actions of 1,25(OH)₂D3 in different innate 
immunity cells.        
 
T cells 
In the adaptive immune system, numerous studies have shown 1,25(OH)₂D3 
also plays a key role in mediating T cell immunity, where 1,25(OH)₂D3 added in vitro 
acts to suppress immune responses [182] by stimulating an increase in numbers of 
Treg cells [158, 159].   Vitamin D also exerts inhibitory actions by suppressing the 
development of Th1 and Th17 cells, resulting in decreased production of pro-
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inflammatory cytokines IFN-У, IL-2 and IL-17 [183].  Further studies have reported 
1,25(OH)₂D3 induces changes in T helper (Th) cell cytokine secretions, or differential 
expression of co-stimulatory molecules upon T cell activation [184].  One of the ways 
in which 1,25(OH)₂D3 suppresses T cell activity is by mediating a shift from Th1 to 
Th2 phenotype and reducing their proliferation [185, 186]; this Th cell polarisation 
shift inhibits pro-inflammatory IFN-У producing Th1 cells, and augments IL-10 
producing Th2 cells.  High doses of 1,25(OH)₂D3 in culture also acts on CD4+ T cells 
by suppressing their activation [187].  Similarly in murine models, the effect of 
1,25(OH)₂D3  on T cells includes inhibition of IFN-У and IL-17 secretion and reduced 
proliferation, and induction of Tregs and IL-4 secretion [188].  The 
immunomodulatory role of vitamin D on T cell subset function is described in greater 
detail in Chapter 6 of this thesis.   
 
B cells 
B cells play an important role in the adaptive immune response by secreting 
antibodies after differentiation into plasma cells, as well as being involved in antigen 
presentation and cytokine secretion.  They are also responsible for the production of 
autoreactive antibodies in autoimmune disease.  B cells express VDR but despite 
their importance in immune function there have been limited and conflicting reports 
on the action of 1,25(OH)₂D3 on B cells.  Both indirect and direct effects of 
1,25(OH)₂D3 on B cells have been reported, with indirect effects of 1,25(OH)₂D3  
thought to inhibit B cell function via the impairment of CD4+ T cell signalling [189].  
Conversely, direct effects of 1,25(OH)₂D3 may involve the inhibition of IgE production 
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by B cells [190],  blocking B cell differentiation and proliferation [191, 192] and 
inducing apoptosis [193], suggesting 1,25(OH)₂D3  plays an important role in 
maintaining B cell homeostasis by controlling the abundance of plasma cells and 
therefore autoreactive antibodies produced.  Indeed, deficiency of 1,25(OH)₂D3  in 
serum appears to be a contributing factor in the development and severity of B cell-
mediated systemic lupus erythematosus (SLE) [194], further defining the important 




Figure 2.5. The relationship between vitamin D and the innate and adaptive immune 
systems 
Vitamin D acts via the VDR intrinsically expressed by cells of the innate and adaptive 
immune systems.  Monocytes and macrophages also express CYP27B1 allowing the 
synthesis of 1,25(OH)₂D3 from 25(OH)D.  Active vitamin D, when bound to the VDR, elicits 
anti-inflammatory effects on cells of the adaptive immune system including T cell subsets.  
Treg and Th2 cell activity is up-regulated and primed to release anti-inflammatory cytokines, 




Overall the active form of vitamin D acts to suppress immune responses 
through decreased T cell activation, decreased DC maturation, and increased DC 
tolerogenesis.  Together, these molecular changes suggest that 1,25(OH)₂D3 has 
great potential to regulate inflammation in the innate and adaptive immune system.   
 
2.7 Vitamin D and microRNAs 
Introduction to microRNAs  
The first endogenous microRNA (miRNA) was discovered in C. elegans in 
1993, where scientists found that lin-4 was essential in controlling post-embryonic 
development via the negative regulation of LIN-14 protein [195].  This led to the 
concept that small endogenous molecules were capable of functioning in a regulatory 
fashion but in non-protein encoding roles. This challenged the previous central 
dogma that protein translation only involved a single direction of genetic information 
flow via mRNAs.  It was only in the early 2000s that miRNAs were classed as distinct 
biological regulators [196], with their link to vitamin D emerging almost a decade later 
[197, 198].    
It is now known that miRNAs are small single-stranded non-coding RNAs that 
are highly conserved amongst eukaryotes [199].  Around 16-22 nucleotides in length, 
they play a host of different functions which ultimately involve regulating gene 
expression at the post-transcriptional level [200].  MiRNAs are functionally similar to 
siRNAs, and exert their function by base pairing to target mRNAs to inhibit gene 
translation and, in some cases, destabilizing mRNA transcripts, thereby ultimately 
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suppressing protein synthesis of the miRNA target transcript.  Understanding the 
mechanism of action of miRNAs has provided the tools for prediction of many 
potential miRNA targets in the human genome.  It is predicted that over 40% of 
protein coding genes in the human body are regulated by miRNAs [201, 202], with 
many of these miRNAs acting in immune regulation.  In recent years, dysregulation 
of a number of miRNAs has been linked to a range of diseases in humans, including 
but not limited to autoimmune diseases.   
To date, over 2500 mature miRNAs have been experimentally validated in the 
human genome (miRBase21) and due to the important regulatory role they play it is 
likely that at least some of these will be dysregulated in disease, thus placing 
miRNAs at the forefront of disease-based therapeutic research.  The relationship 
between miRNAs and the immune system has only recently been discovered, and 
research is still ongoing to decipher this link.  Multiple studies have shown a strong 
link between miRNAs and their role in immune cell regulation and development, via 
modulating gene expression or other epigenetic regulations.  As miRNAs are found 
ubiquitously, it is likely that miRNAs target genes required for immune cell 
differentiation and survival, hence any dysregulated miRNA activity may also impact 
upon cells of the immune system. Multiple miRNAs may be responsible for targeting 
a single RNA sequence, hence it is often difficult to pinpoint gene dysregulation as a 
result of a single miRNA.  The level of gene repression is also dependent on the 





miRNA expression and function 
MiRNAs are first transcribed within the cell nucleus by RNA Pol II and III to 
form the primary miRNA (pri-miRNA), a long double-stranded structure with a hairpin 
loop on the end.  The pri-miRNA is further cleaved in the nucleus to leave the 60-70 
nucleotide hairpin loop structure known as the precursor miRNA (pre-miRNA) [204].  
This step requires the action of the microprocessor complex made up of DROSHA 
and its co-factor DGCR8.  DGCR8 is responsible for guiding DROSHA to cleave the 
pre-miRNA, leaving a 2 nucleotide overhang on the 3’ end.  The pre-miRNA is 
exported out of the nucleus into the cytoplasm by exportin-5, a nuclear transport 
receptor that is dependent on Ran and GTP [205].  In the cytoplasm the pre-miRNA 
undergoes further cleavage mediated by TRBP and DICER, an RNAse III nuclease 
enzyme which generates a 22 nucleotide double-stranded RNA complex comprising 
the passenger and guide strand.  DICER cleaves the 5’ end of the pre-miRNA by 
recognising the 3’ end, leading to the production of both 3’ and 5’ end miRNAs [206].  
It is thought that TRBP alone does not contribute to pre-miRNA processing, but 
instead it is important for forming part of the RNA-induced silencing complex (RISC) 
[207].  The miRNA duplex is then incorporated onto Ago2, the passenger strand is 
degraded, and the guide strand remains bound to the Ago2-RISC complex as the 
mature miRNA.  The mature miRNA guides RISC to its target mRNA, where it exerts 
its silencing actions via mRNA cleavage, translational repression or mRNA 









Figure 2.6. Mechanism of miRNA synthesis in humans   
Pri-miRNA cleavage by DROSHA and DGCR8 takes place in the nucleus, and pre-miRNA 
cleavage by DICER and TRBP takes place in the cytoplasm.  The mature miRNA is 
incorporated into RISC and responsible for subsequent silencing actions on target mRNA.  
Image cited and adapted from Nature Cell Biology [209].      
 
The exact mechanism by which miRNAs process their target genes for 
degradation is more complex than previously thought; studies have suggested this 
process is not only mediated by complementary base pairing which triggers Ago 
protein slicer activity, but also involves other processes such as mRNA de-capping, 
deadenylation and exonuclease digestion [210, 211].  Others have suggested 
42 
 
miRNAs mediate translational repression of their target mRNA through the 
accumulation of target mRNAs in processing bodies (p-bodies), which are not 
involved in the translational process themselves [212].  Nucleotides 2-7 of the 5’ end 
of a miRNA, also known as the seed strand which is highly conserved amongst 
vertebrates, have been shown to be necessary for miRNAs to complementary base 
pair to their target mRNA [203, 213].  Conversely, the 3’ end of a miRNA is not 
generally required to be complementary to the mRNA.  Whilst mRNA non-
complementarity to the 3’ region of miRNAs does not appear to hinder miRNA 
function, it is likely that mRNA complementarity to both the 5’ and the 3’ ends greatly 
enhances miRNA-mediated gene silencing.      
Pre-miRNAs can arise from exons or introns of gene transcripts, the former of 
which is retained, and the latter spliced out.  It has been shown that a large majority 
of mammalian miRNAs are found within intron regions of protein-coding genes.  
These miRNA host genes encode proteins that are involved in a wide range of 
biological functions from metabolism to cell cycle control [214].  This finding suggests 
that miRNAs located in intron regions of their host genes may be involved in their 
transcriptional regulation.        
 
2.8 A role for miRNAs in the immunomodulatory actions of vitamin D  
 
It is well established that vitamin D influences immune function by acting as a 
transcriptional regulator in conjunction with the VDR [215, 216].  Over the years, key 
studies have emerged from the analysis of vitamin D-regulated transcription on 
immune function [217-220], detailing the important role of vitamin D-mediated 
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transcriptional modulation on both the innate and adaptive immune system.  In 
addition to transcription, it is clear that vitamin D can also influence epigenetic 
mechanisms, including modulating activity of the VDR promoter [221, 222], CYP24A1 
[223, 224] and CYP27B1 [225-227] by DNA methylation or histone acetylation.  
Additionally, the VDR protein can directly interact with co-activator and co-repressor 
proteins which are in contact with chromatin modifiers such as histone 
acetyltransferases (HATs), which in turn interact with the VDR/RXR heterodimer to 
induce transcriptional activation [228].  These studies suggest that the vitamin D 
system is highly dependent on epigenetic modifications of its receptor and associated 
enzyme coding genes.     
One prominent epigenetic target for vitamin D is miRNAs.  Extensive studies 
have demonstrated that various miRNAs can be dysregulated in a variety of cell 
types from cancer cells [229, 230] to fibroblast-like synoviocytes in rheumatoid 
arthritis [231, 232], although far fewer studies have been dedicated to exploring the 
role of vitamin D on miRNA modulation in these cells. The majority of studies 
involving vitamin D and miRNA modulation have been performed using cell lines.  A 
summary of published vitamin D-mediated miRNAs in different cell types is shown in 








Table 2.2. List of published vitamin D-regulated miRNAs in different cell types 
 
MiRNAs play particularly important roles in vitamin D-mediated immune 
responses.  Studies using immune-challenged monocytes have shown that miR-21 
suppresses expression of CYP27B1 which leads to inhibition of cathelicidin (CAMP), 
an anti-bacterial protective response normally induced by intracrine vitamin D 
signalling [235].  Validated gene targets of miR-21 include BCL-2 and PTEN, which 
are involved in the vitamin D antimicrobial response [259].  Other vitamin D 
metabolism genes such as CYP24A1 have also been reported to be targeted by 
miRNAs including miR-125b [250].  MiR-125b [258] as well as miR-27b and miR-298 
have been suggested to target the VDR [260].     
Cell type miRNAs regulated by vitamin D 
Osteoblast miR-125 [233], miR-146a [234], miR-637, miR-1228 [63] 
Monocyte miR-21 [235], miR-146a, miR-130a [236] 
Colon cancer (SW480-ADH, 
HCT116) 
miR-346 [237], miR-22 [238] 
Dendritic cell miR-378, miR-155 [239, 240], miR-29a, miR-146a, miR-
193a, miR-387, miR-770 [241] 
Pancreatic  miR-326 [242] 
Prostate cancer (LNCaP) miR-29a, miR-1915, miR-663, miR-134, miR-542 [243], 
miR-98 [244], miR-100, miR-125b  
Lung cancer (A549) miR-17 [229], miR-298 [245], miR-27b [245], let-7a [246] 
Pulmonary fibroblast miR-27b [245] 
Ovarian cancer (OCa) miR-498 [247, 248] 
Breast cancer (MCF-7) miR-125b [249, 250] 
Cervical cancer (SiHa)    DICER, miR-22, miR-296-3p, miR-498 [251] 
Kidney (NRK-52) miR-125b [252] 
Bladder cancer (253J) 94 miRNAs [253] 
PBMC miR-589, miR-601, miR-573, miR-138, miR-926, miR-423, 
mIR-484 [254], miR-181, miR-130, miR-135b, miR0146a 
[255] 
HUVEC miR-181c, miR-15a, miR-20b, miR-411, miR-659, miR-126, 
miR-510 [256] 
Melanocytes (MeWo) miR-302c, miR-520c [257], miR-125b, miR-27b [258] 





In the experimental HeLa cell models for cancer, calcitriol binding to the VDR 
has been shown to directly up-regulate DICER expression through targeting its 
VDRE region [251].  This stimulation, in turn, up-regulated the expression of a subset 
of miRNAs including miR-22, miR296-3p and miR-498 found to be involved in anti-
tumorigenesis.  The importance of vitamin D-mediated effects on gene expression 
beyond VDR-dependent mechanisms was further elucidated by a study using human 
osteoblasts, which found that differential regulation of multiple miRNAs following 
10nM 1,25(OH)₂D3  in culture coincided with gene regulation in a VDR-independent 
manner [63]. This study provides strong evidence that the effects of 1,25(OH)₂D3 are 
not restricted to classical VDR-mediated transcriptional responses.   
A recent study in human adipocytes found the expression of miR-146a and 
miR-155, two of the most well-profiled miRNAs in inflammation, to be up-regulated by 
TNF-α, with 1,25(OH)₂D3 preventing this up-regulation [261].  NF-kB signalling was 
found to be the driving force behind the induction of these miRNAs, suggesting the 
mechanism of regulation by 1,25(OH)₂D3 was due to the ability of 1,25(OH)₂D3 to 
deactivate NF-kB signalling.  MiR-146a and miR-155 up-regulation by TNF-α and 
down-regulation by 1,25(OH)₂D3 was also observed in transgenic mouse models of 
inflammation, indicating a ubiquitous regulatory role of these miRNAs across species.     
The key role that miR-155 plays in all aspects of immune cell function 
suggests exogenous targeting of this miRNA in particular could ameliorate disease, 
by preventing over-expression of the miRNA which in turn prevents aberrant 
silencing of its target genes.  Thus 1,25(OH)₂D3 could be a potential therapeutic 
treatment to modify expression of miR-155 in immune cells.  There have already 
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been studies showing down-regulated miR-155 expression following 1,25(OH)₂D3 
treatment in immune cells [262, 263]. 
Other miRNAs have also shown potential as immunomodulatory targets for 
vitamin D.  MiR-22 has been reported to be induced by 1,25(OH)₂D3 in colon cancer 
cells, with its induction regulating gene expression in a VDR-dependent manner 
[238].  MiR-125b, which regulates VDR via a repression mechanism [197] has been 
reported to be one of many miRNAs down-regulated in cancer.  Logically, the de-
repression of VDR in cancer should augment the capacity for response to 
1,25(OH)₂D3, and by extension, its immunomodulatory properties.   
MiRNAs act within tissues but also circulate in serum.  Circulating miRNA 
expression has been linked to the concentration of serum 25(OH)D in pregnancy, 
diabetes and pregnancy-related pre-eclampsia [99, 264], although studies on the link 
between serum 25(OH)D and miRNAs are limited.  The link between 1,25(OH)₂D3 
and miRNAs has been more widely studied, however results are still varied and 
controversial.  A pilot study comparing miRNA expression in 1,25(OH)₂D3-
supplemented groups versus non-supplemented groups found the expression of let-
7a, a predicted target of VDR, to be significantly elevated in the 1,25(OH)₂D3 
supplementation group.  Others have found the entire let-7 miRNA family elevated in 
the presence of 1,25(OH)₂D3 [246], reaffirming the relationship between let-7, the 
VDR and vitamin D.  It remains very likely that other miRNAs may be important 
targets for the immunomodulatory effects of 1,25(OH)₂D3, with implications in both 




2.9 Project aims and objectives 
 
The central hypothesis for this Ph.D. project is that microRNAs (miRNAs) play 
a pivotal role in mediating innate and adaptive immune responses to vitamin D, and 
this may be particularly important in the autoimmune disease rheumatoid arthritis 
(RA). To test this hypothesis the project involved three specific aims: 
i)  To use RA patient serum and synovial fluid to investigate the relationship 
between circulating vitamin D metabolites and miRNAs in RA disease activity 
(Chapter 4). 
ii)  To use primary cultures of human cells to investigate the role of miRNAs as 
mediators of the innate immune effects of 1,25(OH)₂D3 on DC (Chapter 5). 
iii)  To use primary cultures of human cells to investigate the role of miRNAs as 









CHAPTER 3.  
MATERIALS AND METHODS 
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3. Introduction  
 
The aim of the inflammatory arthritis (RA) patient section of this PhD project 
(Chapter 4) was to use serum and SF to quantify the concentration of 25(OH)D2, 
25(OH)D3, 3-epi-25(OH)D3, 24,25(OH)₂D3 and 1,25(OH)₂D3 in order to correlate 
metabolite concentration with RA disease activity markers CRP (C-reactive protein), 
ESR (erythrocyte sedimentation rate), SJC (swollen joint count) and TJC (tender joint 
count).  These vitamin D metabolites were selected for analysis as they are 
intermediate or catabolic products that arise from the vitamin D synthesis pathway.  
The biological significance of the metabolite 3-epi-25(OH)D3 has been debated in 
literature, however since it has the ability to bind VDR to potentially give rise to 
genetic and epigenetic modifications [265], we have focused on this metabolite along 
with the active form 1,25(OH)₂D3.   
The rationale for including reactive arthritis (ReA) patient samples in Chapter 
4 was to use these as a control cohort, since ReA does not have the inflammatory 
progression associated with RA.  The listed RA disease activity markers were 
measured either during structured clinical assessment, or by routine hospital assays 
service (Birmingham, UK).  The expression of miR-146a and miR-155, two major 
inflammatory miRNAs, was quantified in the RA patient samples and correlated with 
vitamin D metabolites and patient disease activity markers.  Figure 3.1 shows a 
schematic representation of the human samples used in Chapter 4 and the 
methodologies used to analyse these samples.  
The aim of in vitro studies in Chapter 5 and Chapter 6 was to develop cell 
culture models to investigate: 1) the effects of 1,25(OH)₂D3 on DC differentiation and 
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miRNA expression; 2) the effects of 1,25(OH)₂D3 on T cell phenotype and miRNA 
expression.  Figure 3.2 shows a schematic representation of the DC and T cell 
models used in Chapter 5 and Chapter 6 respectively, and the methodology used to 

























Figure 3.1. Workflow for patient studies 
Paired RA (n=20) and ReA (n=7) serum and SF were obtained from patients according to 
existing ethical agreements.  Serum from n=23 heathy cohort was used as disease-free 
controls.  Methodologies used to analyse these samples were: miRNA isolation, LC-
MS/MS and ELISA.  RA=rheumatoid arthritis; ReA=reactive arthritis. 
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Figure 3.2. Workflow for in vitro studies 
Both DC and T cell cultures were derived from healthy donor peripheral blood 
mononuclear cells (PBMC). CD14+ monocytes were cultured over 6 days into DC; CD4+ 
CD25- T cells were cultured over 3 days.  Both cell models were left treated or untreated 
with 1,25(OH)
2
D3.  Methodologies used to analyse these models were: flow cytometry, 
mRNA expression and miRNA expression (target and array profiling).     
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Healthy human peripheral blood mononuclear cells (PBMC) were obtained 
from fully anonymised blood cones obtained from the National Blood Service, 
Birmingham, UK, in accordance with ethical agreement ERN_14-0446. 
 
3.1.2 Isolation of PBMC from whole blood 
 
PBMC were isolated from whole blood leukocyte cones from healthy donors.  
10mL whole blood was diluted with 40mL phosphate buffered saline (PBS), and 
pipetted drop-wise into two 50mL falcon tubes containing 15mL LymphoPrep 
Separation Media (Stem Cell Technologies) in each tube.  The preparation was 
separated by density gradient centrifugation at 2700rpm (revolutions per minute) for 
20 minutes, with acceleration set at 9 and brake set at 0 so as not to disturb the 
pellet.  The resulting preparation separated the blood into layers allowing the PBMC 
layer to be isolated using a Pasteur pipette.  Following isolation of this layer, PBS 
was then added to a total of 50mL, and the preparation was centrifuged a further 3 
times for 5 minutes each, re-suspending the resulting pellet in 50mL PBS following 
each centrifugation.  Centrifuge settings were set at 2200rpm, 1100rpm and 1500rpm 
respectively for successive centrifugation runs to separate the pellet based on 
density.  The final preparation was re-suspended in ice-cold MACS (magnetic-
activated cell sorting) buffer following a cell count using a haemocytometer, to 
achieve around 50million PBMCs per mL.  MACS buffer was made up of the 
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following: 1.25g bovine serum albumin (BSA; Thermo Fisher Scientific), 1mL 
Ethylenediaminetetraacetic acid (EDTA; Amresco) and PBS (Gibco, Life 
Technologies) to a total of 250mL, and stored on ice until required. 
 
3.1.3 Isolation of CD14+ monocytes 
 
CD14+ monocytes were isolated from PBMC using the EasySep Monocyte 
Isolation Kit (Stem Cell Technologies) as per manufacturer’s instructions.  The 
principle behind immunomagnetic negative selection involved labelling unwanted 
cells with antibody complexes and magnetic particles which were separated from the 
cells of interest using an EasySep magnet.  Labelled unwanted cells were stuck to 
the side of the tube whilst cells of interest were collected by pouring into a fresh tube.  
1mL of PBMC re-suspended at 50 million cells per mL was aliquoted into a fresh tube 
and 50µL Monocyte Isolation Cocktail was added and incubated for 5 minutes at 
room temperature.  50µL D-magnetic particles was then added and incubated for 5 
minutes at room temperature.  The preparation was made up to 10mL with MACS 
buffer and placed in the EasySep magnet for 5 minutes.  The preparation was swiftly 
tipped into a fresh 15ml tube in one smooth motion with the old tube still in the 
magnet, leaving isolated CD14+ cells in the new tube.  The yield of CD14+ 
monocytes achieved from around 500 million PBMC preparations was around 50 
million. The resulting monocytes were transferred to a new tube, and PBS added up 
to 15mL.  Following centrifugation at 1500rpm for 5 minutes, the pellet was re-
suspended in Roswell Park Memorial Institute (RPMI) 1640 Medium (Gibco, Life 
Technologies) supplemented with 5% L-glutamine (Sigma Aldrich) and 10% foetal 
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bovine serum (FBS; Biosera) to achieve 2 million CD14+ monocytes per mL.  These 
cells were processed immediately for purity analysis by flow cytometry, or seeded 
into cell culture plates and differentiated into dendritic cells (DC) for in vitro analyses.     
 
3.1.4 Induction of monocyte-derived DC phenotypes    
 
To study the effects of 1,25(OH)₂D3 on DC phenotype and miRNA expression, 
a model system for DC differentiation was devised (Figure 3.3).  CD14+ monocytes 
derived in 3.1.3 were differentiated for 5 days with granulocyte macrophage-
stimulating colony factor (GM-CSF; 800U/mL, Berlex Laboratories) and Interleukin-4 
(IL-4; 400U/mL), in the presence or absence of 10nM 1,25(OH)₂D3 (Enzo Life 
Sciences; diluted in RPMI 1640 medium from 50µg/mL stock), at 37ᵒC and 5% CO₂.  
Fresh medium supplemented with GM-CSF and IL-4 was added on day 2 and day 5 
of culture.  Immature DC (iDC) were matured on day 6 with 1µg/mL 
Lipopolysaccharide from E. coli (LPS; Sigma Aldrich) in the presence and absence of 
1,25(OH)₂D3 (10nM), and incubated for a further 24 hours.  This gave rise to 6 
distinct DC populations, which were harvested at day 7 of culture, for downstream 










































Figure 3.3. Induction of variable DC phenotypes with lipopolysaccharide (LPS) and 
1,25(OH)₂D3 (1,25D) 
itolDC – immature tolerogenic dendritic cell with 1,25D; mtolDC – mature tolerogenic 
dendritic cell with 1,25D; iDC – immature dendritic cell; mDC – mature dendritic cell; 
iDC+1,25D – immature dendritic cell with 1,25D; mDC+1,25D – mature dendritic cell with 
1,25D.  Monocytes were derived from whole blood leukocyte cones from healthy donors 
(n = 6).   
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3.1.5 Isolation of naïve CD4+ CD25- T cells 
 
Naïve CD4+ CD25- T cells were also isolated from PBMC using the EasySep 
Human CD4+ T cell Enrichment Kit (Stem Cell Technologies) as per manufacturer’s 
directions.  The principle of the isolation process was based firstly on the addition of 
CD4+ enrichment cocktail to the PBMC to enrich the CD4+ population and maximise 
yield, followed by the addition of CD25 magnetic particles for the negative selection 
of CD25+ cells.  The yield of T cells from 500 million PBMC was around 75 million. 
The resulting CD4+ CD25- T cells were centrifuged at 1500rpm for 5 minutes, and 
the pellet was re-suspended in 1mL CellGro GMP DC Medium (CellGenix), to 
achieve 1 million T cells per mL.  T cells were either processed for purity analysis by 
flow cytometry or seeded in cell culture plates for in vitro analysis of cell phenotype 
and miRNA expression.   
 
3.1.6 Naïve CD4+ T cell activation 
 
18.75µL anti-CD3 (1:200 dilution from 1mg/mL stock) and 37.5µL anti-CD28 
(1:100 dilution from 0.5mg/mL stock) plate-coating antibody was added to 3.75mL 
PBS.  250µL of this antibody cocktail was plated per well in a 24-well culture plate, 
and incubated at 37ᵒC for 2 hours to coat the wells.  After 2 hours residual, non-
coated antibodies were removed by two washes; first in 500µL PBS then in 300µL 
serum free media.  To activate T cells with an inflammatory phenotype, a Th17 
cytokine cocktail was also added to the wells pre-coated with anti-CD3 and anti-
CD28.  The Th17 cytokine cocktail was made up in the following concentrations and 
volumes: 0.65µL IL-2 (1:10000 dilution); 1.3µL transforming growth factor β (TGF-β) 
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(1:5000); 2.6µL IL-1β (1:2500); 13µL IL-6 (1:500) and 6.5µL IL-23 (1:1000), to make 
a total of 6.5mL in serum free media.  500µL of cocktail was added per well, followed 
by 500µL of CD4+ T cells obtained from 3.1.5.  The resulting CD4+ T cell culture was 
incubated at 37ᵒC for 20 hours to allow for T cell activation. 
 
3.1.7 T cell 1,25(OH)₂D3 time-course study  
 
Following 20 hours incubation with the Th17 cytokine cocktail, the resulting 
activated CD4+ T cells were treated with either 1,25(OH)₂D3 (10nM) or vehicle (0.1% 
ethanol).  The T cells were then harvested after 0hr, 2hrs, 10hrs, 24hrs, 48hrs or 
72hrs of treatment with 1,25(OH)₂D3 or vehicle.  Unstimulated (no anti-CD3/CD28 or 
Th17 cocktail) naïve CD4+ T cells were also harvested at the 0 hour time point as an 
additional control cell population.  All harvested cells were transferred to 1.5mL 
Eppendorf tubes (Axygen), centrifuged at 1500rpm for 5 minutes, and the 
supernatant discarded.  Cell pellets were re-suspended in 100µL RNALater 
(Invitrogen) and transferred to a -80°C freezer for RNA isolation at a later date.  A 
















Figure 3.4. Induction of CD4+ CD25- T cells with cytokine cocktail and 1,25(OH)₂D3 
(1,25D) 
T cell unstim – unstimulated naïve CD4+ CD25- T cell; T cell stim – CD4+ T cell activated 
with Th17 cytokine cocktail; T cell UT – untreated activated CD4+ T cell (vehicle); T cell 
+1,25D – activated CD4+ T cell+1,25D (10nM).  CD4+ CD25- T cells were isolated from 
PBMC derived from whole blood leukocyte cones of healthy donors (n = 4).  Anti-CD3 and 
anti-CD28 antibodies were coated onto an empty culture plate for 2 hours at 37ᴼC, prior to 
addition of T cells and cytokines for stimulation.  Th17 cytokine cocktail was added to 
promote CD4+ T cell differentiation into a pro-inflammatory Th17 phenotype.  1,25D was 
added at a final concentration of 10nM per well.  T cells were harvested at the following 




3.2 Flow cytometry 
 
Flow cytometry to detect surface and intracellular antigens was performed on 
all DC and T cell populations.  Approximately 50,000 cells were used from each 
sample for flow cytometry processing.   Cells in culture were transferred directly to 
5mL flow cytometry tubes (Axygen, UK) and washed once with 2mL PBS.  Culture 
plates were wrapped in foil and incubated on ice shortly prior to transferring to flow 
cytometry tubes, to allow the cells to detach from the plate.  Unless otherwise stated, 
all tubes were washed following staining, in 2mL PBS and centrifuged at 1500rpm for 
5 minutes.  Following each centrifugation, the wash solution was discarded by 
carefully tipping the tubes in one rapid motion, and any remaining liquid was dabbed 
onto paper towels.    All washing and staining stages were carried out in the absence 
of light.  Stained cells were stored at 4°C wrapped in foil before running on a 
DakoCyAn FACS Machine (Beckman Coulter, High Wycombe, UK).   
 A full list of antibodies, cytokines, volumes used and product numbers is shown 
in Table 3.1.  Rat IgG antibodies conjugated with matching fluorophores were used 























Table 3.1. List of antibodies for flow cytometry 
Flow cytometry antibodies, volumes used and product codes.  All antibodies were purchased 
from BD Pharmingen unless otherwise stated.  Fluorophores used were FITC, Fluorescein 
isothiocyanate conjugate; PE, Phycoerythrin; PerCP, Peridinin-chlorophyll-protein Complex 




3.2.1 DC and T cell surface antigen staining 
 
Approximately 50,000 cells were transferred directly from culture plates into 
flow cytometry tubes, washed once with PBS and centrifuged at 1500rpm for 5 
minutes.  After removing the supernatant, each sample was re-suspended by gentle 
vortex in 100µL LIVE/DEAD Fixable Near-IR Dead Cell Stain (1µL stock in 1mL PBS; 
Life Technologies) to stain for dead cells.  Samples were incubated in the dark on ice 
for 20 minutes, and then washed with PBS and the supernatant discarded.  
Fluorescent cell surface staining antibodies were added to the sample, to a total of 
100µL per sample made up with PBS (for antibody volumes used see Table 3.1).  
Following 30 minutes incubation on ice, samples were washed again and the 
resulting pellet was re-suspended in 200µL PBS for immediate flow cytometry 
analysis, or fixed as below for subsequent analysis at a later date.   
 
3.2.2 Cell fixation with Paraformaldehyde (PFA) 
 
Cells were re-suspended in 400µL 4% paraformaldehyde (PFA; diluted in 
PBS) for analysis at a later date, and incubated in the dark for 10 minutes at room 
temperature.  Following a PBS wash, the cell pellet was re-suspended in 200µL PBS 
and kept at 4°C until analysis.  Samples were kept for no more than 24 hours to 





3.2.3 CD4+ T cell intracellular staining of CTLA-4 expression (using the 
Saponin method) 
 
CD4+ CD25- T cells were stimulated for 5 hours with phorbol myristate 
acetate (PMA) (50ng/mL, Sigma Aldrich) and ionomycin (1µM, Sigma Aldrich) to 
mimic T cell activation by CD3 and CD28 and induce intracellular CTLA-4 
expression.  After 1 hour, Brefeldin A (5µg/mL, Sigma Aldrich) was added to block 
protein secretion.  Cells were incubated at 37°C for a further 4 hours.    Cells were 
transferred to 5mL tubes, washed in PBS, and dead cells stained with 100µL 
LIVE/DEAD Fixable Near-IR Dead Cell Stain.  Following 20 minutes incubation on 
ice, samples were washed once in PBS, then fixed in 400µL 3% paraformaldehyde 
(PFA) and incubated at room temperature for 10 minutes.  Samples were then 
washed with PBS and the resulting pellet was processed for permeabilisation.  To 
permeabilise cells, samples were washed in 1mL 0.1% Saponin (diluted from stock 
concentration of 5%) to permeabilise the cells.  Supernatant was discarded and cells 
were re-suspended in 50µL normal goat serum prepared in 0.1% Saponin for 30 
minutes to block background signals.  Staining antibodies were then added to 
samples for 30 minutes, followed by two washes with PBS.  The samples were re-
suspended in 200µL PBS for FACS analysis of intracellular CTLA-4 expression.   
 
3.2.4 CD4+ T cell intracellular staining of FoxP3 expression (using the 
eBioscience FoxP3 method) 
 
CD4+ CD25- T cells were washed once in PBS and the supernatant was 
discarded.  The pellet was re-suspended in 500µL eBioscience fix buffer (prepared 
as 1 part fixation/permeabilisation concentrate: 3 parts fixation/permeabilisation 
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diluent) to fix the cells.  Cells were incubated at 4ᵒC for 45 minutes then washed with 
PBS.  Following the PBS wash, cells were washed with 1mL 1Xpermeabilisation 
buffer (prepared as 1 part 10X permeabilisation buffer stock: 9 parts PBS).  All 
buffers were made up from fresh stock and used immediately.  Staining antibodies 
were added and samples were incubated at 4°C for 45 minutes. A wash in diluted 
permeabilisation buffer followed by a wash in PBS was then performed, and the final 
pellet was re-suspended in 200µL PBS for flow cytometry.       
      
3.3 DC and T cell gene expression analysis 
 
3.3.1 RNA isolation   
 
Each stage of RNA isolation and centrifugation was carried out at room 
temperate (18°C) unless otherwise stated.  All surfaces and equipment were wiped 
down with RNAse Zap (Invitrogen) and 100% ethanol prior to RNA isolation to 
minimise degradation of sample material by RNAses. 
To generate RNA for downstream mRNA analysis, RNA isolation was carried 
out using TRIzol Reagent (Thermo Fisher) following manufacturer’s protocol for 
human samples, consisting of cell lysis stage, RNA precipitation stage, RNA wash 
stage and solubilisation stage.  Cell lysis stage: 1 million cells per culture well were 
transferred into 1.5mL Eppendorf tubes and centrifuged for 5 minutes at 1500rpm to 
pellet the cells.  The media was discarded and 750µL TRIzol was added to lyse the 
cells, pipetting up and down to homogenise the cells.  After 5 minutes incubation, 
100µL chloroform was added per sample and incubated for a further 5 minutes.  
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Samples were centrifuged at 10,000rpm for 15 minutes at 4°C.  The upper aqueous 
phase containing RNA was transferred to fresh tubes, being careful not to disturb the 
lower phase.  RNA precipitation stage: 300µL isopropanol was added per sample 
and incubated for 10 minutes.  RNA was precipitated by centrifugation at 10,000rpm 
for 10 minutes at 4°C.  RNA wash stage: supernatant was discarded and the pellet 
containing total RNA was re-suspended in 750µL 75% ethanol.  Samples were 
centrifuged at 7500rpm for 5 minutes at 4°C.  Supernatant was discarded and the 
pellet was left to air-dry for 10 minutes.  Solubilisation stage: the RNA pellet was re-
suspended in 50µL RNAse-free water, incubated at 60°C for 10 minutes, and stored 
at -80°C for future use.     
To generate RNA for downstream miRNA analysis, RNA was isolated from 
cultured cells using the mirVana miRNA Isolation Kit (Invitrogen), as per 
manufacturer’s instructions to preserve miRNA recovery (following the Organic 
Extraction protocol).  Cell culture plates were incubated briefly on ice to allow cells to 
detach from the plate.  Cells were harvested directly from the plate by repeated 
pipetting and transferred to 1.5mL Eppendorf tubes (Axygen).  To maximise recovery 
of material, the wells were also washed with ice-cold PBS and contents were 
transferred into the same tubes, which were then centrifuged at 2000rpm for 5 
minutes.  The resulting cell pellets were either re-suspended in 100µL RNALater and 
stored at -20°C, or underwent immediate processing for RNA isolation.  Around 
500,000 cells were harvested from each well for RNA isolation.  The volume of Lysis 
Buffer was adjusted depending on cell number, with the lower recommended volume 
used for fewer cell numbers.  For 500,000 cells, 400µL of Lysis Buffer was used to 
lyse the cells by vigorous pipetting.  After adding Acid-Phenol:chloroform to aid the 
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removal of DNA and vortexing for 60 seconds, cells were centrifuged at 10,000rpm 
for 10 minutes instead of 5 minutes as stated in the protocol, as it was found 5 
minutes was insufficient for a defined aqueous layer to form.  Following 
centrifugation, 360µL of the aqueous layer was aspirated and transferred to a new 
collection tube.  Following the wash stages, filter cartridges were transferred into new 
collection Eppendorf tubes and 50µL pre-heated elution solution was pipetted onto 
the filter.  Eluate was collected from the cartridges and 1µL of RNAse inhibitor 
(Invitrogen) added to each sample to minimise RNA degradation over time. All RNA 
concentrations (ng/µL) and purities were measured on a NanoDrop 2000 
Spectrophotometer (Thermo Fisher) and their values noted for later calculations.  
The ratio of absorbance at 260nm and 280nm was used to assess the purity of RNA, 
with values of ~2.0 considered pure for RNA.  If the 260/280 ratio was below 1.8, this 
indicated the presence of proteins that absorb strongly at 280nm.  The process of 
RNA extraction was repeated for these samples, and all RNA was stored at -80°C.            
         
3.3.2 Reverse transcription  
 
Reverse transcription of isolated RNA to synthesise cDNA was performed 
using the miScript II RT Kit (Qiagen) as per manufacturer’s instructions.  Reverse 
transcription was performed in 8-strip capped PCR tubes (Life Technologies), and 
prepared on ice to ensure enzymes did not denature.  The concentration of template 
RNA was adjusted to 400ng/µL for each sample by calculation, and varying volumes 
of RNAse free water was added to make a total volume of 12µL per reaction tube.  A 
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master mix was then prepared, ensuring 10% excess was made up.  Each reaction 
contained the following master mix reagents: 
4µL 5x miScript HiFlex Buffer  
2µL 10x miScript Nucleics mix  
2µL miScript Reverse Transcriptase mix  
8µL of master mix was pipetted into each reaction already containing 
400ng/µL RNA, to make a total of 20µL per reaction.  The samples were spun briefly 
in a mini centrifuge to evenly mix all the reagents.  cDNA was synthesised using a 
ThermoCycler on the following settings: 37°C for 60 minutes, 95°C for 5 minutes to 
deactivate the transcriptase, followed by a 4°C hold.  Stock cDNA was diluted 1:3 
with RNAse free water (Applied Biosystems) prior to qRT-PCR, and stored at -20°C.  
40µL RNAse free water was added to each 20µL cDNA reaction.      
 
3.3.3 qRT-PCR analysis of mRNA expression  
 
All qRT-PCR reactions were performed with 10µL reaction volumes on 96-well 
semi-skirted PCR plates (Applied Biosystems) unless otherwise stated.  All reagents 
were thawed on ice in the dark due to the light sensitivity of SYBR Green in the 
master mix, and plates were prepared on ice.  A clear plastic cover plate (Applied 
Biosystems) was placed over the prepared plate and edges firmly sealed.  A master 
mix was prepared for each target gene, ensuring there was 10% excess made up.  
Each 10µL qPCR reaction was made up of the following components:  
5µL 2x TaqMan Universal PCR Master Mix (Applied Biosystems) 
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1µL RNAse free water (Applied Biosystems) 
2µL primer assay (Applied Biosystems) 
2µL diluted cDNA  
Prior to running the qPCR, the plate was centrifuged at 1200rpm for 2 minutes 
to ensure all reagents were evenly distributed in each well.  Plates were run on an 
ABI 7500 qPCR machine (Applied Biosystems) using the Standard TaqMan Protocol 
for Quantitative Ct, defined as the cycle number required for the fluorescent signal to 
cross the threshold and exceed background level.  Each run took approximately 90 
minutes.  18S rRNA (Applied Biosystems) was used as the endogenous 
housekeeping gene.  Delta Ct (ΔCt) values were obtained and analysed.  Initial Ct 
values for each mRNA transcript were converted to ΔCt using 18S rRNA ΔCt values. 
Data in results are shown as raw ΔCt values rather than fold-change in gene 
expression.  
For candidate qPCR data, target Ct (threshold cycle) values were obtained as 
the cycle number at which the amplification curve crossed a threshold line 
(automatically calculated).  This value is the relative abundance of the target being 
measured in the sample.   Samples were run in duplicate, and the mean Ct value 
used for subsequent calculations.  Target Ct was normalised against the 
housekeeping Ct to give ΔCt; the standard value used to show relative gene 





3.4 DC and T cell candidate miRNA expression analysis 
 
Preliminary studies on miRNA expression were performed following analysis 
of mRNA expression in DC and T cell populations.  RNA isolation and reverse 
transcription was performed as described in 3.3.1 and 3.3.2.  7 candidate miRNAs 
were chosen due to reported associations with inflammation.  qPCR was performed 
using the miScript SYBR Green PCR Kit (Qiagen).  A master mix was prepared for 
each target, ensuring there was 10% excess made up.  Each 10µL qPCR reaction 
was made up of the following components:  
1µL 10x miScript Universal Primer 
1µL miScript primer assay (Qiagen) 
5µL 2x QuantiTect SYBR Green PCR Master Mix  
1µL RNAse free water (Applied Biosystems) 
2µL diluted cDNA  
qPCR plates were run on an ABI 7500 qPCR machine (Applied Biosystems) 
using the SYBR Green Protocol for Quantitative Ct.  Cycling stage conditions were 
set as per the Qiagen miScript Kit Handbook recommendations: 95°C for 15 minutes 
initially to activate HotStarTaq DNA Polymerase, then 40 cycles of 94°C for 15 
seconds, 55°C for 30 seconds, 70°C for 34 seconds.  The run ended with a melt 
curve stage pre-determined by the machine protocol.  Each run took approximately 
140 minutes.  RNU-6B was used as the endogenous housekeeping gene.  A list of 
















3.5 MiScript HC qPCR array analysis of miRNA expression  
To provide a comprehensive unbiased analysis of miRNA expression in DC and T  
 
3.5 MiScript HC qPCR array analysis of miRNA expression  
To provide a comprehensive unbiased analysis of miRNA expression in DC 
and T cells, PCR array analyses were carried out. MiScript HC miRNA PCR Array 
plates (Qiagen, Manchester, UK) were used, with each plate containing 372 primers 
and probes for human miRNAs most closely linked to inflammation, as well as 12 
endogenous control primers.  One PCR array plate was used to profile miRNA 
expression for each cell treatment. For studies of DC miRNAs, n=6 separate donor 
replicates were used, each incorporating 4 cell treatments. For T cell studies, n=4 
Table 3.2. List of mRNA and miRNA probe  and primers 
List of gene and candidate miRNA primers for qPCR, reporter assay and assay ID. 
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separate donor replicates were used for 1,25(OH)₂D3 and vehicle treated cells for 24 
hour and 72 hour treatment periods.  
 
3.5.1 Reverse transcription for miRNA PCR array 
 
Reverse transcription to synthesise cDNA for the PCR array analyses was 
performed using RNA isolated in 3.3.1, in conjunction with the miScript RT II Kit 
(Qiagen) as described below.  Reverse transcription was performed in 8-strip capped 
PCR tubes, and prepared on ice to ensure enzymes did not denature.  The 
concentration of template RNA was adjusted to 100ng/µL for each sample by 
calculation from values obtained with the NanoDrop 2000 Spectrophotometer 
(Thermo Fisher), and varying volumes of RNAse free water was added to make a 
total volume of 6µL per reaction tube.  The master mix was then prepared, ensuring 
10% excess.  Each reaction contained: 
2µL 5x miScript HiSpec Buffer  
1µL 10x miScript Nucleics mix  
1µL miScript Reverse Transcriptase mix  
4µL of master mix was pipetted into each reaction already containing 
100ng/µL RNA, to make a total of 10µL per reaction.  The samples were spun briefly 
in a mini centrifuge to mix all the reagents.  cDNA was synthesised using a Thermo 
Cycler on the following settings: 37°C for 60 minutes, 95°C for 5 minutes to 
deactivate the transcriptase enzyme, followed by a 4°C hold.   
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Prior to pre-amplification of the cDNA to increase the quantity of cDNA, 10µL stock 
cDNA was diluted with 40µL RNAse free water.  Pre-amplification was performed 
immediately afterwards.    
 
3.5.2 Pre-amplification of cDNA for miRNA array  
 
cDNA generated in 3.5.1 was processed for pre-amplification to increase the 
quantity of specific cDNA targets for downstream gene expression analysis, using the 
miScript PreAMP PCR Kit (Qiagen, UK).   5µL of 20-fold diluted cDNA was used per 
reaction as suggested by the manufacturers’ protocol.  The master mix was prepared 
at room temperature, mixed gently then stored on ice until use.  Each reaction 
contained: 
5µL 5x miScript PreAMP Buffer  
2µL HotStarTaq DNA Polymerase  
5µL miScript PreAMP Primer Mix  
7µL RNAse free water  
1µL miScript PreAMP Universal Primer  
20µL of master mix was pipetted into each reaction tube, and 5µL diluted 
template cDNA added to make a total of 25µL.  The samples were spun briefly in a 
mini centrifuge to mix all the reagents.  cDNA was pre-amplified using a Thermo 
Cycler programmed according to the 384-plex pre-amplification reaction setting:  
1) Initial activation step (to activate HotStarTaq Polymerase): 95°C for 15 minutes   
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2) 3-step cycling (denaturation, annealing, extension): 94°C for 30 seconds, 55°C for 
60 seconds, and 70°C for 60 seconds (repeated for 2 cycles). 
3) 2-step cycling (denaturation, annealing/extension): 94°C for 30 seconds, 60°C for 
3 minutes (repeated for 10 cycles).   
After the run ended, pre-amplified cDNA was diluted appropriately for use in 
downstream miScript HC arrays.  A 20-fold dilution of 25µL pre-amplified cDNA in 
475µL RNAse free water was performed as suggested in the protocol.  
 
3.5.3 qPCR of miScript HC miRNA qPCR arrays 
All miScript HC qPCR miRNA array plates were run on a 7900HT Fast Real-
Time PCR machine (Applied Biosystems) using the SYBR Green Protocol for 
Quantitative Ct.  Cycling stage conditions were set as per the miScript HC PCR Array 
Handbook recommendations: 95°C for 15 minutes initially to activate HotStarTaq, 
then 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds, 70°C for 30 seconds.  
The run ended with a 4°C holding stage.    
Pre-amplified and diluted cDNA generated in 3.5.2 was used for mature 
miRNA expression profiling.  All individual components of the reaction were thawed 
at room temperature and mixed gently.  A reaction mix was prepared as below, 
making around 15% excess: 
2255µL 2x QuantiTect SYBR Green PCR Master Mix  
451µL 10x miScript Universal Primer 
1694µL RNAse free water 
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110µL diluted template cDNA 
Reagents were mixed gently but thoroughly, and transferred into an RT₂ PCR 
Array Loading Reservoir (Qiagen).  10µL reaction mix was added into each well of 
the miScript PCR Array plate using a multichannel pipette.  The plate was sealed and 
centrifuged at 1000rpm for 2 minutes at room temperature.  The 7900HT Fast Real-
Time PCR (Applied Biosystems) was programmed as follows, as suggested by the 
miScript HC PCR Array Handbook (Qiagen): 
1) PCR initial activation step: 95°C for 15 minutes 
2) 3-step cycling (Denaturation, Annealing, Extension): 94°C for 15 seconds, 55°C for 
30 seconds, and 70°C for 30 seconds (repeated for 40 cycles).  The full list of 372 






Table 3.3.1. miScript miRNA PCR Array Human miRBase Profiler HC plate layout 
Diagram shows array plate layout of 372 miRNAs closely related to inflammation, and control 
wells consisting of C. elegans miR-39 endogenous normalisation control, snRNA PCR 
normalisation controls, reverse transcription performance control and PCR performance 
positive controls.  Image sourced from the miScript miRNA PCR Array Handbook (Qiagen, 
Manchester, UK). 




Well miRNA Well miRNA Well miRNA Well miRNA
A01 hsa-let-7a-5p C01 hsa-miR-132-3p E01 hsa-miR-181d-5p G01 hsa-miR-205-3p
A02 hsa-let-7b-5p C02 hsa-miR-132-5p E02 hsa-miR-182-5p G02 hsa-miR-206
A03 hsa-let-7c-5p C03 hsa-miR-1324 E03 hsa-miR-182-3p G03 hsa-miR-208a-3p
A04 hsa-let-7d-5p C04 hsa-miR-133a-3p E04 hsa-miR-183-5p G04 hsa-miR-208b-3p
A05 hsa-let-7d-3p C05 hsa-miR-133b E05 hsa-miR-183-3p G05 hsa-miR-20a-5p
A06 hsa-let-7e-5p C06 hsa-miR-134-5p E06 hsa-miR-184 G06 hsa-miR-20a-3p
A07 hsa-let-7f-5p C07 hsa-miR-135a-5p E07 hsa-miR-185-5p G07 hsa-miR-20b-5p
A08 hsa-let-7g-5p C08 hsa-miR-135b-5p E08 hsa-miR-186-5p G08 hsa-miR-20b-3p
A09 hsa-let-7g-3p C09 hsa-miR-136-5p E09 hsa-miR-186-3p G09 hsa-miR-21-5p
A10 hsa-let-7i-5p C10 hsa-miR-137 E10 hsa-miR-187-3p G10 hsa-miR-21-3p
A11 hsa-miR-1-3p C11 hsa-miR-138-5p E11 hsa-miR-187-5p G11 hsa-miR-210-3p
A12 hsa-miR-100-5p C12 hsa-miR-139-3p E12 hsa-miR-18a-5p G12 hsa-miR-211-5p
A13 hsa-miR-101-3p C13 hsa-miR-139-5p E13 hsa-miR-18a-3p G13 hsa-miR-212-3p
A14 hsa-miR-101-5p C14 hsa-miR-140-3p E14 hsa-miR-18b-5p G14 hsa-miR-214-3p
A15 hsa-miR-103a-3p C15 hsa-miR-140-5p E15 hsa-miR-18b-3p G15 hsa-miR-215-5p
A16 hsa-miR-105-5p C16 hsa-miR-141-3p E16 hsa-miR-190a-5p G16 hsa-miR-216a-5p
A17 hsa-miR-106a-3p C17 hsa-miR-142-3p E17 hsa-miR-1908-5p G17 hsa-miR-217
A18 hsa-miR-106b-5p C18 hsa-miR-142-5p E18 hsa-miR-191-5p G18 hsa-miR-218-5p
A19 hsa-miR-106b-3p C19 hsa-miR-143-3p E19 hsa-miR-191-3p G19 hsa-miR-218-1-3p
A20 hsa-miR-107 C20 hsa-miR-143-5p E20 hsa-miR-1914-3p G20 hsa-miR-219a-5p
A21 hsa-miR-10a-5p C21 hsa-miR-144-3p E21 hsa-miR-192-5p G21 hsa-miR-22-3p
A22 hsa-miR-10a-3p C22 hsa-miR-144-5p E22 hsa-miR-192-3p G22 hsa-miR-22-5p
A23 hsa-miR-10b-5p C23 hsa-miR-145-5p E23 hsa-miR-193a-3p G23 hsa-miR-221-3p
A24 hsa-miR-10b-3p C24 hsa-miR-145-3p E24 hsa-miR-193a-5p G24 hsa-miR-221-5p
B01 hsa-miR-1180-3p D01 hsa-miR-146a-5p F01 hsa-miR-193b-3p H01 hsa-miR-222-3p
B02 hsa-miR-1207-5p D02 hsa-miR-146b-5p F02 hsa-miR-193b-5p H02 hsa-miR-222-5p
B03 hsa-miR-122-5p D03 hsa-miR-147a F03 hsa-miR-194-5p H03 hsa-miR-223-3p
B04 hsa-miR-122-3p D04 hsa-miR-148a-3p F04 hsa-miR-195-5p H04 hsa-miR-223-5p
B05 hsa-miR-1224-3p D05 hsa-miR-148b-3p F05 hsa-miR-195-3p H05 hsa-miR-224-5p
B06 hsa-miR-1224-5p D06 hsa-miR-149-5p F06 hsa-miR-196a-5p H06 hsa-miR-224-3p
B07 hsa-miR-124-3p D07 hsa-miR-150-5p F07 hsa-miR-196a-3p H07 hsa-miR-23a-3p
B08 hsa-miR-124-5p D08 hsa-miR-151a-3p F08 hsa-miR-196b-5p H08 hsa-miR-23a-5p
B09 hsa-miR-125a-3p D09 hsa-miR-151a-5p F09 hsa-miR-197-3p H09 hsa-miR-23b-3p
B10 hsa-miR-125a-5p D10 hsa-miR-152-3p F10 hsa-miR-199b-3p H10 hsa-miR-23b-5p
B11 hsa-miR-125b-5p D11 hsa-miR-153-3p F11 hsa-miR-199a-5p H11 hsa-miR-24-3p
B12 hsa-miR-126-3p D12 hsa-miR-154-5p F12 hsa-miR-199b-5p H12 hsa-miR-25-3p
B13 hsa-miR-126-5p D13 hsa-miR-155-5p F13 hsa-miR-19a-3p H13 hsa-miR-25-5p
B14 hsa-miR-1265 D14 hsa-miR-155-3p F14 hsa-miR-19a-5p H14 hsa-miR-26a-5p
B15 hsa-miR-127-3p D15 hsa-miR-15a-5p F15 hsa-miR-19b-3p H15 hsa-miR-26b-5p
B16 hsa-miR-127-5p D16 hsa-miR-15b-5p F16 hsa-miR-200a-3p H16 hsa-miR-27a-3p
B17 hsa-miR-128-3p D17 hsa-miR-15b-3p F17 hsa-miR-200a-5p H17 hsa-miR-27a-5p
B18 hsa-miR-1284 D18 hsa-miR-16-5p F18 hsa-miR-200b-3p H18 hsa-miR-27b-3p
B19 hsa-miR-129-1-3p D19 hsa-miR-17-5p F19 hsa-miR-200c-3p H19 hsa-miR-27b-5p
B20 hsa-miR-1290 D20 hsa-miR-181a-5p F20 hsa-miR-200c-5p H20 hsa-miR-28-3p
B21 hsa-miR-129-2-3p D21 hsa-miR-181a-3p F21 hsa-miR-202-3p H21 hsa-miR-28-5p
B22 hsa-miR-129-5p D22 hsa-miR-181b-5p F22 hsa-miR-203a-3p H22 hsa-miR-296-3p
B23 hsa-miR-130a-3p D23 hsa-miR-181c-5p F23 hsa-miR-204-5p H23 hsa-miR-298












Table 3.3.2. miScript miRNA PCR Array iRNA list 
List of 372 mature miRNAs profiled, plus 8 endogenous controls and 4 quality controls.   
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Well miRNA Well miRNA Well miRNA Well miRNA
I01 hsa-miR-29a-3p K01 hsa-miR-346 M01 hsa-miR-483-5p O01 hsa-miR-605-5p
I02 hsa-miR-29a-5p K02 hsa-miR-34a-5p M02 hsa-miR-484 O02 hsa-miR-606
I03 hsa-miR-29b-3p K03 hsa-miR-34a-3p M03 hsa-miR-485-5p O03 hsa-miR-608
I04 hsa-miR-29b-2-5p K04 hsa-miR-34b-3p M04 hsa-miR-486-3p O04 hsa-miR-622
I05 hsa-miR-29c-3p K05 hsa-miR-34b-5p M05 hsa-miR-486-5p O05 hsa-miR-626
I06 hsa-miR-300 K06 hsa-miR-34c-3p M06 hsa-miR-488-3p O06 hsa-miR-639
I07 hsa-miR-301a-3p K07 hsa-miR-34c-5p M07 hsa-miR-489-3p O07 hsa-miR-643
I08 hsa-miR-302a-3p K08 hsa-miR-361-5p M08 hsa-miR-490-3p O08 hsa-miR-649
I09 hsa-miR-302a-5p K09 hsa-miR-363-3p M09 hsa-miR-491-5p O09 hsa-miR-652-3p
I10 hsa-miR-302b-3p K10 hsa-miR-363-5p M10 hsa-miR-493-3p O10 hsa-miR-661
I11 hsa-miR-302b-5p K11 hsa-miR-365b-3p M11 hsa-miR-495-3p O11 hsa-miR-7-5p
I12 hsa-miR-302c-3p K12 hsa-miR-370-3p M12 hsa-miR-497-5p O12 hsa-miR-708-5p
I13 hsa-miR-30a-5p K13 hsa-miR-372-3p M13 hsa-miR-498 O13 hsa-miR-708-3p
I14 hsa-miR-30b-5p K14 hsa-miR-373-3p M14 hsa-miR-499a-3p O14 hsa-miR-720
I15 hsa-miR-30c-5p K15 hsa-miR-373-5p M15 hsa-miR-499a-5p O15 hsa-miR-744-5p
I16 hsa-miR-30c-1-3p K16 hsa-miR-374a-5p M16 hsa-miR-500a-5p O16 hsa-miR-765
I17 hsa-miR-30d-5p K17 hsa-miR-374c-5p M17 hsa-miR-504-5p O17 hsa-miR-770-5p
I18 hsa-miR-30d-3p K18 hsa-miR-375 M18 hsa-miR-505-3p O18 hsa-miR-802
I19 hsa-miR-30e-5p K19 hsa-miR-376a-3p M19 hsa-miR-506-3p O19 hsa-miR-885-5p
I20 hsa-miR-30e-3p K20 hsa-miR-376b-3p M20 hsa-miR-508-5p O20 hsa-miR-888-5p
I21 hsa-miR-31-5p K21 hsa-miR-376c-3p M21 hsa-miR-509-3p O21 hsa-miR-9-5p
I22 hsa-miR-31-3p K22 hsa-miR-377-3p M22 hsa-miR-511-5p O22 hsa-miR-9-3p
I23 hsa-miR-32-5p K23 hsa-miR-377-5p M23 hsa-miR-512-5p O23 hsa-miR-920
I24 hsa-miR-32-3p K24 hsa-miR-378a-3p M24 hsa-miR-513a-5p O24 hsa-miR-924
J01 hsa-miR-320a L01 hsa-miR-378a-5p N01 hsa-miR-514a-3p P01 hsa-miR-92a-3p
J02 hsa-miR-320b L02 hsa-miR-379-5p N02 hsa-miR-517b-3p P02 hsa-miR-92a-1-5p
J03 hsa-miR-323b-5p L03 hsa-miR-381-3p N03 hsa-miR-518b P03 hsa-miR-92b-3p
J04 hsa-miR-324-3p L04 hsa-miR-382-5p N04 hsa-miR-519d-3p P04 hsa-miR-92b-5p
J05 hsa-miR-324-5p L05 hsa-miR-383-5p N05 hsa-miR-520f-3p P05 hsa-miR-93-5p
J06 hsa-miR-325 L06 hsa-miR-409-3p N06 hsa-miR-520g-3p P06 hsa-miR-93-3p
J07 hsa-miR-326 L07 hsa-miR-410-3p N07 hsa-miR-522-3p P07 hsa-miR-95-3p
J08 hsa-miR-328-3p L08 hsa-miR-411-5p N08 hsa-miR-524-5p P08 hsa-miR-96-5p
J09 hsa-miR-330-3p L09 hsa-miR-421 N09 hsa-miR-532-5p P09 hsa-miR-98-5p
J10 hsa-miR-331-5p L10 hsa-miR-423-3p N10 hsa-miR-539-5p P10 hsa-miR-99a-5p
J11 hsa-miR-335-5p L11 hsa-miR-423-5p N11 hsa-miR-542-3p P11 hsa-miR-99a-3p
J12 hsa-miR-335-3p L12 hsa-miR-424-5p N12 hsa-miR-542-5p P12 hsa-miR-99b-5p
J13 hsa-miR-337-5p L13 hsa-miR-424-3p N13 hsa-miR-549a P13 cel-miR-39-3p
J14 hsa-miR-338-3p L14 hsa-miR-425-5p N14 hsa-miR-551b-3p P14 cel-miR-39-3p
J15 hsa-miR-338-5p L15 hsa-miR-425-3p N15 hsa-miR-567 P15 SNORD61
J16 hsa-miR-339-3p L16 hsa-miR-4258 N16 hsa-miR-570-3p P16 SNORD68
J17 hsa-miR-33a-5p L17 hsa-miR-429 N17 hsa-miR-574-3p P17 SNORD72
J18 hsa-miR-33a-3p L18 hsa-miR-431-5p N18 hsa-miR-575 P18 SNORD95
J19 hsa-miR-33b-5p L19 hsa-miR-432-5p N19 hsa-miR-580-3p P19 SNORD96A
J20 hsa-miR-340-5p L20 hsa-miR-433-3p N20 hsa-miR-581 P20 RNU6-6P
J21 hsa-miR-340-3p L21 hsa-miR-449a N21 hsa-miR-583 P21 miRTC
J22 hsa-miR-342-3p L22 hsa-miR-451a N22 hsa-miR-588 P22 miRTC
J23 hsa-miR-342-5p L23 hsa-miR-454-3p N23 hsa-miR-589-3p P23 PPC




















Table 3.4. Healthy control patient profiles   
Serum from n=23 healthy controls (HC) were used for age-matched disease-free comparison.  Samples were collected in accordance with 
ethics guidelines.  Patients were mixed for age and sex.  N/A refers to missing data.  HDL, high-density lipoprotein; LP(a), lipoprotein(a); GH, 
growth hormone; SHBG, sex hormone binding globulin; IGF-1, insulin-like growth factor-1; FSH, follicle-stimulating hormone; LH, luteinising 






















Table 3.5. RA and ReA patient clinical data   
Data includes age of patient, disease duration, and disease activty markers tender joint 
count out of 28 joints (TJC28); swollen joint count out of 28 joints (SJC28); erythrocyte 
sedimentation rate (ESR); C-reactive protein (CRP).  NSAID=non-steroidal anti-
inflammatory drug.  N/A refers to missing data.   
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3.6 Profiling serum and SF in rheumatoid arthritis 
 
Matched serum and SF samples from n=20 patients with persistent 
rheumatoid arthritis (RA; defined according to fulfilment of the 2010 classification 
criteria for RA) and n=7 patients with resolving post-infective reactive arthritis (ReA) 
were obtained with patient consent according to existing ethical agreements 
(Reference 12/WM/0258). Both RA and ReA patients had arthritis and active 
inflammation at the time of presentation and sample collection in clinic.  RA patients 
continued to have ongoing inflammatory disease whereas ReA patients had a form of 
reactive arthritis that spontaneously resolved.  Patient ages ranged from 18-82yrs.  
Patients were clinically assessed for various disease activity markers; these included 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and the 28 joint 
tender joint count (TJC) and swollen joint count (SJC).  Disease-free age and sex-
matched subjects were used as healthy control (HC) group for serum analyses. 
Healthy control demographics are shown in Table 3.4, and demographics and clinical 
assessments for RA and ReA patients are shown in Table 3.5. Both serum and SF 
samples were used to quantify various vitamin D metabolites, DBP and albumin and 
also to quantify circulating levels of miRNAs.    
 
3.6.1 MicroRNA isolation from serum and SF 
 
Serum and SF miRNA isolation was performed on all matched RA and ReA 
samples using the miRNeasy Serum/Plasma Kit (Qiagen) to maximise miRNA 
recovery. 200µL serum or SF was used as starting material, and RNA extraction was 
carried out following the manufacturer’s protocol.  All steps were performed at room 
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temperature unless otherwise stated.  1mL QIAzol Lysis Reagent was added per 
sample and vortexed to mix.  The sample was incubated for 5 minutes and 3.5µL 
reconstituted miRNeasy Serum/Plasma Spike-In Control (at 1.6x10⁸ copies/µL) was 
added per sample.  200µL chloroform was added and incubated for 5 minutes, 
followed by centrifugation at 10,000rpm for 15 minutes at 4°C.  The aqueous layer 
was transferred to a fresh tube and 800µL 100% ethanol added.  Samples were spun 
by two centrifugations at 8000rpm for 15 seconds using a RNeasy MinElute spin 
column (supplied in kit), followed by 3 washes with wash buffer (supplied) on the 
same centrifuge settings.  All flow-through was discarded following each 
centrifugation step.  14µL RNAse-free water was added to the tube and samples 
were spun at 10,000rpm for 1 minute to elute the RNA.  After the final step, RNA 
eluate contained the spike-in control at 4x10⁷ copies/µL.  RNA was stored at -80°C. 
 
3.6.2 Reverse transcription for circulating miRNAs 
 
Reverse transcription to synthesise cDNA was performed using the miScript II 
RT Kit (Qiagen) as described below.  Reverse transcription was performed in 8-strip 
capped PCR tubes and prepared on ice.  The master mix was prepared, ensuring 
10% excess was made up.  Each reaction contained: 
4µL 5x miScript HiSpec Buffer (miScript II RT Kit, Qiagen) 
2µL 10x miScript Nucleics mix (miScript II RT Kit, Qiagen) 
2µL miScript Reverse Transcriptase mix (miScript II RT Kit, Qiagen) 
10.5µL RNAse free water (Invitrogen) 
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18.5µL of master mix was pipetted into each reaction, and 1.5µL RNA 
(containing Spike-In control) was added to a total of 20µL per reaction.  The samples 
were spun briefly in a mini centrifuge to evenly distribute the reagents.  Samples 
were processed using an ABI GeneAmp PCR System 2700 (Applied Biosystems) on 
the following settings: 37°C for 60 minutes, 95°C for 5 minutes to deactivate the 
transcriptase, followed by a 4°C hold.  Stock cDNA was diluted in 200µL RNAse free 
water, to bring the Spike-In control to 2.7x10⁵ copies/µL.  Samples were stored at -
20°C prior to qRT-PCR. 
 
3.6.3 Quantification of circulating miRNAs by qPCR 
 
For serum and SF miRNAs, qRT-PCR reactions were performed using 25µL 
reaction volumes on 96-well semi-skirted PCR plates (Applied Biosystems).  All 
reagents were thawed on ice in the dark, and plates were prepared at room 
temperature.  A clear plastic cover plate (Applied Biosystems) was placed over the 
prepared plate and edges firmly sealed to minimise contamination of the samples.  
Prior to running the qPCR, the plate was centrifuged at 1200rpm for 2 minutes to 
ensure all reagents were evenly distributed in each well.  96-well plates were run on 
an ABI 7500 Real Time PCR System (Applied Biosystems, serial no. 275000090), 
using the SYBR Green protocol for miRNA targets.  Targets were defined at the plate 
set-up stage, and cycling conditions were set according to manufacturer’s 
recommendations. ΔCt values were obtained and analysed, to determine miRNA 
expression profiles in serum and SF.  Ce_miR_39_1 (Qiagen) was used as the 
endogenous housekeeping gene to calculate ΔCt values. 
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Each 25µL reaction was made up of the following components:  
12.5µL 2x QuantiTect SYBR Green PCR Master Mix (Qiagen) 
2.5µL 10x miScript Universal Primer (Qiagen) 
2.5µL Primer Assay (Qiagen) 
6.5µL RNAse free water (Invitrogen) 
24µL master mix was pipetted for each reaction, and 1µL diluted cDNA was 
then added.  96-well plates were run on an ABI7500 Real-Time PCR Cycler 
programmed on the following settings:  
1) 95°C for 15 minutes (to activate HotStarTaq DNA Polymerase) 
2) 3-step cycling (Denaturation, Annealing, Extension): 94°C for 15 seconds, 55°C for 
30 seconds, 70°C for 34 seconds (fluorescence data collection performed at this 
step) (Repeated for 40 cycles) 
After the run, Raw Ct values were extracted to calculate the mean Ct and ΔCt value 
for each reaction. 
 
3.6.4 Quantification of serum and SF vitamin D metabolites by LC-MS/MS 
 
Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) was used to 
quantify the following vitamin D metabolites in serum and SF; 25(OH)D3, 3-epi-
25(OH)D3, 25(OH)D2, 24,25(OH)₂D3 and 1,25(OH)₂D3 as described previously 
[266-268] with slight modifications as follows: 200µL serum or SF was used as 
starting material for vitamin D analyte expression.  Due to limited sample volumes 
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this was adapted for the current protocol; for sample volumes less than 200µL the 
maximum available volume was used and the rest made up to 200µL with LC-MS 
grade water (Thermo Fisher).  20µL of vitamin D internal standard was then added to 
each sample.  LC-MS grade methanol (Greyhound Chromatography, Merseyside, 
UK), isopropanol (Sigma Aldrich) and LC-MS grade water were then added to 
precipitate the proteins.  The table below summarises the volume of reagents added 






 Calibrant samples Patient samples 
LC-MS grade methanol  30µL 80µL 
Isopropanol  50µL 50µL 
LC-MS grade water 100µL 150µL 
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Internal reference standards for the following vitamin D metabolites were used 
for analysis: 25(OH)D2, 25(OH)D3, 3-epi-25(OH)D3, 24,25(OH)2D3 and 
1,25(OH)2D3 (Sigma Aldrich). Stock solutions were diluted in methanol to prepare 
standard curves with concentrations between 5–100ng/mL.  External vitamin D 
calibrators and quality controls were purchased from Chromsystems (Am Haag, 
Germany).   
Samples were transferred to 96-well SLE plates (Phenomenex, Macclesfield, 
UK) and prepared for analysis by protein precipitation, using isopropanol to remove 
proteins from the sample that may interfere with downstream LC-MS/MS analysis.  
Samples were extracted using a novel supportive liquid-liquid extraction (SLE) 
method instead of liquid-liquid extraction (LLE), to allow for faster sample preparation 
at lower costs without compromising analyte recovery [268].  Samples were 
derivatized to enable the analysis of compounds that otherwise cannot be readily 
monitored, using 4-(2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl)-
1,2,4-triazoline-3,5-dione (DMEQ-TAD) as previously described [269] with the 
following modifications: 30µL 0.1mg/mL DMEQ dissolved in ethyl acetate was added 
twice for each sample, with 30 minutes incubation at room temperature after the first 
addition, and 60 minutes after the second addition.  Samples were eluted each time 
by applying a vacuum (5Hg) until all the solution was eluted.  Afterwards 40µL pure 
ethanol was added to each sample, and samples were dried under nitrogen for 10 
minutes.  Samples were then reconstituted in 125µL 50/50 methanol/water, and 
stored at -80°C until analysis.   
Analysis of serum by LC-MS/MS was performed by Dr C Jenkinson (Institute 
of Metabolism and Systems Research, Birmingham, UK) on a Waters ACQUITY ultra 
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performance liquid chromatography (uPLC) coupled to a Waters Xevo TQ-S mass 
spectrometer (Waters, Manchester, UK). The LC-MS/MS method has been validated 
on US Food and Drug Administration guidelines for analysis of these metabolites as 
previously described [268].  In brief, ionisation was perfomed in electrospray 
ionisation (ESI) mode, with the mass spectrometer operating in positive ion mode.  
Multiple reaction monitoring (MRM) mode was used to quantify vitamin D 
metabolites, with a total run time of 8 minutes per sample.  The capillary voltage was 
3.88KV and desolvation temperature was 500°C.  Chromatography separation was 
perfromed using a Lux Cellulose-3 chiral column (100mm, 2mm, 3µm) at 60°C, and a 
0.2µm inline filter was added to prevent contamination and blockage of the column.  
The mobile phase was made up of methanol/water/0.1% formic acid at a flow rate of 
330µL/min.  Current assay perfomance data for measuring vitamin D metabolites in 
human serum have been established previously [268], and all vitamin D metabolites 
measured in the current analysis were within reference range of previous literature 
[270-272].   
Utilising LC-MS/MS to quantify vitamin D metabolites in RA SF was a novel 
analysis in this field, hence sample preparation comparisons were performed before 
runing on the LC-MS/MS to check the recovery from SF.  Due to the viscosity of SF it 
was a concern that the fibrous components may interfere with recovery.  A normal 
sample was compared with one that had been sonicated to reduce the viscosity, and 
one that had Hyaluronidase enzyme added to break down the fibres.  Sonication did 
not affect internal standard recovery after running on the LC-MS/MS, and the 
hyaluronidase approach was decided against as it was unknown how it would affect 
LC-MS/MS analysis.  Based on the analyte:internal standard ratios obtained from this 
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sample run, the actual measurments did not differ based on the approach, hence it 
was decided that samples would be prepared for LC-MS/MS without prior sonication 
or enzyme additon.        
 
3.6.5 Quantification of DBP and albumin by enzyme-linked immunosorbent 
assay (ELISA) 
 
In serum and SF, DBP and albumin were quantified using a VDBP ELISA kit 
(Immundiagnostik, Germany) and a human serum albumin ELISA kit (Thermo Fisher, 
UK).  In these assays, the plate wells were pre-coated with antibodies against the 
protein of interest.  All reagents supplied were diluted to the appropriate 
concentrations as stated in the manufacturers’ protocols.  For serum and SF 
samples, the suggested dilution was 1:40,000 for quantifying DBP and at least 
1:500,000 for quantifying albumin, although it was found the optimum dilution factor 
for albumin was 1:1,000,000 due to the abundance of albumin in serum.  Samples 
were serially diluted with dilution reagent provided by the kits.  100µL of the final 
dilution was used per well for analysis, following the manufacturers’ protocols.  All 
steps were carried out at room temperature.  
 
3.6.6 DBP and albumin calibrant quality check 
 
DBP and albumin concentrations in serum and SF were quantified by ELISA.  
Internal standards were provided in ELISA kits and were used to calculate accuracy 
of all other sample values.  Known calibrant concentrations were plotted against their 
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optical density (OD) values with interpolation of control lines, to determine the 
accuracy of sample data measurements shown in Figure 3.5. Calibrant 
concentrations were within the normal range after interpolating the control line, 
confirming DBP measurements for test samples were reliable.  Similarly, calibrant 
OD values for albumin were plotted to produce a standard curve used to determine 










The full list of reagents used in this thesis is shown in Table 3.6.     
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Figure 3.5. DBP and albumin ELISA calibration 
ELISA was used to measure vitamin D binding protein (DBP) and albumin 
concentration in serum and SF.  Optical density at 450nm wavelength was plotted 
against known concentration of calibrant.  Interpolation of linear control line (DBP) and 








Table 3.6.1.  Reagents used for molecular biology studies 
Full list of reagents and catalogue numbers for molecular biology studies. 
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Table 3.6.2.  Reagents used for flow cytometry studies 




 Table 3.6.3.  Reagents used for cell culture studies 




3.7 Statistics and calculations 
 
Unless otherwise stated, all data are shown as mean +/- standard deviation 
(SD), and statistical significance defined as p<0.05.  For paired data comparing 2 
treatment groups, normality was first assessed using the D’Agostino-Pearson 
omnibus normality test.  Parametric data was compared using a paired samples 
Student’s t-test.  In the case of non-parametric paired data, Wilcoxon matched-pairs 
signed rank test was performed, calculated as two-tailed test with 95% confidence 
intervals. 
For paired data comparing 3 treatment groups, data was first assessed for 
Gaussian distribution.  All data passed the Gaussian distribution test, and repeated-
measures (RM) one-way ANOVA with the Greenhouse-Geisser sphericity correction 
was performed.  This was then corrected for post-hoc multiple comparisons using 
Kruskal-Wallis testing.     
For paired data with over 3 categories of comparison, paired repeated-
measures (RM) ANOVA was performed, and data was tested for sphericity using the 
Greenhouse-Geisser test.  In the case of sphericity, p-values from the Huynh-Feldt 
correction test were used instead.  The Bonferroni or Tukey method was used for 
post-hoc multiple-comparison testing.  This was to adjust for multiple comparisons 
corrections, to account for erroneous inferences caused by too many parameters in 
different comparisons.   
For any unpaired data comparisons, non-parametric data was assessed using 
the unpaired Kolmogorov-Smirnov test with descriptive statistics. 
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For miRNA qPCR array data, the raw Ct value obtained for each individual 
miRNA was normalised against the mean of 6 endogenous reference genes 
(SNORD61, SNORD68, SNORD72, SNORD95, SNORD96A and RNU6-6P).  Non-
parametric repeated measures (RM) ANOVA was performed across all treatment 
conditions for individual donors, with post-hoc Kruskal-Wallis multiple comparisons 
test performed to assess the significance of each treatment condition compared to all 
other conditions.   
For ELISA assays, absorption was determined immediately after adding acidic 
solution to stop the reaction, on a WALLAC Victor3 1420 Multilabel Counter plate 
reader set at 450nm wavelength.  690nm and 550nm wavelengths were used as 
references for DBP and albumin measurements, respectively.  The 450nm values 
were subtracted from the reference values, and a dose-response graph of optical 
density (OD at 450nm) against standard concentration was generated, producing a 
linear line or standard curve.  Values depending on this line or curve were 
interpolated to derive all other sample values for DBP or Albumin.  All derived values 
were multiplied by the dilution factor to calculate the final concentration of BDP and 
Albumin in serum and SF samples.        
Estimations of free and bioavailable 25(OH)D were performed using 
mathematical algorithms adapted from the original calculations [48] to incorporate Gc 
polymorphic variations in DBP binding affinity and DBP concentration.  Levels of free 
25(OH)D in serum and SF were calculated using this novel extra-cellular steady state 
(eSS) mathematical model [273].   
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Pathway analysis of miRNA gene targets was performed using Cytoscape 
v.6.3.1 in conjunction with publicly available miRNA repository database MiRBase, to 
identify experimentally validated miRNA gene targets.  Using this software, over-
representation was tested for using the hypergeometric test, with further Benjamini 
and Hochberg False Discovery Rate correction.  ClueGo v.2.3.3 gene ontology (GO) 
analysis was then performed as an extension to the Cytoscape software, to identify 
those genes with enriched biological processes.  Results were visualised in gene 
networks and statistical significance of enriched genes in the network was calculated 
by Bonferroni step-down, with only genes showing p<0.05 included in the network.  





Data from flow cytometry was analysed using FlowJo Version 10 (Tree Star, 
Ashland, OR).  Data analyses were performed on GraphPad PRISM Version 6.07 
software (San Diego, CA, USA).  Cytoscape v3.1.6, miRTarBase and ClueGo were 
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4.1.1 Rheumatoid arthritis: diagnosis, prevalence and pathogenesis  
Rheumatoid arthritis (RA) is a systemic inflammatory disease characterised by 
the symmetrical onset of multiple painful swollen joints, often leading to permanent 
joint destruction, loss of mobility and increased risk of mortality [279].  There is 
currently no cure for RA, although many treatments are available that aim to slow 
disease progression and reduce the severity of symptoms.  As with most chronic 
diseases early diagnosis and intervention is vital for the best response to treatment 
[280].        
RA affects 1% of the worldwide population, with an annual prevalence of 2-4 
cases per 10,000 adults [281].  Difficulty in the diagnosis of early RA lies in the 
symptom similarity with other types of inflammatory arthritis, for example presence of 
joint pain, swelling and stiffness (hallmarks of inflammatory arthritis) which can also 
be seen in other conditions such as seronegative spondyloarthropathies and 
connective tissue diseases, and the presence of shared abnormalities on laboratory 
tests such as elevated C-reactive protein (CRP), a systemic non-specific marker of 
inflammation.  However elevated CRP can be helpful when taken in combination with 
other disease markers, and together can be used to classify patients as having RA 
(according to 2010 classification criteria for RA). 
Clinically the diagnosis of RA is defined by the European League Against 
Rheumatism (EULAR) Classification Criteria updated in 2010, which replaced the 
previous criteria established in 1987.  Amongst the 1987 classification criteria are the 
presence of bony erosions shown on patient X-rays; this has since been removed as 
a classification criterion due to their presence only at late stages of the disease, by 
which time aggressive forms of therapy are usually required.  The new set of criteria 
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allows for earlier detection of RA and thus more effective treatment.  The new 
classification criteria are composed of a points-based system with multiple categories 
(Table 4.1), where a score of ≥6 allows patients to be classified as having RA.  
Patients may fulfil these criteria immediately or cumulatively.   
 
  
JOINT DISTRIBUTION (0-5) Score 
1 large joint  0 
2-10 large joints 1 
1-3 small joints  2 
4-10 small joints 3 
>10 joints (at least 1 small joint) 5 
SEROLOGY (0-3)   
Neg. RF and neg. ACPA 0 
Low pos. RF or low pos. ACPA 2 
High pos. RF or high pos. ACPA 3 
SYMPTOM DURATION (0-1)   
<6 weeks 0 
≥6 weeks 1 
ACUTE PHASE REACTANTS (0-1)   
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Table 4.1. The 2010 EULAR Classification Criteria for RA diagnosis   
Table created from criteria defined by the American College of Rheumatology (EULAR).  
Patients are reviewed using a scoring system, with a score of ≥6 indicating RA diagnosis.  
RF, rheumatoid factor; ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate; pos, positive; neg, negative.  
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RA is amongst the most common of the autoimmune rheumatic diseases but 
its pathogenesis and aetiology remains complex and the subject of ongoing study.  
Due to the systemic nature of RA, inflammation is likely to involve a host of immune 
cells of the innate and adaptive systems, including T cells and DC.  In the initial 
stages of disease onset, up-regulated peptide citrullination triggers activation of 
dendritic cells which present foreign antigens to other immune cells [282].  Following 
this, the activation of B cells and subsequent secretion of antibodies promotes further 
immune cell autoreactivity, which is further augmented by the repeated activation of 
innate immune cells leading to loss of tolerance [283]. Persistent inflammation, 
coupled with the activation of bone-resorbing osteoclasts by macrophages, and by 
activated T and B cells expressing RANKL, and synovial cell hyperplasia, leads to 
irreversible cartilage damage in the joint space as well as other secondary conditions 
such as vasculitis [284].  RA synovial fibroblast cells play a key effector role in the 
inflammatory process and pathogenesis of RA [285]; these cells appear to be 
intrinsically active which results in the increased production of matrix 
metalloproteinases (MMPs) that contribute to permanent joint destruction [286].     
Mature DC present in the RA synovial tissue and synovial fluid (SF) may 
mediate the inflammatory process of RA disease.  Studies have shown these cells to 
be potent stimulators of T cells and subsequent inflammatory cytokine production by 
Th1 subsets [287-289].  In turn, cytokines present in the inflamed joint synovium 
further facilities DC maturation leading to chronic inflammation.  In RA, synovial 
tissue is dramatically infiltrated by large numbers of DC which go on to present self-
antigens to autoreactive CD4+ T cells, leading to the subsequent activation of B cells 
and the production of autoantibodies.  DC are thus likely to be key players of 
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autoimmunity in RA, supported by the presence of pro-inflammatory cytokines in the 
SF of RA joints which may stimulate DC activation.  Cells that are induced by DC 
include Th1 and Th17 [290] populations that have been well-implicated in models of 
autoimmune disease.  Activated Th1 cells have been found to preferentially 
accumulate in synovial joints of RA patients [291, 292].  DC are a source of cytokines 
that influence the immune pathway of Th cells.  Amongst these cytokines, DC 
release IL-12 which induces the Th1 pathway and leads to the production of IFN-γ 
[293]; IL-23 can induce the Th17 pathway to release IL-17 [294].  Together these 
cytokines contribute to the active inflammation that is characteristic of RA disease.   
In autoimmunity, an imbalance of pro- versus anti-inflammatory cytokines is 
usually the driving force behind disease-related inflammation.  It is therefore 
important to understand the function of cytokines and their signalling networks in the 
pathogenesis of autoimmune disease.  The interaction between pro-inflammatory 
cytokines plays a pivotal role in the process of RA inflammation, and mainly involves 
the actions of inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IL-17 [295].  
These cytokines activate genes associated with inflammatory responses, leading to 
dysregulation of immune activity and associated tissue damage.  In the context of 
synoviocytes, it has been suggested that RA pathogenesis involves impaired 
synoviocyte programmed cell death (apoptosis), leading to the destruction of articular 
cartilage [296].   
Other studies have shown that the elevated presence of several RA markers 
including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) are 
good early predictors of future RA development [297]; these are also key variables 
within the 2010 ACR/EULAR criteria set for RA classification.  The search for other 
100 
 
RA diagnostic biomarkers has been the focus of more recent research, with the aim 
being to improve the relative ease of detection using non-invasive methods, where 
markers enable disease progression to be monitored [298].  Often in the pre-RA 
stage of disease before the appearance of clinical symptoms, increased blood 
biomarker expression can be the only indication or predictor of future disease onset.  
In the context of RA, a meta-analysis of fourteen studies was performed comparing 
the accuracy of the established biomarker anti-CCP with that of a potential new 
biomarker anti-MCV (mutated citrullinated vimentin antibodies) in predicting RA.  
Data from these studies concluded that serological levels of anti-MCV were equally 
as effective at predicting RA as anti-CCP [299].  When anti-CCP and anti-MCV are 
tested together, the diagnostic accuracy for early RA may be as high as 98% [300] 
compared to 95% specificity of anti-CCP alone [301].  The culmination of these 
studies confirms the importance of using multiple markers to accurately diagnose RA, 
and that other unstudied markers, including the use of miRNAs, may also have 
diagnostic potential.      
 
4.1.2 Vitamin D deficiency and RA disease activity 
Initial interest in the potential link between vitamin D and RA was prompted by 
the established anti-inflammatory properties of vitamin D in many other autoimmune 
diseases including Type 1 Diabetes and Multiple Sclerosis [302] (see Chapter 2).  
Meanwhile other studies have presented evidence that RA patients frequently 
present with low vitamin D status [73, 303, 304].  To further strengthen the link 
between vitamin D and RA, the presence of VDR has been detected in synovial cells 
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[305], indicating that these cells have the potential to respond to 1,25(OH)2D3.  Other 
studies have demonstrated a significant correlation between low vitamin D status and 
RA disease risk and activity [71, 306] although others have not [307].  The debate 
regarding vitamin D deficiency as a cause or effect of RA disease etiology is ongoing.    
Multiple studies have analysed the link between RA disease activity and 
vitamin D deficiency, including studies in African-American [73], Mediterranean [304] 
and European [308] populations.  Some of these studies found significant 
correlations between RA disease activity and vitamin D status whereas others found 
only trends towards this correlation.  The conclusions from these studies varied 
widely, perhaps due to differences in the number of patients recruited, geographic 
location, length of RA disease and, to a degree, the definition of vitamin D deficiency 
in the patients.  For example in the African-American cohort [73], vitamin D deficiency 
was defined as a serum 25(OH)D concentration of <15 ng/mL (25 nmol/L), compared 
to the more generally agreed 20 ng/mL (50 nmol/L).  Whilst this difference may 
appear small, studies have shown the amount of vitamin D required to increase 
vitamin D status to above 20 ng/mL is around 5,000 IU (125 µg)/day [309]. 
A meta-analysis performed six years ago concluded that there was an inverse 
association between vitamin D status (serum 25(OH)D) and the risk of developing RA 
[310].  This study was however unable to establish a definitive correlation between 
vitamin D status and RA disease activity due to the limited study numbers and the 
heterogeneity of patients.  Since this meta-analysis was performed, many more 
studies have focused on the association of vitamin D and RA disease activity, 
allowing for a more recent meta-analysis to be performed [311].  Results from this 
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study concluded that RA patients generally exhibited lower serum 25(OH)D levels 
compared to healthy controls, and that serum 25(OH)D was inversely correlated with 
RA disease activity [311].  Despite the inclusion of many more studies than used in 
the previous report, the current meta-analysis had some limitations.  For example, 
due to the relatively long serum half-life of 25(OH)D compared to other vitamin D 
metabolites, even a transient change in serum 25(OH)D levels, such as by exposure 
of skin to UV-light, can markedly elevate 25(OH)D in serum leading to elevated 
vitamin D status.  This issue has also been raised in previous studies that measured 
25(OH)D in serum, thus the validity of using this metabolite alone to define vitamin D 
status in disease studies is open to debate.       
A large-scale observational study performed in 2017, the COMORA study, 
evaluated the link between vitamin D and RA disease activity in patients across 
fifteen countries worldwide [312].  They observed that vitamin D insufficiency was 
present in over half of the RA cohort across all fifteen countries, confirming that low 
vitamin D status is prevalent amongst RA patients. This varied widely between 
different countries, with the lowest prevalence of low serum vitamin D in RA at 36% 
and the highest at 71%, which could potentially be explained by latitude and 
availability to sun exposure [312].  Interestingly this study found vitamin D deficiency 
and RA prevalence was also evident in countries with plenty of sun exposure.  
Possible explanations for this could be the avoidance of sunlight in hotter climates, or 
lower synthesis of parental vitamin D in the epidermis of people with darker skin 




The COMORA study also observed that non vitamin D-supplemented patients 
had lower vitamin D status, and that low vitamin D was inversely correlated with the 
RA disease activity (DAS28) score (p<0.001).  However, it is worth remembering that 
the COMORA study is an observational study, and hence it still has the limitations of 
all other observational association studies. One major limitation of the COMORA 
study is that the methods and amounts of vitamin D supplementation were not 
uniform across cohorts, therefore doses were not optimised.  Other studies have also 
addressed the link between vitamin D status and RA, reaching similar conclusions to 
that observed in the COMORA study, that vitamin D deficiency inversely correlates 
with RA disease activity [314, 315].  In particular, a strong negative correlation 
between 25(OH)D levels and DAS28 was found, with significant inverse correlations 
between 25(OH)D and CRP and ESR also observed [314, 315].  This correlation was 
seen in both the northern and southern hemisphere, underlining the importance of 
vitamin D in RA disease activity globally.   
The genetic components of the vitamin D receptor (VDR) and RA have also 
been studied with regard to disease development and activity.  For example, 
polymorphisms of the VDR gene have been studied in the context of RA prevalence 
and disease activity [316-318].  Certain VDR genotypes may be associated with the 
outcome of RA; experimental studies have found the Fokl polymorphism of VDR 
occurred significantly more frequently in RA patients compared to disease-free 
controls [319], and the bb genotype of the Bsml polymorphism of VDR was 
associated with reduced disease activity [320, 321].  However other studies have 
found no significant role of VDR polymorphisms in RA disease susceptibility or 
activity [322-324].  A meta-analysis performed in 2015 reviewed the association 
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between VDR gene polymorphisms and RA disease and found that only Taql and 
Fokl polymorphisms contributed significantly to increased risk and activity of RA 
[325].  The role of distinct receptor variants and the influence on RA disease 
susceptibility is an area that requires further research.       
Whilst the majority of literature on vitamin D and RA has been focused on the 
correlation between serum 25(OH)D and disease activity in established RA, more 
research is required regarding the risks of vitamin D deficiency at early or even pre-
established RA stages.  Significant inverse correlations between serum 25(OH)D 
levels and markers of RA disease activity in new-onset RA have been found [326, 
327].  In addition, low serum 1,25(OH)2D3 has recently been shown to correlate with 
disease activity in early RA patients [328].  As the physiologically active form of 
vitamin D, 1,25(OH)2D3 status may provide an alternative to 25(OH)D as a marker 
for predicting the development of RA in patients with early arthritis, although the 
relatively short half-life in serum means that repeated analysis of this form of vitamin 
D may be required.  Collectively, these studies have underlined the potential 
importance of maintaining sufficient vitamin D levels in RA patients, especially at 
early disease stages when they may be most responsive to therapies. A summary of 
these studies showing associations between vitamin D status and RA disease activity 
is shown in Table 4.2.  A PubMed (NCBI) advanced database search was performed 
with all experimental studies within the last 20 years (1998-2018) included, with RA 
patients from different geographical locations.  All reported studies measured vitamin 
D status as the level of serum 25(OH)D, with the exception of a recent Danish study 
which measured 1,25(OH)2D3 instead as they justified this active metabolite was 
more physiologically relevant in RA disease status [329].   Overall the outcomes of 
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these studies were contradictory, with some observing a significant correlation 
between low vitamin D status and worsened RA disease activity [302, 304, 315, 330-
337] whilst others found only some associations [104, 338-341] or no significant link 
at all [73, 342-351].  Despite this, a common theme amongst the studies that 
included a healthy control cohort was that 25(OH)D levels were consistently lower in 
RA patients compared to disease-free controls [71, 104, 302, 304, 332, 333, 339, 
343, 348, 352-356].  However, serum vitamin D status may simply be a marker of RA 
disease progression rather than a contributory factor in the pathogenesis of RA. To 
determine whether improved serum 25(OH)D levels are beneficial to patients with RA 
disease has required studies to investigate the effects of vitamin D supplementation, 




Study details (year, lead 
author) 
Population size and 
ethnicity 
Study outcome 
1998, Oelzner [357]  RA=96, Germany High RA disease activity was associated with altered vitamin D metabolism   
2006, Cutolo [315] RA=118, HC=75, Estonia 
and Italy  
Serum 25(OH)D status correlated negatively with DAS28 
2010, Craig [73] RA=266, African American 25(OH)D insufficiency was not significantly associated with DAS28, VAS or 
SJC 
2010, Haque [330] RA=62, USA 25(OH)D deficiency in active RA was negatively correlated with DAS28 and 
VAS.  This correlation was not found in patients in remission 
2010, Rossini [304] RA=1191, HC=1019, Italy 25(OH)D levels inversely correlated with patient DAS28.  RA patients 
commonly displayed vitamin D deficiency  
2011, Braun-Moscovici [71] RA=85, Israel The majority of RA patients were vitamin D deficient, despite the levels of 
sunshine being above average in this country 
2011, Turhanoglu [331] RA=65, HC=40, Turkey Serum 25(OH)D levels were significantly inversely correlated with CRP and 
DAS28 in RA patients  
2012, Kostoglou-Athanassiou 
[302] 
RA=44, HC=44, Greece Vitamin D deficiency was highly prevalent in RA patients compared to healthy 
controls.  25(OH)D status was negatively correlated with DAS28, CRP and 
ESR. 
2012, Attar [358] RA=100, HC=100, Saudi 
Arabia  
Serum 25(OH)D levels in RA patients were not significantly different to those in 
healthy controls, although significantly lower 25(OH)D levels was associated 
with poorer response to treatment in RA 
2012, Heidari [342] RA=108, HC=239, Iran No significant correlations were found between vitamin D status and disease 
activity in RA 
2013, Atwa [343] RA=55, HC=40, Egypt Serum 25(OH)D levels were significantly lower in RA patients compared to 
healthy controls, however 25(OH)D was not correlated with DAS28, CRP or 
ESR 
2013, Sabbagh [332] RA=39, HC=56 25(OH)D was significantly lower in RA patients compared to controls.  Low 
25(OH)D correlated with significantly increased risk of higher disease activity in 
RA 
2013, Furuya [344] RA=4793, Japan 25(OH)D deficiency was not correlated with RA risk or activity 
2013, Higgins [338] RA=126, New Zealand 25(OH)D status was not correlated with DAS28, although there was a 
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significant inverse relationship between 25(OH)D levels and patient VAS 
scores 
2013, Haga [352] RA=302, Denmark 25(OH)D3 deficiency was detected in 33.4% of the RA patients.  Patients with 
severe vitamin D deficiency <15 nmol/L were all positive for RF and had very 
high DAS28 scores 
2014, Yazmalar [345] RA=71, HC=70, Turkey No significant correlations were found between 25(OH)D levels and DAS28 in 
RA patients 
2014, Sahebari [346] RA=99, HC=68, Iran There was no significant correlation between serum 25(OH)D levels and 
DAS28 in RA patients 
2014, Gheita [353] RA=63, HC=62, Egypt 25(OH)D levels were significantly lower in RA compared to controls, with 
50.8% RA cohort being classed as vitamin D deficient.   
2014, Sharma [333] RA=80, HC=80 90% of RA patients were vitamin D deficient, compared with 70% of healthy 
controls.  Serum 25(OH)D levels in RA were significantly lower than HC.  Low 
serum 25(OH)D was correlated inversely with high DAS28 
2014, Hong [339] RA=130, HC=80 RA patients had lower 25(OH)D levels compared to HC, and low 25(OH)D3 
was associated with higher disease activity in RA patients 
2014, Hiraki [359] Pre-RA=166, HC=490 25(OH)D levels were not significantly lower in RA compared to HC 
2014, Cote [347] RA=120, HC=1341, USA 25(OH)D status was not associated with increased risk of RA 
2015, Raczkiewicz [348] RA=97, Poland 76.3% RA patients were vitamin D deficient, however vitamin D status was not 
correlated with RA disease activity 
2015, Matsumoto [354] RA=181, HC=186, Japan Serum 25(OH)D levels were lower in RA patients compared to HC.  25(OH)D 
was not significantly correlated with DAS28 
2015, Azzeh [334] RA=102, Saudi Arabia 25(OH)D levels were significantly inversely correlated with DAS28 in RA 
patients  
2015, Brance [355] RA=34, HC=41, Argentina RA patients had significantly lower 25(OH)D levels than HC, although 25(OH)D 
status was not correlated with disease activity 
2015, Cen [349] RA=116, China Serum 25(OH)D levels was not correlated with RA disease activity  
2016, Cecchetti [104] RA=894, HC=861, multiple 
countries 
COMEDRA study.  RA patients had more prevalent vitamin D deficiency 
compared to HC.  Vitamin D levels were inversely correlated with CRP but not 
ESR, in RA patients 




2016, Wang [335] Early RA=154, HC=60, 
China 
Serum 25(OH)D was inversely correlated with RA disease activity  
2016, Zakeri [340] RA=66, Iran Serum 25(OH)D in RA patients was inversely correlated with TJC, SJC and 
VAS, but not ESR 
2017, Mateen [356] RA=100, HC=50 RA patients had lower serum 25(OH)D compared to HC 
2017, Hajjaj-Hassouni [336] RA=1413, 15 countries Low 25(OH)D status was associated with increased disease activity in RA 
2017, Vojinovic [341] RA=625, HC=276,  
13 European countries 
Serum 25(OH)D levels in RA patients were significantly lower compared to HC.  
Inverse correlations were found between 25(OH)D and CRP in RA patients 
2018, Herly [329] RA=160, Denmark 1,25(OH)2D3 was inversely correlated with CRP in RA patients 
2018, de la Torre Lossa [351] RA=100, Ecuador No significant correlations were found between 25(OH)D levels and RA 
disease activity 
2018, Khoja [337] RA=41, HC=41 Serum 25(OH)D in RA patients was inversely correlated with DAS28  
Table 4.2. Summary of studies on the relationship between vitamin D status and RA disease 
DAS28, disease activity score of 28 joints; SJC, swollen joint count; TJC, tender joint count; RA, rheumatoid arthritis; HC, healthy control; VAS, 
visual analogue scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor
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4.1.3 Vitamin D supplementation and RA disease activity 
There are multiple observational studies on the association between dietary 
intake of vitamin D and RA symptoms, progression and disease activity.  Strong 
associations have been made between vitamin D status and RA disease activity, 
however contradictions in the literature mean a definitive conclusion cannot be 
drawn.  The majority of existing studies have correlated the effect of existing dietary 
vitamin D intake in RA patients against disease activity, however often these patients 
are still vitamin D deficient or insufficient.  As a result, these studies have not found 
significant correlations between dietary vitamin D and RA disease activity [73, 341, 
360, 361].   
Randomised control vitamin D supplementation trials for RA patients have also 
been reported; these trials have noted associations between RA disease activity and 
vitamin D supplementation dosage and are summarised in Table 4.3.  Some studies 
reported a positive effect of vitamin D supplementation on RA disease activity 
markers such as SJC and TJC [362-364] as well as a significant increase in serum 
vitamin D levels [364].  Buondonno et al. [365] found that 1,25(OH)2D3 combined 
with methotrexate significantly reduced inflammation in early RA patients compared 
to using methotrexate alone, however these patients received a very high dose of 
1,25(OH)2D3 and results could not be replicated in another study on established RA 
patients given a lower dose of vitamin D [366].  Yang et al. [367] reported that RA 
patients in remission who had vitamin D deficiency were significantly more likely to 
have recurring RA compared to those with sufficient vitamin D levels, however 
vitamin D supplementation did not reduce recurrence rates.  Similarly other studies 
have not reported a significant effect of vitamin D supplementation on different RA 
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outcome measures [307, 366] although it is difficult to directly compare results due to  
varying study design, supplementation  quantity and the type of medication already 




Study  Study participants 
(number + 
medications) 
Treatment groups and dosage Summary of key findings 
Andjelkovic et al. 
1999 [362] 
RA=19 (on standard 
DMARDs) 
2 µg/day oral alphacalcidiol 
(vitamin D analogue) in 2 
groups; moderate + highly 
active RA   
CRP, SJC, TJC were all significantly decreased after 3 months’ 
treatment. 
RF and CRP were decreased but this was not statistically 
significant 
Gopinath et al. 
2011 [363] 
RA=121 (on triple 
DMARDs) 
500 IU 1,25(OH)2D3 given in 
n=59 vitamin D group, and not 
given in n=62 control group 
Patients supplemented with 1,25(OH)2D3 reported significantly 
higher pain relief after 3 months, compared to control group 




50,000 IU 25(OH)D or placebo 
given. Randomized double-blind 
trial  
 
Vitamin D supplemented group did not show improvement in 
outcome measures compared to the placebo group 
Dehghan et al. 
2014 [307] 
RA=80  Patients randomly allocated to 
receive vitamin D supplement or 
placebo, in a double-blind trial 
The DAS28 score was not significantly different between the 
treatment group and the placebo group  




Patients were divided into 
normal vitD group and vitD-
deficient group based on their 
baseline levels.  VitD deficient 
group were subdivided to 
receive +/- vitamin D.    
The RA recurrence rate was significantly lower in the normal 
vitD group compared to the deficient –vitD subgroup.  There 
was no difference in recurrence rates between the deficient –
vitD subgroup and the deficient +vitD subgroup  





Patients received standard 
methotrexate treatment +/- 
single dose 300,000 IU 
1,25(OH)2D3, in a randomised 
double-blind trial 
Significantly reduced numbers of pro-inflammatory IL-23 was 
found in the group that received methotrexate + 1,25(OH)2D3, 
compared to the methotrexate-only group 
Chandrashekara 
et al. 2017 [364] 
RA = 73 (on 
DMARDs)  
Patients received 60,000 
IU/week of vitamin D 
supplements for 6 weeks, then 
60,000 IU/month for 3 months  
 
Supplementation of RA patients led to significantly lower CRP 
score compared to pre-supplementation score.  Serum vitamin 
D also increased from 10.05 to 24.77 ng/mL  
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Table 4.3. Vitamin D supplementation trials in rheumatoid arthritis 
CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count; RF, rheumatoid factor; DAS28, disease activity score of 28 joints; 




In addition, a large-scale association study aimed to identify the link between 
serum 25(OH)D levels and RA disease activity compared to healthy controls.  The 
study involved 1191 RA patients (of whom over half were not taking vitamin D 
supplements) and 1019 healthy non-supplemented controls [304].  The authors found 
that serum 25(OH)D deficiency (<20 ng/mL) was similarly prevalent in non-
supplemented healthy controls compared to supplemented RA patients, and that 
despite supplementation one-third of RA patients remained vitamin D-deficient.  
Higher serum 25(OH)D levels were however inversely correlated with RA disease 
activity, suggesting that vitamin D deficiency is common amongst RA patients.     
The role of vitamin D supplementation in the recurrence of RA in patients in 
remission has also recently been studied.  RA patients in remission who are vitamin 
D sufficient have a lower risk of disease recurrence and lower disease activity, 
compared to those who are vitamin D deficient.  However the risk of recurrence is not 
significantly different with and without vitamin D supplementation in patients with RA 
who are already deficient [367].  This study suggests the earlier vitamin D 
supplementation is given, the better the prognosis and more likely the chances of 
recurrence is prevented, thus cementing the importance of maintaining a sufficient 
vitamin D profile in healthy individuals who may be at risk of RA. 
 
4.1.4 Immunological mechanisms of vitamin D in RA 
Vitamin D has the potential to exert potent anti-inflammatory effects on cells of 
the immune system (see Chapter 2).  This may be particularly important in RA, 
where an initial step in development of RA involves the activation of T cells leading to 
a pro-inflammatory Th1 or Th17 phenotype.  The Th1 response involves subsequent 
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activation, proliferation and recruitment of synovial and pro-inflammatory cells, 
leading to further pro-inflammatory cytokine secretion and excess antibody 
production [305].  With this in mind, it is possible for vitamin D to modulate immune 
responses associated with RA at a variety of different facets of the disease.     
In vitro, 1,25(OH)2D3 has been shown to antagonise RA-related pro-
inflammatory processes in synoviocytes, by promoting p53 apoptosis mechanism in 
MH7A cells [296].  Interestingly, the up-regulation in apoptosis was only seen when 
1,25(OH)2D3 was applied in conjunction with TNF-α, a master regulator of 
inflammation normally associated with worsening RA pathogenesis on its own. 
1,25(OH)2D3 is known to induce production of tolerogenic dendritic cells (tolDC) 
which have immunosuppressive functions, suggesting 1,25(OH)2D3-induced tolDC 
could be a viable treatment for RA in future.  The immunosuppressive functions of 
tolDC, including induction of antigen-specific regulatory T cells (Treg), are critically 
dependent on the actions of TNF-α [368], further supporting the TNF-α and 
1,25(OH)2D3 synergy theory.  However, anti-TNF-α therapy is a highly effective 
method of RA treatment [369, 370], involving suppression of pro-inflammatory 
cytokines and leading to TNF-α effects being antagonised [371].  The idea that 
1,25(OH)2D3 can have potent anti-inflammatory effects even in the presence of TNF-
α is still poorly understood.  The current proposed mechanism for TNF-α and 
1,25(OH)2D3 synergy is that an inflammatory environment may first be required to 
stimulate the conversion of 25(OH)D3 to 1,25(OH)2D3.  1,25(OH)2D3 then acts back 
on inflammatory cells to reduce inflammation [84].  In this way, high levels of TNF-α 
provide a trigger for the negative feedback system regulated by 1,25(OH)2D3. Hence 
previously established methods of anti-TNF-α therapies must be reconsidered in RA 
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patients when used in tandem with tolDC therapy due to potential adverse counter-
effects.  In RA the function of Tregs is impaired as a result of down-regulated CTLA-4 
expression; in vitro studies have shown the 1,25(OH)2D3 analogue TX527 can 
promote a CD4+ Treg profile by up-regulating CTLA-4 expression, leading to 
favoured migration to sites of inflammation [372, 373].  So far there are no studies 
that have been able to replicate this Treg effect using 1,25(OH)2D3, but given the 
positive data from epidemiological studies and clinical trials, the use of 1,25(OH)2D3 
holds promise as a viable therapy in RA. Cartilage erosion in joint spaces involves 
the action of matrix metalloproteinases (MMPs), and 1,25(OH)2D3 is thought to be a 
regulatory factor in MMP expression [374].  The pathophysiology of RA has been 
associated with pro-inflammatory cytokines including IL-1β and IL-6.  Although direct 
regulation was not seen in this study [374], others have found 1,25(OH)2D3 inhibits 
IL-1β-induced expression of MMP and reduces migration and invasion of synovial 
fibroblast cells to the inflamed joint space [375].  
In murine models of RA, mice with knockout of the Cyp27b1 gene displayed 
exacerbated articular damage, decreased synoviocyte apoptosis and increased TNF-
α secretion; these effects were reversed after administration of 1,25(OH)2D3 [296].  
The authors suggested 1,25(OH)2D3 therefore prevented RA pathogenesis by 
inducing synoviocyte apoptosis.  Despite this, the high doses of 1,25(OH)2D3 
administered to the mice (1 µg/kg body weight) must be taken into consideration 
when interpreting the results.  Such high doses are rarely replicated in human trials 
due to risks associated with vitamin D toxicity.  In mice, tolDC can significantly inhibit 
RA disease activity and progression, which coincides with an up-regulation of IL-10 
producing CD4+ T cells and decreased numbers of pro-inflammatory Th17 cells 
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[376].  Murine models of inflammatory disease mimicking human RA, when 
supplemented with 1,25(OH)2D3, prevented the progression of more severe disease 
[377, 378].  Vdr knockout mice with chronic arthritis have significantly more synovial 
joint damage when compared to mice with normal Vdr function, suggesting that VDR 
signalling plays an important role in limiting the inflammatory phenotype in RA mouse 
models [379].  
1,25(OH)2D3 production has been shown at sites of RA inflammation including 
the SF of arthritic joints [380]; furthermore, VDR can be found in synovial tissues.  
The local production of 1,25(OH)2D3 in an autocrine fashion has also been well 
documented in other cell types including bone [381, 382] and keratinocytes [383].  
The presence of VDR has been reported in cells from SF, indicating that these cells 
have the capacity to synthesise and respond to 1,25(OH)2D3 [384].  Indeed, previous 
studies have highlighted the aberrant synthesis of 1,25(OH)2D3 from 25(OH)D3 in SF 
macrophages of RA patients [385, 386].  1,25(OH)2D3 metabolism in RA synovial 
macrophages is under autocrine control, by promoting its own catabolism via the 
intrinsic up-regulation of CYP24A1 in a VDR-dependent manner [387].   
 
4.1.5 RA pathogenesis and miRNAs 
To better understand the mechanisms that underpin the immune dysregulation 
associated with RA, several studies have characterised the transcriptomic changes 
that occur in different types of immune cells associated with RA [388-391].  However, 
in recent years there has been increasing attention paid to the role of epigenetic 
factors in diseases such as RA.  This includes DNA methylation [392-395] and 
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histone acetylation [396], and how these mechanisms may influence the immune 
dysregulation associated with RA disease onset and progression. Another key 
component of epigenetic regulation is non-coding RNA i.e. RNA that is not translated 
but which nevertheless modulates protein expression via a variety of mechanisms 
[397-399]. Non-coding RNAs include transfer RNAs (tRNA), ribosomal RNAs (rRNA) 
and small RNAs such as miRNAs, all of which are abundant and functionally 
important.  The different types of non-coding RNAs and their functions in regulation 





















Figure 4.1. Types of non-coding RNAs and their functions in gene expression 
RNA, ribonucleic acid; mRNA, messenger RNA; snoRNA, small nucleolar RNA; snRNA, small nuclear RNA; RNAi, RNA interference; miRNA, 
microRNA; siRNA, small interfering RNA   
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Prominent amongst the non-coding RNAs are miRNAs. As detailed in Chapter 
2, page 38, miRNAs are small non-coding RNAs that modulate the stability and 
translation of mRNA. MiRNAs have been shown to play an important role in immune 
function (see Chapter 2, page 42) Studies have provided compelling evidence of 
miRNA dysregulation in the pathogenesis of RA [232, 400-402].  Of over two 
thousand miRNAs currently validated in humans, the role of two miRNAs in 
particular, miR-146a and miR-155, have been major focuses of RA-related research 
[403, 404].     
In vitro studies on the dysregulation of cellular miRNAs in RA have been 
centred mainly on the role of miRNAs in immunoregulatory processes such as Th17 
differentiation, B cell activation and inflammatory cytokine production.  IL-6 and IL-1β 
are important inflammatory cytokines associated with RA pathogenesis, and studies 
have linked differential miRNA expression with the production of these cytokines in 
RA.  Up-regulated miR-221 expression has been documented in synovial cells of RA 
patients compared to healthy controls, and is associated with increased production of 
MMPs in the joint space, and the increased production of IL-6 and IL-1β [405, 406].  
Up-regulated expression of miR-18a, miR-22, miR-203 and miR-346 in RA synovial 
cells have also been linked to the increased production of IL-6 and IL-1β [407].  MiR-
125b is known to participate in the role of B cell differentiation and TNF production, 
and RA patients with low synovial miR-125b expression have worse disease 
outcomes compared to patients with higher miR-125b expression [408].  The over-
expression of miRNAs in the PBMC of RA patients compared to disease-free 
individuals has also been a key theme in miRNA-related RA research.  MiR-146a 
plays an important role in regulating the NF-kB pathway.  Significantly higher 
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expression of miR-146a in the PBMC of RA patients have been found compared to 
non-inflammatory osteoarthritis (OA) patients, as well as a correlation with higher 
disease activity [409, 410].  Higher circulating miR-155 expression has also been 
observed in RA versus OA PMBC, but not in RA versus healthy PMBC [411], and 
another study found that high miR-155 expression in RA correlated with CRP, DAS28 
and levels of TNF-α [412].  In contrast, miR-21 expression was significantly lower in 
RA patients compared to healthy controls, and this dysregulation is thought to cause 
an imbalance of Th17 versus Treg cells leading to persistent inflammation [413].  In 
addition, polymorphisms in several miRNAs have been associated with a higher risk 
of developing RA; a polymorphism found in miR-499 which regulates genes encoding 
proteins in the TNF-α pathway has been found as an independent risk factor for joint 
erosions associated with RA, as well as higher DAS28 scores, elevated CRP, ESR 
and RF [414, 415].  A polymorphism in miR-146a in RA patient has also been 
associated with higher DAS28 scores and increased disease risk [415-417].   
MiRNAs can exist as circulating miRNAs, and this has also been a key focus 
of the link between miRNAs and RA [418-420].  Inflammatory miRNAs miR-146a and 
miR-155 are up-regulated in the serum and SF of RA patients compared to healthy 
controls [404, 421, 422]; this up-regulation has been observed along with up-
regulated ESR and anti-CCP, and correlated positively with RA disease activity  
[423].  However the role of miR-155 in RA pathogenesis is still contradictory; an in 
vitro study found miR-155 was up-regulated in RA patients but suggested the up-
regulation could offer a protection factor against joint inflammation by silencing its 
target gene IKBKE [411].  These contradictory results could be explained by the 
multifunctional role of miR-155 in a wide range of actions including in both the 
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activation of T cells and suppression of Tregs, making it difficult to pinpoint specific 
gene targets of miR-155.  Furthermore the actions of miR-155 are likely to be very 
different between in vitro and in vivo studies, as extracellular factors may contribute 
to its regulation [424].  MiR-16 and miR-223 have also been well studied in the 
context of circulating miRNAs in RA.  Over-expression of both miRNAs have been 
found in the SF of RA patients compared to the SF of OA patients who lack the 
inflammatory phenotype associated with RA [425, 426], with serum miR-223 
positively correlating with CRP and RA disease activity [427].  Additionally, miR-16 
and miR-223 are highly expressed in established RA serum compared to early RA 
serum, marking these miRNAs as potential markers of disease progression.  Hence 
all the above miRNAs may be viable targets for the attenuation of RA-related 
inflammation and joint destruction.   
Due to the relative abundance and ease of detection of miRNAs in most 
tissues of the body, miRNAs have been proposed as potential novel biomarkers for 
the diagnosis and monitoring of diseases.  MiRNAs appear to fit the criteria used to 
define suitable biomarkers which include: high tissue specificity [426], sensitivity to 
detection [428] and non-invasive detection methods [429].  In addition, miRNAs in 
circulation are protected from endogenous RNAse degradation [430, 431] and are 
resistant to degradation by changes in pH and boiling and freeze-thaw cycles, 
making them an ideal marker for detection in research.  The role of circulating 
miRNAs as novel biomarkers of RA therefore requires further research before 
diagnostic use in a clinical setting.  As described earlier in this chapter, low vitamin D 
status has been implicated in the activity and progression of RA.  The immunological 
mechanisms involved in the inflammatory process are likely to involve dysregulated 
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miRNA expression, and vitamin D may be acting upon select miRNAs to mediate 
inflammation in RA.       
 
4.2 Chapter outline 
The aims of experiments presented in this chapter were as follows: 
1) To investigate the link between serum vitamin D status and disease activity in RA 
patients, but to extend analysis to include multiple vitamin D metabolites beyond 
25(OH)D i.e. to assess the vitamin D metabolome. 
2) To compare the serum vitamin D metabolome in RA patients and patients with 
another form of arthritis - Reactive Arthritis (ReA). 
3) To compare the serum vitamin D metabolome in RA and ReA patients with the 
serum metabolome from aged-matched healthy controls. 
4) To compare the serum vitamin D metabolome in RA and ReA patients with the SF 
vitamin D metabolome using paired samples. 
5) To quantify circulating levels of two miRNAs - miR-146a and miR-155 in serum 
and SF of RA and ReA patients. 
6) To compare the serum and SF vitamin D metabolome with RA disease activity 





4.3.1 Serum vitamin D metabolites in RA, ReA and HC 
Data in Figure 4.2 showed that of the 5 serum vitamin D metabolites 
analysed, only 3-epi-25(OH)D3 was significantly different in serum from RA (median 
0.788 with 95% confidence limits 0.573-0.997, p<0.01) relative to healthy controls 
(HC) (median 1.17 with 95% confidence limits 0.832-1.59). Comparing ReA serum 
metabolites with HC serum metabolites, 3-epi-25(OH)D3 (median 0.361 with 95% 
confidence limits 0.197-1.69, p<0.05) and 25(OH)D2 (median 0.315 with 95% 
confidence limits 0.247-0.452, p<0.01) were significantly lower in ReA serum 
compared to HC serum.  25(OH)D3, 24,25(OH)₂D3 and 1,25(OH)₂D3 were not 
significantly different between HC and ReA serum.  Data for serum vitamin D 
metabolites in RA, ReA and HC were unaffected by donor sex, age, or duration of 
disease (Figures 4.20-4.22).  RA disease activity markers were also not significantly 
different between genders (Figure 4.23).   
 
4.3.2 Serum versus SF vitamin D metabolites in RA and ReA 
With the exception of 25(OH)D2, all vitamin D metabolites showed significantly 
lower concentrations in SF compared to paired serum from RA patients (Figure 
4.3A). However, only SF 25(OH)D3 (p<0.0001) and 3-epi-25(OH)D3 (p=0.0053) 
showed significant linear correlation with serum levels of the same metabolites 
(Figure 4.3B).  In patients with ReA, 25(OH)D3, 24,25(OH)2D3 and 1,25(OH)2D3 
were statistically lower in SF compared to paired serum (Figure 4.4A), whilst only 
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25(OH)D3 (p=0.0002) and 24,25(OH)₂D3 (p=0.0002) in ReA SF correlated 
significantly with the same metabolites in serum (Figure 4.4B).    
Correlating 25(OH)D3 concentration with other metabolites in RA serum and 
SF, 25(OH)D3 showed significant positive correlation with 3-epi-25(OH)D3 in both 
RA serum and SF (Figure 4.5A; 4.5B), whilst 25(OH)D3 correlated with 
24,25(OH)₂D3 and 1,25(OH)2D3 in serum only.  The relationship between 
24,25(OH)₂D3 and 1,25(OH)2D3 showed a positive correlation between these 
metabolites in RA serum and HC serum, but not RA SF (Figure 4.24).        
 
4.3.3 Serum and SF vitamin D metabolites and disease activity in RA 
Vitamin D metabolites 25(OH)D3, 25(OH)D2, 3-epi-25(OH)D3, 24,25(OH)₂D3 
and 1,25(OH)₂D3 in RA serum and SF were correlated with RA disease markers 
CRP (C-reactive protein), ESR (erythrocyte sedimentation rate), SJC (swollen joint 
count) and TJC (tender joint count).  Serum 25(OH)D2 correlated directly with serum 
levels of CRP (Figure 4.6).  Serum 25(OH)D2 also correlated with SJC (Figure 4.8).  
In SF, 25(OH)D3 and 3-epi-25(OH)D3 both correlated inversely with SJC (Figure 
4.8).  Other metabolites did not show significant correlation with RA disease markers 
in serum or SF.  The relationship between serum or SF 25(OH)D3, 25(OH)D2, 3-epi-
25(OH)D3, 24,25(OH)₂D3 and 1,25(OH)₂D3 and markers of RA disease (CRP, ESR, 




4.3.4 Serum and SF vitamin D binding protein, albumin and free vitamin D 
The abundance of DBP and albumin in RA and ReA serum and SF samples 
was quantified to gain insight into the role of DBP and albumin in mediating free and 
bioavailable vitamin D in an inflammatory context.  Concentrations of DBP were 
significantly lower in SF (median 33 with 95% confidence limits 24.37-43.19) vs 
paired serum (median 117 with 95% confidence limits 95.38-149.8) in both RA 
(median 85.66 with 95% confidence limits 68.48-103.1, p<0.0001) and ReA (median 
35.82 with 95% confidence limits 19.25-77.98, p=0.0156) patients (Figure 4.10). 
Albumin concentrations were also significantly lower in RA SF (median 1.423 with 
95% confidence limits 1.398-1.712) vs paired serum (median 2.22 with 95% 
confidence limits 2.054-2.602, p=0.0005).  Albumin concentration was significantly 
higher in ReA SF compared to RA SF (p=0.0195); this was not significant in ReA 
serum (p=0.61). 
Based on the quantification of DBP and albumin levels and total 25(OH)D3 
values it was possible to calculate free 25(OH)D3 (not bound to DBP or albumin) and 
bioavailable 25(OH)D3 (not bound to DBP) for serum and SF samples (Figure 4.25). 
These values showed no significant difference between RA and ReA serum. 
However, in contrast to the decreased total serum 25(OH)D3 observed for SF versus 
paired serum (see Figure 4.3), free 25(OH)D3 levels were significantly higher in RA 
SF compared to RA serum (p=0.0046). Bioavailable 25(OH)D3 showed no significant 
variations in RA vs ReA for either serum or SF.  
Correlating DBP and albumin with RA disease markers, serum DBP was positively 
correlated with CRP and inversely correlated with SJC, but only in the SF of RA 
patients (Figure 4.11).  None of the other disease markers showed significant 
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correlation with DBP concentrations in either serum or SF.  Albumin was not 
significantly correlated with any RA disease markers (Figure 4.12).    
 
4.3.5 Serum and SF miRNAs in RA and ReA 
 The differential expression of specific inflammatory miRNAs, in particular miR-
146a and miR-155, has previously been reported in RA patient serum and SF [432, 
433].  Current data showed no significant difference in miR-146a expression between 
RA and ReA serum vs SF (Figure 4.13).  MiR-155 expression was significantly 
higher in the SF of RA, but not ReA, patients compared to matched serum 
(p=0.0348).  The relationship between the expression of these miRNAs and RA 
disease activity was assessed by linear correlation analysis with RA disease markers 
CRP, ESR, SJC and TJC, in both serum and SF of RA patients.  Neither miR-146a 
nor miR-155 showed statistically significant correlations with any of the disease 
markers (Figure 4.15). The relationship between serum and SF miRNAs and vitamin 
D metabolites was also assessed and all correlation graphs shown in Figures 4.16-
4.19, in both RA and ReA patient cohorts.  MiR-155 was significantly correlated 
(p=0.0287) with 3-epi-25(OH)D3 in RA serum (Figure 4.16).  There was a significant 
inverse correlation between serum miR-146a and serum 25(OH)D2 (p=0.0012) but 
only in ReA patients (Figure 4.18).  Similarly, serum miR-155 also showed a 
significant inverse correlation with serum 25(OH)D2 (p=0.0011) only in ReA patients 
(Figure 4.19).   




























































































































Figure 4.2. Rheumatoid arthritis and the serum vitamin D metabolome 
Serum from n=20 persistent RA (RA) patients, n=7 reactive arthritis (ReA) patients and n=23 healthy controls (HC) were analysed by LC-
MS/MS for: 25(OH)D3 (ng/mL); 3-epi-25(OH)D3 (ng/mL); 25(OH)D2 (ng/mL); 24,25(OH)₂D3 (ng/mL); 1,25(OH)₂D3 (pg/mL). * = significantly 
























Figure 4.3. Serum vs SF vitamin D metabolites in patients with persistent RA 
A) Comparison of serum and synovial fluid (SF) concentrations for: 25(OH)D3; 3-epi-
25(OH)D3; 25(OH)D2; 24,25(OH)2D3 (ng/mL); 1,25(OH)2D3 (pg/mL).  B) Correlation of 
serum and SF concentrations for: 25(OH)D3; 3-epi-25(OH)D3; 25(OH)D2; 24,25(OH)2D3 
(all ng/mL); 1,25(OH)2D3 (pg/mL). n=20 matched for serum and SF (One-way ANOVA).  
Linear regression was performed by best-fit values ± SD. Coefficient of determination (r2) 





Figure 4.4. Serum vs SF vitamin D metabolites in patients with reactive arthritis 
(ReA) 
A) Comparison of serum and synovial fluid (SF) concentrations for: 25(OH)D3; 3-epi-
25(OH)D3; 25(OH)D2; 24,25(OH)2D3 (ng/mL); 1,25(OH)2D3 (pg/mL).  B) Correlation of 
serum and SF concentrations for: 25(OH)D3; 3-epi-25(OH)D3; 25(OH)D2; 24,25(OH)2D3 
(all ng/mL); 1,25(OH)2D3 (pg/mL). n=7 matched for serum and SF (One-way ANOVA).  
Linear regression was performed by best-fit values ± SD. Coefficient of determination (r2) 




Figure 4.5.  Vitamin D metabolite correlations in RA patient serum and SF 
Correlation between 25(OH)D3 and other vitamin D metabolites from persistent 
rheumatoid arthritis (RA) patients in A) serum; B) SF.  Linear regression was performed 
by best-fit values ± SD.  Coefficient of determination (r
2
) values are shown for correlations 



























Figure 4.6.  Correlation of the RA disease activity marker CRP with serum/SF 
vitamin D metabolites  
Correlation of C-reactive protein (CRP) with 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; 
D) 24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from RA patients. Linear regression 
was performed by best-fit values ± SD. Coefficient of determination (r2) values are shown 





























Figure 4.7.  Correlation of the RA disease activity marker ESR with serum/SF 
vitamin D metabolites  
Correlation of erythrocyte sedimentation rate (ESR) with 25(OH)D3; B) 3-epi-25(OH)D3; 
C) 25(OH)D2; D) 24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from RA patients. 
Linear regression was performed by best-fit values ± SD. Coefficient of determination (r2) 




Figure 4.8.  Correlation of the RA disease activity marker SJC with serum/SF 
vitamin D metabolites 
Correlation of swollen joint count (SJC) with 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; 
D) 24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from RA patients. Linear regression 
was performed by best-fit values ± SD. Coefficient of determination (r2) values are shown 




Figure 4.9.  Correlation of the RA disease activity marker TJC with serum/SF 
vitamin D metabolites 
Correlation of tender joint count (TJC) with 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; 
D) 24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from RA patients. Linear regression 
was performed by best-fit values ± SD. Coefficient of determination (r2) values are shown 















Figure 4.10. DBP, albumin and free versus bioavailable 25(OH)D in serum and SF   
Serum and SF from n=20 RA and n=7 ReA patients were used to measure concentrations 
of DBP and albumin, and calculate free and bioavailable 25(OH)D.  Statistical significance 
is taken as *p<0.05.  Wilcoxon matched-pairs signed rank test was performed for matched 
serum vs SF samples.  Mann-Whitney unpaired t-test was performed for non-matched 


















Figure 4.11.   Correlations between DBP and RA disease activity markers in RA serum and SF   
CRP, ESR, SJC and TJC measurements in matched RA serum and SF were correlated against concentrations of DBP.  Linear regression 








Figure 4.12.   Correlations between albumin and RA disease activity markers in RA serum and SF   
CRP, ESR, SJC and TJC measurements in matched RA serum and SF were correlated against concentrations of albumin.  Linear 
regression was performed by best-fit values ± SD. Coefficient of determination (r2) values are shown for correlations that were statistically 






















Figure 4.13. miR-146a and miR-155 expression in serum and SF 
MiR-146a and miR-155 expression in RA (n=20) and ReA (n=7) matched serum vs SF.  Serum vs SF comparison performed by Wilcoxon 

















Figure 4.14. miR-146a expression vs disease activity markers, in serum and SF 
CRP, ESR, SJC and TJC measurements in matched RA serum and SF were correlated against miR-146a expression.  Linear regression 







Figure 4.15. miR-155 expression vs disease activity markers, in serum and SF 
CRP, ESR, SJC and TJC measurements in matched RA serum and SF were correlated against miR-155 expression.  Linear regression was 
performed by best-fit values ± SD. Coefficient of determination (r
2












Figure 4.16. miR-146a expression vs vitamin D metabolites, in RA serum and SF 
Correlation of miR-146a with A) 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; D) 
24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from RA patients. Linear regression was 
performed by best-fit values ± SD. Coefficient of determination (r2) values are shown for 











Figure 4.17. miR-155 expression vs vitamin D metabolites, in RA serum and SF 
Correlation of miR-155 with A) 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; D) 
24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from RA patients. Linear regression was 
performed by best-fit values ± SD. Coefficient of determination (r2) values are shown for 










Figure 4.18. miR-146a expression vs vitamin D metabolites, in ReA serum and SF 
Correlation of miR-146a with A) 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; D) 
24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from ReA patients. Linear regression 
was performed by best-fit values ± SD. Coefficient of determination (r2) values are shown 











Figure 4.19. miR-155 expression vs vitamin D metabolites, in ReA serum and SF 
Correlation of miR-155 with A) 25(OH)D3; B) 3-epi-25(OH)D3; C) 25(OH)D2; D) 
24,25(OH)₂D3; E) 1,25(OH)₂D3 in serum and SF from ReA patients. Linear regression 
was performed by best-fit values ± SD. Coefficient of determination (r2) values are shown 






4.4.1 The serum and SF vitamin D metabolome in health and inflammation 
The aim of the work carried out in this chapter was to determine if vitamin D 
metabolites other than 25(OH)D, including active 1,25(OH)₂D3, could be better suited 
to predicting the activity of RA. Current literature has shown that low serum 
concentrations of 25(OH)D3 are a feature of inflammatory diseases such as RA [104, 
311, 341, 434] although this is not a universal observation [104].  Consistent with the 
latter report, data from the current study showed no significant difference between 
serum 25(OH)D3 concentration in RA or ReA serum compared to HC serum (Figure 
4.2). However, it is important to recognize that in the cohorts analysed in our study, 
the median serum concentrations for 25(OH)D3 were relatively low for all three of the 
groups we studied (14.9 ng/mL, 17.8 ng/mL, 11.1 ng/mL for HC, RA, ReA 
respectively).  Only 10 of the RA/ReA patients and 7 HC subjects, had serum levels 
of 25(OH)D3 >20 ng/mL (50 nmol/L) which is the vitamin D-sufficiency level proposed 
by the Institute of Medicine [56].  Only 6 of all 47 samples had serum 25(OH)D3 
levels >30 ng/mL (75 nmol/L), the optimal levels recommended by the US Endocrine 
Society [435]. Interestingly, 16 of the total 47 samples measured (34%) had serum 
25(OH)D3 levels <10 ng/mL (25 nmol/L), the target level for minimum vitamin D 
status recommended by the UK Science Advisory Council on Nutrition [58], indicating 
that severe vitamin D-deficiency was common to all of the groups. As such, 
increased rates of 25(OH)D deficiency in RA patients were unlikely to be observed. 
With these observations in mind it is clear that larger studies are required to better 
understand the scale of low vitamin D status in RA patients from the UK, but the data 
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in this study also suggest that measurement of serum 25(OH)D alone has limited 
value in assessing diseases such as RA.  
Notably the one vitamin D metabolite that was significantly lower in serum 
from RA and ReA patients relative to healthy controls was 3-epi-25(OH)D3.  The 
physiological importance of C-3 epimerisation has yet to be elucidated, but all of the 
vitamin D metabolites can be converted to 3-epi forms with varying degrees of activity 
[436]. The 3-epi form of 1,25(OH)2D3 can bind to the VDR and induce transcription 
[437], but the impact of 3-epi-25(OH)D3 and other 3-epi vitamin D metabolites on 
human physiology and diseases such as  RA is still unclear.  It was previously 
thought that 3-epi-25(OH)D3 was only present in serum from neonates, however the 
use of recent improved LC-MS/MS detection methods has found 3-epi-25(OH)D3 
present in most healthy adults [438, 439], at levels which vary between 0.1% and 
25% of 25(OH)D3 in the same sample [438]. These studies also found the 
concentration of 3-epi-25(OH)D3 was positively correlated with levels of 25(OH)D3; 
similarly strong posititve correlations between both serum and SF 25(OH)D3 with 3-
epi-25(OH)D3 were also observed in RA patient samples (Figure 4.5A; 4.5B).  
Additionally, due to the almost identical molecular structure of 25(OH)D3 and 3-epi-
25(OH)D3 and the direct correlation in concentration between the two molecules, 3-
epi-25(OH)D3 levels could affect measurements of 25(OH)D3 if insensitive detection 
methods are used.  Accounting for 3-epi-25(OH)D3 when measuring vitamin D status 
is therefore important to avoid misclassification of patients as vitamin D sufficient 
[440].  The precise function of 3-epi-25(OH)D3 in vitamin D physiology is still unclear, 
and interpretation of data is complicated by the fact that levels of this metabolite are 
closely linked to serum 25(OH)D3.    
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In addition to a lower concentration of 3-epi-25(OH)D3 in RA and ReA serum 
compared to HC serum, a lower serum concentration of 25(OH)D2 in ReA patients 
compared to HC patients was also observed (Figure 4.2).  The basis for this is 
unclear as, unlike 25(OH)D3, 25(OH)D2 is derived exclusively from dietary or 
supplementation sources, and the most likely explanation is that this simply reflects 
the small number of samples in the ReA cohort, as well as the possibility that some of 
the subjects were taking vitamin D2 supplements. Although levels of serum 
24,25(OH)2D3 and 1,25(OH)2D3 were not significantly different between HC, RA or 
ReA cohorts, it was important to measure their concentrations in serum.  As the 
active metabolite, 1,25(OH)2D3 levels may be a more physiologically relevant 
measure of vitamin D status in health and disease as opposed to 25(OH)D currently 
measured (this is discussed in more detail in 4.4.2).  The physiological significance of 
24,25(OH)2D3 remains to be elucidated, however 24-hydroxylase activity may still 
have a significant impact on the analysis of 25(OH)D (and 1,25(OH)2D3) levels [441]. 
In particular, genetic variations in CYP24A1 expression are known to influence serum 
levels of 1,25(OH)2D3 by suppressing its catabolism.   
 
4.4.2 Vitamin D metabolites in serum versus SF 
A key observation in the current study is the lower vitamin D metabolite 
concentrations in SF versus paired serum samples (Figure 4.3; Figure 4.4).  For 
25(OH)D3 the mean ratio of serum/SF concentrations was 1.74, whilst for 
1,25(OH)2D3 this was 6.07. Similar observations have been reported previously for 
25(OH)D3 [380, 442], although levels of 25(OH)D3 in serum and SF in those studies 
varied considerably.  By contrast, previous analysis of 1,25(OH)2D3 in RA patients 
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reported similar [443] or modestly suppressed [380] concentrations in SF relative to 
serum. One possible explanation for the significantly lower levels of SF 1,25(OH)2D3 
in the current study could be the use of more reliable LC-MS/MS technology for 
quantification of 1,25(OH)2D3, compared to the relatively non-specific radioreceptor 
[443] or radioimmunoassays [380] used to measure 1,25(OH)2D3 in the previous 
studies. Previous studies also reported strong correlations between serum and SF 
1,25(OH)2D3, and between SF 25(OH)D3 and SF 1,25(OH)2D3 [380], which was not 
observed in the current study. The inference from previous studies is that 
inflammatory factors promote enhanced extra-renal synthesis of 1,25(OH)2D3 via 
immune cell activity of 1α-hydroxylase [385]. Based on this model, enhanced vitamin 
D status (higher serum levels of 25(OH)D3), leads to increased SF 25(OH)D3, and 
this in turn promotes SF production of 1,25(OH)2D3.  Data in the current study do not 
appear to support this mechanism, with 1,25(OH)₂D3 being below the lower limit of 
LC-MS/MS quantification (<8.00 pg/mL) in 13/20 RA SF samples, and 4/7 ReA 
samples. This may reflect the efficacy of the anti-inflammatory therapies currently 
used to manage RA, with several of the treatments used in the current study being 
potential inhibitors of the 1α-hydroxylase enzyme involved in SF synthesis of 
1,25(OH)2D3 [385]. However, it is also possible that synthesis of 1,25(OH)2D3 within 
SF is tightly regulated and limited to the immediate immune microenvironment, for 
example the local actions of 1,25(OH)2D on synoviocytes in the inflamed joint space. 
This would maximize anti-inflammatory responses to 1,25(OH)₂D3, whilst limiting the 
potential for spill-over of 1,25(OH)2D3 into the general circulation.  
1,25(OH)2D3 was directly correlated with 25(OH)D3 in RA serum in the current 
study (Figure 4.5A); a previous study also showed that levels of these metabolites 
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were linked in serum, and suggested this was likely reflecting the efficiency of the 
vitamin D hydroxylases [444].  Whilst availability of 25(OH)D3 is necessary for 
1,25(OH)2D3 synthesis, it is mainly 1α-hydroxylase and 24-hydroxylase activities that 
define the concentration of 1,25(OH)2D3 although these enzymes cannot be 
measured in serum.  The same correlation between 25(OH)D3 and 1,25(OH)2D3 
observed in serum was not seen in RA SF. This may be due to differential regulation 
of 1α-hydroxylase and 24-hydroxylase activities in synovial local environment versus 
the kidney (the main sources of circulating 1,25(OH)2D3), but could also be due to 
the lower concentration and activity of vitamin D hydroxylases in SF compared to 
serum [387, 445].  These studies also found levels of 1,25(OH)2D3 correlated with 
24,25(OH)2D3 via the self-promoted up-regulation of 24-hydroxylase activity by 
synovial fibroblasts, likely in a VDR-dependent fashion.   
Synovial fibroblasts and active macrophages within the SF environment can 
produce 1,25(OH)2D3 in vivo in an inflammatory RA setting [380, 446]; these studies 
proposed that local synthesis of 1,25(OH)2D3 is important in immunoregulation within 
inflamed joints.  Results from the current study differed from those found in the above 
studies; a significant positive correlation between 24,25(OH)2D3 and 1,25(OH)2D3 
was found in RA serum but not in RA SF (Figure 4.24), perhaps due to the reduced 
presence of hydroxylases in SF compared to serum as mentioned previously [445]. A 
strong positive correlation between 24,25(OH)2D3 and 1,25(OH)2D3 in HC serum 
was also observed in the current study. Overall these results showed direct 
correlation between 25(OH)D3 with 24,25(OH)2D3, where a strong correlation 
between these two metabolites was also found in a previous study using LC/MS 
analysis on RA patient serum [269].  In RA serum, but not SF, 25(OH)D3 and 
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1,25(OH)2D3, and 24,25(OH)2D3 and 1,25(OH)2D3 all showed direct correlation with 
each other,  suggesting interplay between the different enzymes involved in vitamin 
D metabolism, and underlining the advantage of measuring the vitamin D 
metabolome rather than a single vitamin D metabolite. 
 
4.4.3 Vitamin D metabolites and RA disease activity 
In common with other previous studies, the current study was unable to obtain 
SF from control HC subjects due to the invasive nature of sample collection.  It is 
therefore unclear whether decreased 1,25(OH)2D3 is a feature of SF in general, or 
whether it is specific to SF affected by inflammatory disease. It is also unclear 
whether SF 1,25(OH)₂D3 is a more informative marker of vitamin D function than 
more conventionally measured 25(OH)D3. In SF, 1,25(OH)2D3 did not appear to 
correlate with markers of RA disease activity (Figures 4.6-4.9), whereas SF 
25(OH)D3 and 3-epi-25(OH)D3 were both inversely related to swollen joint count 
(SJC), an important parameter for assessing RA disease activity (Figure 4.8).  One 
challenge with the interpretation of data in this chapter is that measures of 
inflammation were made at the ‘whole patient’ level (i.e. systemic inflammatory 
markers or total joint counts) rather than at the level of the individual joint from which 
SF was studied and in which levels of vitamin D metabolites were measured.  
Indeed, markers currently used to assess RA disease activity include factors such as 
CRP that are circulating measures of joint inflammation. Thus, the relevance of these 
markers to vitamin D activity in the SF of individual inflamed joints is debatable-
especially in situations where the level of arthritis activity in the sampled joint is 
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different from that of other joints.  In support of this, no significant correlations were 
observed between CRP and vitamin D metabolite concentrations in SF; CRP was 
statistically correlated with 25(OH)D2 in RA serum, but this was likely a false positive 
with regard to one outlier measurement.  Previous studies also found no significant 
correlation between vitamin D metabolites and CRP levels [447, 448]. In this study 
those classified as vitamin D deficient in the former study (25(OH)D <20 ng/mL), with 
high CRP levels, produced higher levels of pro-inflammatory cytokines relative to 
those with sufficient vitamin D.  Overall, data from the current study linking SF 
25(OH)D3 rather than 1,25(OH)2D3 with RA inflammation scores would endorse a 
proposed intracrine model for SF metabolism of 25(OH)D3 [41], with locally 
synthesised 1,25(OH)2D3 acting at a cellular level to promote anti-inflammatory 
responses and inhibit disease markers independent of serum 1,25(OH)2D3.  
Regarding other markers of RA disease status, erythrocyte sedimentation rate 
(ESR) is commonly measured to assess the degree of inflammation on a systemic 
level. However, ESR is measured in blood and is an indicator of systemic 
inflammation, thus its levels can be raised in many other inflammatory conditions.  
Thus measuring ESR is a useful tool to obtain an overall indication of inflammation, 
but can be unreliable if not used in parallel with other, more specific, markers of RA 
activity.  The current study found no significant correlation between 25(OH)D and 
ESR in serum (Figure 4.7), consistent with some previous studies [311, 346]. 
However other studies have found strong correlations between serum 25(OH)D3 and 
RA disease activity [69], although the study was limited by the sole use of ESR as a 
measure of RA disease activity.  Another marker, DAS28, has also been correlated 
with vitamin D status, the advantage with this marker being that it accounts for ESR 
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as well as other parameters of disease activity such as the patient’s global disease 
activity score (as measured using a visual analogue scale; VAS) [449].  In some 
studies DAS28 showed significant inverse correlation with 25(OH)D3 status in the 
serum of RA patients [450, 451], whereas previous studies correlating ESR or CRP 
alone did not, but this observation is not universal [70, 350].  Due to the inclusion of 
the patient’s VAS scores and the patient’s tender joint count when calculating 
DAS28, results are subjective and can be influenced by other comorbidities such as 
depression, thus influencing the final DAS28 score.  Thus the controversy regarding 
the role of 25(OH)D3 specifically in RA disease activity remains unsolved, but overall 
there are suggestions that low 25(OH)D3 levels in serum and SF contribute to higher 
RA disease activity. Another factor to consider when correlating vitamin D metabolite 
concentrations with RA disease activity markers is the type of medication that is used 
by patients at the time of sample collection.  Certain RA medications such as 
hydroxychloroquine may influence vitamin D levels and metabolism by inhibiting the 
conversion of 25(OH)D to 1,25(OH)2D [452, 453]; these studies found patients 
treated with hydroxychloroquine showed marked improvements in other parameters 
including SJC but not ESR.  Patients using other drugs such as prednisolone may 
also expect adverse effects on their vitamin D status compared to patients not on 
treatment or using non-steroidal anti-inflammatory drugs (NSAID).  However the 
majority of patients in the current study were not taking medications or only using 
NSAIDs, which so far have not been reported to affect vitamin D status.  Hence the 
adverse effects on vitamin D status are likely minimal when these patients are 
considered as a group.  The data presented in this chapter highlight the importance 
of monitoring vitamin D status not only as a predictive measure of RA activity, but 
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also during the course of RA treatment, and should be accounted for when relating to 
RA disease activity. 
 
4.4.4 DBP, albumin and free and bioavailable vitamin D 
As well as studying the impact of vitamin D metabolites on RA disease activity, 
serum and SF levels of DBP and albumin were also measured. Interestingly SF DBP 
correlated inversely with SJC (Figure 4.11). This may simply reflect the association 
between DBP and SF concentrations of 25(OH)D3, but 25(OH)D3-independent DBP 
activities have been described, including effects as a macrophage-activation factor 
[454] with actin-binding capacity [455], that have the potential to influence RA 
disease activity.  In common with most vitamin D metabolites and consistent with 
previous publications [442], concentrations of DBP in RA and ReA were lower in 
patient SF relative to serum. The current study also observed lower concentrations of 
albumin in SF (Figure 4.10) as previously reported [456].  
The net effect of these observations is that calculated levels of 25(OH)D3 not 
bound to DBP or albumin (free 25(OH)D3), and 25(OH)D3 not bound to DBP 
(bioavailable 25(OH)D3), were the same for RA and ReA SF as paired serum values. 
Although this suggests that vitamin D binding proteins (DBP/albumin) are regulated 
in SF to maximise free or bioavailable 25(OH)D3, it is important to recognise that the 
values presented in the current study are calculated estimates of unbound 
25(OH)D3.  Direct measurements of free 25(OH)D3 as recently described in other 
studies [457] could not be performed in the current study, and it is possible that other 
factors present in SF may significantly enhance or impede protein binding of 
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25(OH)D3.  Further studies are required to determine more accurately the 
proportions of bound and unbound 25(OH)D3 in SF from RA patients. 
Cells such as macrophages [458] and DC [459] express 1α-hydroxylase, but 
do not appear to express the DBP receptor megalin [41]. In this setting, synthesis of 
1,25(OH)2D3 and associated immune functions may be dependent on macrophage 
uptake of 25(OH)D3 that is not bound to DBP (free or bioavailable 25(OH)D3) [41].  
Albumin is the most abundant protein in the human body, acting as a binding site for 
endogenous proteins and steroids including vitamin D derivatives.  The proportion of 
25(OH)D3 bound to albumin is exempt from free, but included in bioavailable, 
25(OH)D3 calculations.  This is due to the low binding affinity of albumin for steroid 
hormones, contributing to easier off-loading and bioavailability of 25(OH)D3 at target 
sites [460].  It is estimated that a significant proportion of steroid hormones are 
carried bound to albumin in circulation despite the low binding affinity.  Due to the 
lipophilic nature of 25(OH)D3, it is thought that its biological actions are exerted 
through the unbound 25(OH)D that is able to diffuse across cell membranes – the so-
called free hormone hypothesis [49, 50].  The current study was unable to 
demonstrate that free or bioavailable 25(OH)D3 are better correlates of inflammatory 
RA disease than total 25(OH)D3 (Figure 4.26). However, the fact that the limited 
inverse correlations with RA disease identified involved SF rather than serum further 
supports the view that circulating concentrations of vitamin D provide only a very 
limited perspective on the anti-inflammatory actions of vitamin D. This appears to be 
particularly true in diseases such as RA where tissue-specific concentrations of 




4.4.5 MiRNAs and RA disease activity     
 
The present study found that both miR-146a and miR-155 were up-regulated 
in RA SF compared to RA serum, with the difference in expression being statistically 
significant for miR-155 (Figure 4.13) and almost significant for miR-146a (p=0.051).  
This is consistent with previous studies for miR-155 expression [420, 461, 462], and 
miR-146a [421, 463]. Mechanistic studies have identified gene targets for miR-146a 
such as IL-1β and TRAF6, with the latter being a key component for TNF-α signal 
transduction in the inflammatory activation pathway [464].   Murata et al. also showed 
that miR-146a and miR-155 was up-regulated in RA synovial tissue compared to 
healthy controls or synovium from osteoarthritis (OA) patients, suggesting that these 
two miRNAs play a key role in inflammation to regulate the condition of the joint 
space.  Since OA does not have the level of inflammation typically associated with 
RA, it is likely that miR-155 contributes to another regulatory role in RA 
pathogenesis, further highlighting the potential role that miRNAs play in the 
development and maintenance of RA-associated inflammation.  Murata et al. further 
showed the SF miRNA profile was similar to that of synovial tissues yet distinct to the 
miRNA profile in serum and plasma, suggesting synovial tissue cells themselves are 
the major sources of SF miRNAs.  In contrast, serum miRNAs can be made up of 
secretions from many different tissues.  This supports the previously stated idea of a 
localised environment of inflammatory regulation within the SF and surrounding 
inflamed joints, giving rise to a specific environment within the joint space.   
Similar to the project data presented in this thesis, Murata et al. did not find a 
significant correlation between TJC and miR-146a expression in RA SF.  Consistent 
with this, and other null findings [465], the present study did not find significant 
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correlations between any of the RA disease markers CRP, ESR, SJC and TJC with 
miR-146a or miR-155 expression in serum or SF.  This could be due to a number of 
reasons.  Firstly, despite the promising evidence of miRNAs as potential novel 
biomarkers of RA, the pathogenesis and progression of RA is complex and 
multifactorial.   Each miRNA regulates multiple gene targets so it is difficult to define 
one specific gene dysregulated in RA [466], and even more difficult to identify the 
specific miRNA responsible for silencing that gene.  This may account for the 
variability of data between studies depending on the abundance and expression of 
other miRNAs between individual patients.  Additionally, whilst qPCR remains a 
sensitive and reproducible method to detect miRNA expression [467], caution must 
be taken when selecting an appropriate endogenous control that is stably expressed 
and not targeted by miRNAs.  Other factors to consider include the sex of patients as 
well as environmental factors, which may all contribute to data variability seen 
between different studies.  Furthermore, since many miRNAs are not exclusively 
linked to RA and are differentially expressed in other inflammatory diseases [468], 
miRNA expression studies should be analysed together with other parameters of RA 
disease activity such as TJC and ESR, in order to best interpret the role of miRNAs in 
RA.  However, often in the early stages of RA disease the only indication of 
abnormality is the alteration in miRNA expression profile compared to healthy 
individuals.  By studying miRNA profiles of early arthritis patients before the onset of 
classical RA symptoms and signs, and comparing expression to healthy individuals, it 
may be possible to predict which patients go on to develop RA in future.   
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4.4.6 Vitamin D metabolites in RA: the influence of patient sex, age and 
disease duration 
The influence of sex on vitamin D metabolite concentrations has been debated 
in the context of both health and disease [469-471].  The present study did not find 
significant differences between RA patient sex and serum vitamin D metabolite 
concentrations, nor were there differences between sex-matched comparisons of RA 
patients and healthy controls (Figure 4.20).  A previous study comparing vitamin D 
metabolite concentrations from sex-matched healthy control serum with RA serum 
also did not find any significant differences [472], although a similar study reported a 
significant decrease in serum 25(OH)D levels in female RA patients versus sex-
matched controls [473].  Females have a higher risk and prevalence of RA compared 
to males, and it has been proposed that this may be due to the role of oestrogen in 
autoimmune regulation - termed the hormonal theory [474, 475].  However, males 
may have increased RA activity compared to females [476].  Male RA patients have 
been reported to exhibit higher TJC and CRP counts compared to age-matched 
female RA patients, indicating more severe RA symptoms and disease activity.  This 
correlation has so far not been reported in female RA patients, which could perhaps 
be due to the synergistic actions of vitamin D with oestrogen to protect against 
autoimmune processes [474, 477].  The present study found no significant 
differences between male and female patients and markers of RA disease activity 
(Figure 4.23), although the numbers of patients in the study were low and there was 
an uneven number of each sex.  However the majority of male RA patients in the 
previous study were vitamin D deficient [476]. Coupled with the lower serum 
25(OH)D previously observed in female RA patients [473], it is unclear whether low 
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25(OH)D is a cause or effect of RA.  It is most likely that RA disease activity is 
associated with low 25(OH)D levels rather than associated with patient sex.  The 
current study also found no significant correlations between patient age and serum 
and SF vitamin D metabolite concentrations (Figure 4.21), or RA disease duration 
and vitamin D metabolite concentrations (Figure 4.22), similar to previous studies 
[472, 473]. Together, results from the current study suggest that vitamin D metabolite 
concentrations in RA patients are unlikely to be affected by patient age, sex or 
disease duration, meaning the variations in metabolites concentrations between 
healthy, RA and ReA serum and SF are more likely a result of disease 





The work detailed in this chapter firstly indicates that serum 25(OH)D3 
provides only limited insight into the role of vitamin D in RA. Alternative serum 
metabolites such as 3-epi-25(OH)₂D3, and SF metabolites and, notably, lack of SF 
1,25(OH)₂D3, may be more closely linked to RA disease activity.  Secondly, the 
current study showed up-regulated expression of the inflammation-associated 
miRNAs miR-146a and miR-155 in RA SF compared to serum, however since there 
was a lack of correlation between miRNA expression and RA disease markers in 
serum or SF, it is unlikely that these miRNAs are actively mediating gene silencing to 
cause inflammation within the local environment; it is possible they are maintained as 
a reserve of miRNAs not associated with their target gene [478].  Hence the role of 
miR-146a and miR-155 in the pathogenesis of RA remains unclear.  Despite this, 
past and current research indicates miRNAs show promising potential in the field of 
diagnostic biomarker and inflammation research.  To date, one study has profiled all 
human miRNAs covered in the MiRBase database to create a miRNA expression 
profile specific to RA, however its study limitations include a small patient sample 
size and lack of heterogeneity [479]. Future work on the contribution of miRNAs to 
various aspects of RA pathogenesis is required and holds great potential.     
Lastly, the best correlations of RA disease so far relate to 25(OH)D 
measurements rather than 1,25(OH)2D3, which supports a synovium-specific 
intracrine model, with local SF conversion of 25(OH)D3 to 1,25(OH)2D3 linking 
vitamin D with RA pathogenesis.  However, the actual levels of 1,25(OH)2D3 present 
within the SF appear to be very low or undetectable.  This suggests that any 
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1,25(OH)2D3 generated within the synovial microenvironment may be restricted to 
the cells involved in immunoregulation within this tissue. Collectively the data from 
this chapter of the thesis indicate that the role of vitamin D metabolites, especially 
active 1,25(OH)2D3, in the synovium of RA patients is still far from clear and further 
investigation of the link between 1,25(OH)2D3 and miRNAs is the focus of the next 




CHAPTER 5. VITAMIN D AND 


















5.1.1 Dendritic cells and innate immunity 
Dendritic cells (DC) are antigen-presenting cells (APC) of the innate immune 
system that are capable of capturing and presenting foreign antigens to T cells, thus 
serving as the translator from innate to adaptive immunity [480].  The innate immune 
system functions to provide a rapid but non-specific response to foreign antigens, 
whereas the adaptive immune system provides a latent but antigen-specific response 
to generate an immune memory.  Neutrophils, macrophages, natural killer (NK) cells 
and DC are the most notable populations of innate immune cells, whereas the major 
players in adaptive immunity are T and B lymphocytes (T cells and B cells) [481].  
Populations of innate and adaptive immune cells are present in the general 
circulation, but are also important in specific target tissues associated with immune 
regulation [482]. Although these tissue-resident immune cells are the best 
representation of normal and disease immune function, their availability in humans is 
often restricted based on tissue availability. In recent studies our group used T cells 
isolated from the SF of inflamed joints of RA patients to study their role in 
inflammatory response [483], but the relatively small number of cells available from 
these samples severely restricts the scope of possible experiments. In contrast, 
recent studies of DC have utilised the greater abundance of circulating immune cells 
to develop in vitro cell culture model systems using circulating populations of DC 
precursor monocytes, and a variant of this model forms the basis of the current 
chapter of this thesis.   
In humans there are two main types of DC: 1) conventional myeloid or 
monocyte DC (moDC) located in lymphoid tissue which are closely related to 
monocytes and which stimulate CD4+ and CD8+ T cells upon detection of foreign 
163 
 
antigens [484]; 2) plasmacytoid DC (pDC) which are stimulated via TLR-7 and TLR-9 
and produce IFN-α [97]. The origins and distinguishing markers of the DC subtypes 
are summarised in Figure 5.1.  The work in this chapter focuses on the use of an ex 
vivo model of differentiation and activation of moDC, which, for simplicity’s sake, are 














Figure 5.1. Origins of conventional, plasmacytoid and monocyte-derived DC 
cDC and pDC arise from a common progenitor cell, whereas moDC are derived from 












stem cell  
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DC maturation is an essential step for immune regulation and the subsequent 
activation of cells in the adaptive immune system.  In vivo, immature DC (iDC) are 
recruited to sites of inflammation following an immune challenge, where they rapidly 
internalize foreign antigens, triggering their maturation and migration to lymphoid 
organs.  During the journey from peripheral tissue to secondary lymphoid organs, 
they process foreign antigens and undergo a functional shift to a mature phenotype 
[485].  The process of maturation involves a series of functional and phenotypical 
changes that include the redistribution of major histocompatibility type II (MHC II) 
from endosomal compartments to the cell surface, the up-regulated surface 
expression of T cell co-stimulatory molecules such as cluster of differentiation (CD)80 
and CD86, and the development of characteristic dendrites which facilitate DC 
migration from tissues to lymphoid organs [486].  Following these phenotypic 
changes, mature DC (mDC) present foreign antigens on their MHC II complex, for 
recognition by naïve CD4+ T cells and peptide binding by CD8+ T cells.  The mDC 
maturation process can be influenced by a variety of factors including the 
inflammatory cytokine milieu of the local environment, which is able to determine 
different DC states and functions [487, 488].  In the absence of infection, DC exist in 
an immature steady state in peripheral tissues to maintain immune surveillance and 
tolerance, expressing constitutively low levels of MHC II but not co-stimulatory 
molecules [489, 490].  In this state they present self-antigens to T cells to maintain 
the production of induced Tregs, which are immunosuppressive and down-regulate 
the induction of effector T cells to prevent inappropriate immune responses [488].  
Populations of iDC can be derived in vitro for experimental study by culturing 
PBMC-derived monocytes in the presence of granulocyte macrophage-colony 
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stimulating factor (GM-CSF) and interleukin-4 (IL-4) [491, 492].  In vitro DC were first 
identified in 1998 by Randolph et al. [493], who found that culturing mononuclear 
blood cells on a collagen matrix evoked cells that were capable of functions similar to 
conventional DC such as the ability to stimulate allogenic T cells.  DC maturation in 
vitro can be triggered by the presence of immune activator molecules such as 
lipopolysaccharide (LPS), a ligand for toll-like receptor-4 (TLR-4). The differentiation 
from blood-derived monocytes to iDC in culture can be monitored by flow cytometry 
to study changes in surface marker expression as DC mature towards mDC.  This 
includes down-regulation of the monocyte marker CD14 and an up-regulation of the 
T cell co-stimulatory molecules CD86 and CD80 [494].  Other major markers of DC 
maturation include up-regulation of the maturation marker CD83, the MHC II 
molecule HLA-DR, and CD209 (DC-SIGN). The latter can be used to distinguish sub-
types of DC [495], where up-regulated expression of DC-SIGN is found in cultured 
DC in the presence of GM-CSF and IL-4.  Myeloid DC are distinguished by CD11c 
marker whereas the plasmacytoid DC are distinguished by CD123 [496].  
As well as immature and mature differentiation states, DC can also exist as 
tolerogenic DC (tolDC), that act to limit immune cell activation by promoting the 
induction of tolerogenic regulatory T cells (Tregs) [497].  There has been debate 
regarding whether tolDC status is a result of DC maturation (similar to the transition 
from iDC to mDC) or the result of a separate tolDC lineage [498, 499], with the most 
likely mechanism being the maturation status of the DC.  In both mice and humans, 
the presence of the anti-inflammatory cytokine IL-10 has been shown to favour Tregs 
[500, 501], and IL-10 plays a key role in the differentiation of tolDC [502].  To 
facilitate T cell stimulation, DC normally produce a host of cytokines including IL-12. 
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As part of tolDC function, these cytokines are inhibited by IL-10 to impair T cell 
activation and thus prevent further production of pro-inflammatory cytokines and 
promote tolerance [503].  In experimental mouse models of tolDC function, iDC have 
been shown to express high amounts of TNF-α which mediate their maturation and 
induce CD4+ Treg activation [504].  In contrast, LPS-matured iDC shifted the balance 
of T cell differentiation to favour the inflammatory Th1 fate.  Previous studies have 
also found differences in DC function depending on their maturation stimulus [505].  
LPS-stimulated DC up-regulate the expression of genes that control inflammation, 
whereas TNF-α stimulated DC do not. These studies lead to the conclusion that the 
immunogenic versus tolerogenic fate of DC is decided by differences in DC 
stimulation signals [506].  The differences in DC fates by maturation is described in 





















5.1.2 Immunological actions of vitamin D on dendritic cells 
Initial studies on the action of vitamin D in DC were prompted by the discovery 
of the vitamin D receptor (VDR) in purified tissue DC  [507].  A later study then 
provided evidence that 1,25(OH)2D3 could act to suppress the numbers and function 
of antigen-presenting cells in populations of DC isolated from skin [508].  These 
studies involving isolated DC from lymphoid tissues gave rise to the idea that 
1,25(OH)2D3 could affect DC function, but in recent years studies using monocyte-
derived DC have further elucidated the role of vitamin D in DC.  Now the actions of 












CD4+ T cells (Th1, Th2, 
Th17), CD8+ T cells, NK 
cells, B cells 
Figure 5.2. Differential DC fates upon maturation 
The functional fate of immature DC (iDC) is influenced by the type of signals received by 
resting DC.  Inflammatory signals produce a mature immunogenic DC capable of activating T 
cells, NK cells and B cells of the adaptive immune system, whilst steady state signals favour 
a tolerogenic fate to induce Tregs.  itolDC, tolerogenic DC; mDC, mature DC.  
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459], promoting tolerogenic DC [509] and enhancing activation of Tregs [510].  In 
vitro, DC cultured in the presence of 1,25(OH)2D3 have decreased IL-12 [459] but 
increased IL-10 [511] production, exhibit down-regulated CD80/CD86 expression and 
are less capable of inducing T cell proliferation.  Based on these observations it was 
then discovered that 1,25(OH)2D3 could promote tolerance via a tolDC phenotype 
[154].  1,25(OH)2D3 has been shown to regulate DC maturation via a VDR-mediated 
mechanism, by inhibiting down-regulation of CD14 and maintaining an immature 
phenotype [512].  When DC are exposed to 1,25(OH)2D3 during monocyte to iDC 
differentiation, DC exhibit reduced ability to differentiate and mature, impairing their 
stimulatory capacity for T cells [155, 158, 513].  Furthermore, following maturation of 
DC with LPS in the presence of 1,25(OH)2D3, mDC exhibit down-regulated 
expression of CD80/CD86, CD83 and HLA-DR compared to mDC matured without 
1,25(OH)2D3 [511, 514].   
A seminal study in the field of DC-related vitamin D research compared the 
effect of 1,25(OH)2D3 on pDC versus mDC function.  The authors found that 
1,25(OH)2D3 preferentially regulated mDC, leading to a reduced capacity for mDC to 
induce inflammatory Th1 cell development [515].  Interestingly 1,25(OH)2D3 had no 
significant effects on the tolerogenic properties of pDC, despite both pDC and mDC 
expressing similar levels of VDR.  It is hence likely that tolerogenic pDC may respond 
to 1,25(OH)2D3 via an alternate local intracrine mechanism.  Local production of 
1,25(OH)2D3 from its inactive precursor 25(OH)D3 is likely to be an important 
mechanism for the contribution of 1,25(OH)2D3 to immune regulation.  A key study 
supported this idea by showing that monocyte-derived DC express the enzyme 1α-
hydroxylase (CYP27B1), required for the conversion of 25(OH)D3 to 1,25(OH)2D3 
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[516].  These DC were able to intrinsically produce 1,25(OH)2D3 following stimulation 
with LPS, with mature DC then producing 1,25(OH)2D3 to suppress the differentiation 
of precursor cells in a paracrine fashion.  Subsequent studies then demonstrated that 
the local conversion of 25(OH)D3 to 1,25(OH)2D3 by DC was able to drive functional 
T cells responses, shown by the up-regulated expression of CTLA-4 to suppress 
immune responses [517].  The mechanism behind this response is described in detail 
later in this thesis (see Chapter 6).             
The actions of 1,25(OH)2D3 on DC have also been studied in mouse models.  
The ability of 1,25(OH)2D3 to maintain DC tolerance was also endorsed by studies in 
mice underdoing pancreatic islet allografts, showing that mice treated with 
1,25(OH)2D3 had lower transplant rejection rates compared to untreated mice [283].  
Importantly, this 1,25(OH)2D3 response was likely due to reduced DC maturation or 
enhanced Treg induction.  The ability of 1,25(OH)2D3 to maintain an immature DC 
state is dependent on the expression of VDR in both mice (Vdr) and humans (VDR).  
Vdr knockout mice are not resistant to DC maturation and exhibit increased numbers 
of mDC and enlarged lymph nodes compared to wild-type mice expressing Vdr [157].   
Surprisingly, Vdr knockout mice also exhibit reduced numbers of Th1 cells as 
opposed to the elevated levels predicted [518].  Together these studies show that DC 
differentiation can occur in the absence of the VDR, but 1,25(OH)2D3-induced 
differentiation absolutely requires VDR.  In the non-obese diabetic (NOD) mouse 
model for Type 1 diabetes, 1,25(OH)2D3 can induce DC to develop a tolerogenic 
phenotype and subsequently induce an increased population of Tregs [519, 520].  In 
murine models fed a vitamin D-deficient diet, an overproduction of Th1 and Th17 
inflammatory responses was seen, as well as a reduction in numbers of tolDC [521].  
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Vitamin D is able to reduce the inflammation by inhibiting the production of 
inflammatory cytokines and reducing Th1 and Th17 responses [522].  In Cyp27b1 
knockout mice deficient of 1α-hydroxylase, mice induced to develop inflammatory 
colitis showed exacerbated disease symptoms due to excessive IL-1 and IL-17 
production in the colon, suggesting that vitamin D deficiency may produce similar 
effects [523].      
In humans, exposure of mDC to 1,25(OH)2D3 promotes the production of C-C 
motif chemokine ligand 22 (CCL22), a chemokine which attracts Tregs and 
suppresses the production of CCL17 [524, 525].  Currently there are two proposed 
pathways of mDC regulation by 1,25(OH)2D.  During the early stages of inflammation 
the chemokine IL-8, encoded by CXCL8, is up-regulated by 1,25(OH)2D3 binding to 
the VDR, mediating direct binding to the CXCL cluster [526].  Further sequencing 
revealed that CXCL8 is under the direct control of the nearby VDR binding site, so in 
this way 1,25(OH)2D3-mediated VDR activation leads to the control of IL-8 
expression, which is an important chemokine during the immune response [526].  At 
later stages of inflammation, 1,25(OH)2D3 prevents an over-active immune response 
in mDC by decreasing translocation of the p65 subunit of NF-κB [525].  Others have 
found similar actions of 1,25(OH)2D3 on repressing the transcription factor NF-κB 
[527], whose activity has been associated with the production of pro-inflammatory IL-
12, CCL7, CCL22 and MHC II [527].  Furthermore, DC exposed to 1,25(OH)2D3 
show reduced chemotaxis to the chemokine receptor (CCR) 7 and CCL21 [524, 528], 
which are required for the migrations of DC to the draining lymph node.   
The mechanisms of 1,25(OH)2D3 with regard to monocyte to DC 
differentiation have been studied, with the consensus that 1,25(OH)2D3 also exerts 
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anti-inflammatory effects at this early stage of DC development.  The differentiation 
of monocytes to iDC is mediated by Type 1 Interferon including interferon-alpha (IFN-
α), which is also a target of 1,25(OH)2D3 [529].  When 1,25(OH)2D3 was added to 
freshly isolated monocytes in vitro, the differentiation of IFN-mediated DC was 
inhibited.  Furthermore, the presence of 1,25(OH)2D3 prevented iDC from maturing, 
as demonstrated by a lower expression of CD83.  Others have found a similar ability 
of 1,25(OH)2D3 to redirect the fate of iDC; iDC differentiated from monocytes in the 
presence of 10nM 1,25(OH)2D3 showed up-regulated CD14 expression, thus 
1,25(OH)2D3 acts on iDC to maintain their immature status and inhibit T cell 
stimulatory potential [158, 530].     
 
5.1.3 MiRNAs and dendritic cells  
The process of DC differentiation and maturation involves the regulation of 
expression of many genes, and an increasing body of literature suggests that some 
of these genes may also be regulated by miRNAs [153, 531, 532].  The expression of 
various cytokines and cell intrinsic factors can modify the miRNA expression profile in 
DC [532].  Depending on the signals received from the pro- or anti-inflammatory 
pathway, different stimuli are able to induce or down-regulate the expression of 
specific miRNAs that are linked to DC function.  Following DC maturation, up-
regulated expression of miR-155, let-7i, miR-22, miR-34a and miR-126 has been 
linked to a pro-inflammatory mDC phenotype associated with T cell activation, whilst 
up-regulated expression of miR-29, miR-146a, miR-148, miR-152 and miR-451 has 
been associated with anti-inflammatory tolDC phenotype [153].  Amongst these 
miRNAs, miR-155 and let-7i have been most strongly associated with DC maturation 
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and function.  MiR-155 expression is strongly up-regulated following DC maturation 
[533, 534], which results in decreased expression of the transcription factor PU.1 
which regulates the mDC marker DC-SIGN [534].  MiR-155 has also been implicated 
in controlling cytokine release; inhibition of miR-155 expression in mDC leads to 
increased pro-inflammatory cytokine expression [535, 536] therefore the role of miR-
155 appears to be able to promote and inhibit inflammation in DC.   
Let-7i has also been associated with DC maturation and is thought an 
essential miRNA for the normal maturation of DC [537].  Let-7i was one of the first 
miRNAs to be discovered, deriving from the let-7 family of miRNA precursors 
involved in the post-transcriptional control of innate immune responses to pathogens.  
Immune-stimulated macrophages are able to down-regulate the expression of 
several members of the let-7 family to relieve suppression of IL-6 and IL-10 
cytokines.  To clarify, let-7 targets genes encoding IL-6 and IL-10 and thus down-
regulation of let-7 enhances their expression. In this way let-7 can act as a tumour 
suppressor, amongst other immunosuppressive functions.  In DC, let-7i has been 
shown to be up-regulated in response to DC maturation [537, 538]; Kuppusamy et al. 
indicated that the let-7 family of miRNAs may be important mediators of cell 
maturation and immune responses.  Other studies support this idea; LPS-induced 
DC maturation was found to require the up-regulation of let-7i, where inhibition of let-
7i expression prevented DC maturation shown by suppressed expression of CD80 
and CD86 mDC surface markers, and impaired downstream T cell responses [539].  
Dynamic regulation of miR-155 and let-7i are responsible for fine-tuning DC 
maturation and immune response by targeting and inhibiting suppressor of cytokine 
signalling 1 (SOCS1) [540].  SOCS1 is a crucial gene that is up-regulated during DC 
173 
 
maturation [541] and controls immune responses via a negative feedback loop that 
regulates the intensity and duration of cytokine signalling.  On the other hand, miR-
155 targets SOCS1 to block the negative feedback loop [542].  SOCS1 is a 
confirmed target of both let-7i and miR-155, where over-expression of let-7i [537] and 
miR-155 [541] leads to excessively suppressed SOCS1 protein expression in DC and 
increased production of pro-inflammatory IL-12.  In miR-155-deletion mice, the 
addition of 1,25(OH)2D3 suppresses inflammation and stimulates SOCS1 by down-
regulating miR-155 [240].  Together these studies indicate that miR-155 and let-7i 
play important roles in DC development and immune regulation.  
Other miRNAs are associated with an anti-inflammatory phenotype, and act to 
prevent DC maturation by reducing MHC II expression or inhibiting the release of 
pro-inflammatory cytokines [543].  MiRNAs such as miR-148 and miR-146a fulfil this 
anti-inflammatory role; miR-146a impairs DC maturation by targeting components of 
the NF-κB pathway, as well as inhibiting the up-regulation of CD80/CD86 and HLA-
DR expression on DC [544].  Other miRNAs such as miR-142 are down-regulated in 
mDC to promote an anti-inflammatory phenotype by increasing IL-6 expression [540].  
MiR-146a suppresses IL-6 and IL-8 expression by silencing its target gene IRAK1 
which is a crucial component of the inflammatory IL-1 signalling pathway [545].  The 
other target of miR-146a, TRAF6, is linked to attenuation of signalling processes in 
DC [546].   
As well as being influenced by cytokine expression, several miRNAs have 
been shown to modify the release of cytokines themselves.  MiR-21, miR-10 and 
miR-148a all inhibit pro-inflammatory IL-12 production [543, 547, 548].  Other 
miRNAs have been associated with a tolDC.  Gene sequencing revealed miR-30b, 
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miR-99a and miR-125a are up-regulated in tolDC compared to other DC phenotypes, 
both in vitro and in vivo [549].  In mice, differential expression of 391 miRNAs has 
been observed during the differentiation of iDC to mDC [549].  The method of DC 
activation is also an important consideration for the differential expression of 
miRNAs; for example LPS-induced mature DC show a distinct miRNA expression 
profile compared to other induction methods [550].    
One miRNA can also control the expression of another miRNA.  The 
expression of miR-155 has been linked to the expression of miR-142; increased miR-
155 down-regulates miR-142, due to miR-155 targeting the PU.1 promotor region 
which is necessary for miR-142 expression [540], whereas inhibiting miR-155 
expression results in an up-regulation of miR-142 expression [551].  These studies in 
DC have provided miR-155 with the term ‘master miRNA regulator’, where the 
expression of other miRNAs only occurs in the presence or absence of miR-155 
[551].  Following DC maturation, the presence of miR-155 allows the induction of 
miR-210-3p, whereas miR-445-3p is only induced in its absence, underlining a 
hierarchy of miRNA-mediated miRNA regulation [552].    
 
5.2 Chapter outline 
DC are initiators of adaptive immune responses and are thus important targets 
for the immunomodulatory actions of 1,25(OH)2D3 [152, 153].   The mechanisms by 
which 1,25(OH)2D3 influences DC differentiation, maturation and function have yet to 
be fully elucidated but include important changes in gene expression that have 
highlighted novel immunomodulatory mechanisms, including effects on cellular 
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metabolism [274, 553, 554]. However, it is also likely that epigenetics will play a role 
in mediating changes in DC differentiation and function [555]. The aim of studies in 
this chapter of the thesis were therefore to investigate the contribution of one 
component of epigenetic regulation – miRNAs – on the DC modulatory effects of 
1,25(OH)2D3.   
Previously, Chapter 4 described miRNAs including miR-155 in an 
inflammatory autoimmune disease setting, as well as the correlation between the 
vitamin D metabolome with inflammatory markers and miRNA expression.  It is 
therefore likely that miRNAs also play an important role in maintaining an appropriate 
level of immune response in healthy individuals, and are sensitive to 
immunomodulation by 1,25(OH)2D3.  The journey from monocyte to DC bridges the 
innate and adaptive immune systems; a crucial stage for healthy immune response 
and a potential target for 1,25(OH)2D3 mediated regulation of miRNAs. 
The work described in the current chapter tested the central hypothesis that 
the ability of 1,25(OH)2D3 to modulate DC differentiation and function is 
associated with the specific regulation of miRNAs that influence DC immune 
function.   Distinct DC phenotypes were generated to study the effect of 
1,25(OH)2D3 on miRNA expression at different stages of DC development.  
Candidate gene and miRNA expression was quantified in these DC populations, and 
unbiased analysis of miRNAs was carried out using PCR array analysis.  Finally, 
gene ontology analyses were performed for differentially regulated miRNAs using a 
bioinformatics approach to predict miRNA targets related to immune function and 




5.3.1  Induction of distinct DC phenotypes 
The basis for the studies forming this chapter involved the induction of 6 
distinct DC phenotypes as detailed in Materials and Methods (Chapter 3).  
Monocytes were isolated from peripheral blood mononuclear cells in fresh whole 
blood and cultured in GM-CSF and IL-4 to stimulate differentiation of iDC and mDC.  
Both stages of differentiation and maturation involved the presence and absence of 
1,25(OH)2D3.  The 6 distinct DC populations generated were: immature tolerogenic 
DC (itolDC); mature tolerogenic DC (mtolDC); immature DC (iDC); iDC+/-
1,25(OH)2D3; mature DC (mDC); mDC+/-1,25(OH)2D3 (see Figure 3.3).  All 6 DC 
populations were used for candidate gene and miRNA expression analysis, and DC 
populations (iDC, mDC, itolDC and mDC+1,25(OH)2D3) were used for cell surface 
antigen characterisation and unbiased analysis of miRNA expression (Figure 5.3).  
 
5.3.2  Flow cytometry validation of monocyte-derived DC phenotypes 
 
Flow cytometry was used to validate the projected DC phenotypes for iDC, 
mDC, itolDC and mDC+1,25(OH)2D3 by quantifying specific cell surface markers.  
Representative flow cytometry plots showed that long-term treatment with 
1,25(OH)2D3 to generate itolDC from iDC decreased HLA-DR and CD80 (Figure 
5.4A), and CD68 (Figure 5.4B), whilst increasing CD14 (Figure 5.4A). Short-term 
treatment with 1,25(OH)2D3 to generate mDC+1,25(OH)2D3 from mDC decreased 
HLA-DR and CD83 (Figures 5.4A and 5.4B), whilst increasing CD14 (Figure 5.4A).  
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Transition from iDC (no treatment during differentiation or maturation) to mDC (LPS 
treatment for maturation only) was associated with increased numbers of cells 
expressing HLA-DR (Figure 5.4A), CD209 and CD83 (Figure 5.4B).  In addition to 
analysis of the number of cells expressing specific cell-surface markers, flow 
cytometry was also used to characterise the relative levels of expression for cell 
surface antigens using mean fluorescence intensity (MFI). Data shown in Table 5.1 
showed that long-term 1,25(OH)2D3 treatment (itolDC) suppressed HLA-DR (MFI 
6.55), CD80 (MFI 4.88), CD83 (MFI 3.09) and CD86 (MFI 2.79) compared to iDC 
populations (HLA-DR MFI 199; CD80 MFI 6.15; CD83 MFI 3.57; CD86 MFI 6.41), 
and increased expression of CD14 (MFI 12.7 vs 7.42 in iDC).   
Short-term treatment with 1,25(OH)2D3 (mDC vs mDC+1,25(OH)2D3) 
suppressed expression of HLA-DR (MFI 250 vs 275 in mDC), CD80 (MFI 29.0 vs 
63.1 in mDC), CD209 (MFI 1.01 vs 14.9 in mDC), CD83 (MFI 1.52 vs 7.2 in mDC) 
and CD86 (MFI 1.3 vs 44.9 in mDC).  Similar to that observed with long-term 
1,25(OH)2D3, CD14 expression was up-regulated by short term 1,25(OH)2D3 
treatment (MFI 3.29 to 23.4).   
Maturation by LPS (iDC vs mDC) increased expression of HLA-DR (MFI 199 
to 277; iDC vs mDC), CD80 (MFI 6.15 to 63.1), CD209 (MFI 2.71 to 14.9), CD83 
(MFI 3.57 to 7.2) and CD86 (MFI 6.41 to 44.9).  As expected, iDC to mDC maturation 
led to the down-regulation of CD14 expression (MFI 7.42 to 3.29).  Together these 
results confirm the different phenotypes of the different monocyte-derived DC and 




5.3.3 Effect of 1,25(OH)2D3 on vitamin D-related gene expression in DC 
 
Following on from phenotype characterisation by flow cytometry, all 6 DC 
populations were used to investigate expression of components of the vitamin D 
metabolism and signalling by assessing mRNA expression of VDR, CYP24A1 and 
CYP27B1 (see Figure 5.5).  Data from these studies showed that all DC phenotypes 
expressed mRNA for VDR. Expression of VDR was higher in mDC vs iDC and 
mtolDC, and higher in mDC+1,25(OH)2D3 vs mtolDC.  Similar to VDR, expression of 
mRNA for CYP27B1 was higher in mDC than iDC, and in mDC+1,25(OH)2D3 vs 
iDC+1,25(OH)2D3. The VDR target gene CYP24A1 is potently induced by 
1,25(OH)2D3, but this was only statistically significant with long term 1,25(OH)2D3 in 
the presence of LPS. 
 
5.3.4 Effect of 1,25(OH)2D3 on candidate miRNA expression in DC 
 
Having shown that the different DC phenotypes express VDR and respond to 
treatment with 1,25(OH)2D3 by changes in cell surface antigens and CYP24A1 
mRNA expression, the next stage of the project investigated possible changes in 
miRNA expression in the different DC types. qRT-PCR analysis was performed on 7 
candidate miRNAs (miR-21, miR-29a, miR-145, miR-146a, miR-155, miR-627 and 
let-7i) closely related to immune cell function and inflammation according to previous 
literature [556-562].  In particular, miR-146a and miR-155 have been consistently 
linked to inflammatory disease risk and outcome.  Of these, only miR-155 and let-7i 
showed any significant change in expression between the different DC populations.  
MiR-155 was up-regulated by LPS (mDC vs iDC; p=0.0311). MiR-155 was also up-
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regulated in the presence of LPS and short-term 1,25(OH)2D3 (mDC+1,25(OH)2D3 
vs iDC+1,25(OH)2D3; p=0.0091). LPS treatment of long-term 1,25(OH)2D3 cultured 
DC (mtolDC vs itolDC) also increased miR-155 (p=0.049) (Figure 5.6E).  Let-7i 
expression was up-regulated by LPS but only in the presence of short-term 
1,25(OH)2D3 (mDC+1,25(OH)2D3 vs iDC+1,25(OH)2D3; p=0.0012) (Figure 5.6G).  
These results indicated that miRNAs are targets for 1,25(OH)2D3 in DC, but also 
showed that analysis of candidate miRNAs based on previously reported literature 
may not be the most effective approach for determining DC miRNAs for 
1,25(OH)2D3. Therefore, in the next stage of the project we carried out unbiased 
analysis of miRNAs using PCR array analyses. 
 
5.3.5 Array miRNA expression by LPS maturation and 1,25(OH)2D3 
 
Using mRNA isolated from DC cultures and previously analysed by qRT-PCR 
(5.3.3 and 5.3.4), qPCR miRNA arrays were performed to profile the expression of 
372 validated human miRNAs most closely linked to immune function and 
inflammation.  The miRNA arrays included the previously selected candidate 
miRNAs.  Because of the significant costs associated with this, only 4 of the 6 DC 
phenotypes shown in Figure 5.3 were processed for array analysis; the selected 
populations were itolDC, iDC, mDC, and mDC+1,25(OH)2D3.  This selection of DC 
phenotypes allowed us to carry out an unbiased analysis of miRNAs that would 
assess the effect of long-term 1,25(OH)2D3 alone (iDC vs itolDC), short-term 
1,25(OH)2D3 when used in combination with LPS (mDC vs mDC+1,25(OH)2D3), and 
LPS maturation alone (iDC vs mDC).   
180 
 
5.3.5.1 Preliminary analysis of differentially regulated miRNAs 
 
Data from the qPCR arrays were initially obtained as delta Ct (ΔCt) values for 
each miRNA/PCR plate well. These raw PCR values were then used to carry out 
statistical analyses to assess changes in miRNA expression for: 1) long-term 
treatment with 1,25(OH)2D3 (iDC vs itolDC); 2) short-term 1,25(OH)2D3 in 
combination with LPS (mDC vs mDC+1,25(OH)2D3); 3) LPS maturation alone (iDC 
vs mDC). Data was analysed using SABiosciences PCR Array Data Analysis 
software (SABiosciences) recommended for the arrays, and were initially visualised 
as representative PCR plate heat-maps for the PCR arrays based on log fold-change 
in miRNA expression for specific 1,25(OH)2D3 or LPS treated DC relative to 
untreated controls (Figures 5.7A – 5.7C).    
Data were also visualised as scatter plots also showing log fold-change in 
miRNA expression.  Only miRNAs with a fold-change >2 were shown as significant in 
the preliminary analyses (Figures 5.8A-5.10A).  Preliminary analysis indicated that 
long-term 1,25(OH)2D3 (itolDC vs iDC) down-regulated expression of 193 miRNAs 
(>2 fold change). Short-term 1,25(OH)2D3 (mDC+1,25(OH)2D3 vs mDC) down-
regulated expression of 172 miRNAs, and up-regulated 2 miRNAs.  LPS maturation 
(mDC vs iDC) down-regulated expression of 15 miRNAs and up-regulated the 
expression of 29 miRNAs; these miRNAs are visualised as red or green dots on the 
scatter plots (Figures 5.8B-5.10B). Huynh-Feldt statistical testing was then 
performed on all miRNAs showing >2 fold regulation in these DC populations, to 
identify miRNAs that showed statistically significant differences in expression 
following treatment with 1,25(OH)2D3 or LPS based on n=6 different donor DC 
populations.  Only these significantly regulated miRNAs are listed in the figure table.      
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5.3.5.2 Huynh-Feldt significant miRNAs  
 
Huynh-Feldt statistical analysis identified 8 miRNAs that were significantly 
down-regulated following long term 1,25(OH)2D3 (Figure 5.8B) and 14 miRNAs that 
were significantly down-regulated following short-term 1,25(OH)2D3 (Figure 5.9B). In 
contrast only 2 miRNAs were significantly regulated by maturation with LPS (Figure 
5.10B); miR-155-5p was up-regulated (p=0.049) and miR-221-5p was down-
regulated (p=0.001). All Huynh-Feldt significantly-regulated miRNAs are shown in full 
graphical format for long-term 1,25(OH)2D3 (itolDC vs iDC) (Figure 5.11), short-term 
1,25(OH)2D3 (mDC+1,25(OH)2D3 vs mDC) (Figure 5.12) and LPS maturation (mDC 
vs iDC) (Figure 5.13).                 
Interestingly, miR-155-5p was significantly up-regulated by LPS maturation in 
the array data (iDC to mDC) (Figure 5.10B), then down-regulated following short-
term 1,25(OH)2D3 (mDC to mDC+1,25(OH)2D3) (Figure 5.9B).  This highlights miR-
155-5p as a potential regulator of inflammation, and a promising target for 
1,25(OH)2D3 based anti-inflammatory therapies.   
 
5.3.6 Predicted targets for miRNAs: a bioinformatics approach  
 
A full list of significantly regulated miRNAs as identified by Huynh-Feldt 
analysis is shown in Table 5.2, with different miRNAs regulated by LPS or 
1,25(OH)₂D3 highlighted accordingly.  Following the identification of these miRNAs 
from the qPCR arrays, a bioinformatics approach was used to identify their predicted 
target genes.  Firstly, MiRTarBase database was used to find predicted gene targets 
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for all significantly regulated miRNAs.  All gene targets on miRTarBase have been 
experimentally validated and ranked according to the number of research articles 
verifying the targets, then given a target prediction score out of 100.  The top 5 target 
genes for each miRNA identified by Huynh-Feldt analysis in the current study were 
ranked and compiled in Table 5.2; target genes were ranked from most to least 
validated, and the established cut-off target prediction score was set at 95 and above 
to exclude experimentally ‘weak’ targets. 
To further analyse and validate the functionality of select miRNA gene targets, 
bioinformatics approaches were used to identify predicted gene targets of these 
miRNAs.  MiRBase miRNA database was combined with Cytoscape software to 
produce a list of significant (p<0.05) experimentally validated gene targets of 
miRNAs.  By combining Cytoscape analysis with ClueGo gene ontology (GO) 
analysis, target genes were grouped according to enriched biological functions.  This 
approach was used to analyse the expression of miR-155-5p due to its differential 
regulation in response to LPS and 1,25(OH)2D3.  Target genes of miR-155-5p were 
found to function in a variety of biological processes including immune regulation 
(Figure 5.14A), underlining the potential for miR-155 mediated regulation of the 
immune system.  Additionally, gene ontology analysis was performed to produce 
networks to visualise miRNA gene regulation with regard to immune function.  The 
first network analysed all miRNAs that were significantly regulated in response to all 
treatments; long term 1,25(OH)2D3, short term 1,25(OH)2D3 and LPS (Figure 5.14B) 
where gene targets were involved in immune regulation.  Figures 5.14C-5.14E show 
networks created from miRNAs down-regulated by long term 1,25(OH)2D3 treatment, 
miRNAs down-regulated by short term 1,25(OH)2D3, and miRNAs regulated by LPS.  
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This bioinformatics approach identified many genes that were potentially targeted by 
1,25(OH)2D3-sensitive miRNAs, with some genes involved in regulation of immune 
responses, hence there is great potential for 1,25(OH)2D3-mediated miRNA 
modulation for immune health and disease.  
 
5.3.7 Effect of 1,25(OH)2D3 on miRNA synthesis genes in DC 
  
Due to the global miRNA down-regulation observed with long term 
1,25(OH)2D3 and short term 1,25(OH)2D3 treatment, genes involved in the miRNA 
synthesis pathway were also quantified by qRT-PCR in all 6 DC populations, to study 
the effect of long and short term 1,25(OH)2D3 and LPS maturation on gene 
expression.  Genes analysed were DROSHA, DICER1, AGO2, DGCR8, RAN, 
TARBP2 and XPO5, which encode proteins forming the key components of the 
miRNA synthesis machinery.  LPS-induced DC maturation in the absence of 
1,25(OH)2D3 (iDC to mDC) significantly down-regulated the expression of 5 out of 
the 7 genes; these were DROSHA (p=0.0212), DICER1 (p=0.0253), DGCR8 
(p=0.0334), RAN (p=0.0024) and XPO5 (p=0.0071) (Figure 5.15).  LPS-induced DC 
maturation in the presence of 1,25(OH)2D3 (itolDC to mtolDC) down-regulated the 
expression of DGCR8 (p=0.0087) and RAN (p=0.013).  Conversely, already mature 
DC populations in the presence of 1,25(OH)2D3 (mDC to mDC+1,25(OH)2D3; mDC 
to mtolDC) did not significantly regulate the expression of any genes.  Long term 
1,25(OH)2D3 treatment in the immature phenotype in the absence of LPS (iDC to 
itolDC) significantly down-regulated the expression of DROSHA (p=0.0266), RAN 
(p=0.0289), TARBP2 (p=0.0368) and XPO5 (p=0.0333).  Short term 1,25(OH)2D3 
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treatment in the absence of LPS (iDC to iDC+1,25(OH)2D3) also significantly down-
regulated the expression of DROSHA (p=0.0306), DICER1 (p=0.0209) and RAN 
(p=0.0124).  Interestingly, LPS or 1,25(OH)2D3-driven regulation of DROSHA or 




















Figure 5.3. Induction of variable DC phenotypes with lipopolysaccharide (LPS) and 
1,25-dihydroxyvitamin D (1,25(OH)2D3) 
itolDC – immature tolerogenic dendritic cell with 1,25(OH)2D3; mtolDC – mature 
tolerogenic dendritic cell with 1,25(OH)2D3; iDC – immature dendritic cell; mDC – mature 
dendritic cell; 1,25(OH)2D3 – immature dendritic cell with 1,25(OH)2D3; 
mDC+1,25(OH)2D3 – mature dendritic cell with 1,25(OH)2D3.  Monocytes were derived 
from whole blood leukocyte cones from healthy donors (n=6).  All 6 phenotypes were 
used for candidate mRNA and miRNA analysis.  The 4 cell phenotypes indicated were 























































































Figure 5.4 Flow cytometry staining validation of DC phenotype 
Populations were stained for surface markers A) HLA-DR, CD80, CD14; B) CD68, CD209 (DC-SIGN), CD83 and CD11c.  Isotype stain or a 
control population was used as the experimental control.  Data is shown as histogram overlay plots, with the median fluorescence intensity 
































HLA-DR CD80 CD14 CD209 CD83 CD11c CD86 CD40
Isotype 3.64 3.02 2.18 1 1.56 3.35 3.46 11.5
iDC 199 6.15 7.42 2.71 3.57 326 6.41 9.5
itolDC 6.55 4.88 12.7 4.01 3.09 311 2.79 8.78
mDC 277 63.1 3.29 14.9 7.2 351 44.9 12.8
mDC+1,25(OH)2D3 250 29 23.4 1.01 1.52 306 1.3 8.58
Cell population
Median Fluorescence Intensity (MFI)
Table 5.1. Expression of DC surface antigens by flow cytometry  
Relative expression of DC surface antigens measured by flow cytometry are shown as median fluorescence intensity (MFI) values.  iDC, 























Figure 5.5. Expression of genes associated with vitamin D metabolism and function in different DC phenotypes  
Data for qRT-PCR analysis of mRNA represents an individual donor (n=6). Data are shown as: mean ± SD raw Delta Ct (ΔCt) values from 
qRT-PCR (left panels), and fold-change in mRNA expression (right panels) of: A) VDR; B) CYP24A1; C) CYP27B1 in each of the 6 different 
DC phenotypes shown in Figure 5.3.   
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Figure 5.6. Expression of candidate miRNAs in different DC phenotypes  
Data for qRT-PCR analysis of miRNA represents an individual donor (n=6). Data are shown as: mean ± SD raw ΔCt values from qRT-PCR 
(left panels), and fold-change in miRNA expression (right panels) of: A) miR-21; B) miR-29a; C) miR-145; D) miR-146a; E) miR-155; F) miR-
627; G) let-7i, in each of the 6 different DC phenotypes shown in Figure 5.3.   
 





























































































































































































































































iDC vs itolDC 




iDC vs mDC 
  
Figure 5.7. Array miRNA expression shown as representative heat-maps  
Green and red plots represent downregulation and up-regulation of miRNA expression 
respectively, calculated as log₂ fold change for 372 miRNAs.  Heat-maps show miRNA 
expression change to treatment of DC with A) long term 1,25(OH)2D3 (iDC vs itolDC); B) 
short term 1,25(OH)2D3 (mDC vs mDC+1,25(OH)2D3); C) LPS maturation (iDC vs mDC).  
Coordinates on the heat-map correspond to individual miRNAs profiled in the array, which 




























Figure 5.8. qPCR array of miRNA expression in response to long term treatment of 
DC with 1,25(OH)2D3 
A) Scatter plot showing miRNA expression changes following long term 1,25(OH)2D3 (10 
nM, 120hrs) in itolDC (x-axis) vs iDC (y-axis) populations.  Individual green and red dots 
represent downregulation and up-regulation of a single miRNA respectively, calculated as 
log₂ fold change; B) Huynh-Feldt statistical analysis of statistically significant miRNAs 
differentially regulated following long term 1,25(OH)2D3.  Huynh-Feldt test was performed 
on normalised data, and significance taken as p<0.05.  
A 
B 
iDC vs itolDC 





















Figure 5.9. qPCR array of miRNA expression in response to short term treatment of 
DC with 1,25(OH)2D3 
A) Scatter plot showing miRNA expression changes following short term 1,25(OH)2D3 (10 
nM, 24hrs) in mDC+1,25(OH)2D3 (x-axis) vs mDC (y-axis) populations.  Individual green 
and red dots represent downregulation and up-regulation of a single miRNA respectively, 
calculated as log₂ fold change; B) Huynh-Feldt statistical analysis of statistically significant 
miRNAs differentially regulated following short term 1,25(OH)2D3.  Huynh-Feldt test was 
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Figure 5.10. qPCR array of miRNA expression in response to maturation of DC with 
LPS 
A) Scatter plot showing miRNA expression changes following LPS maturation (24hrs) in 
mDC (x-axis) vs iDC (y-axis) populations.  Individual green and red dots represent 
downregulation and up-regulation of a single miRNA respectively, calculated as log₂ fold 
change; B) Huynh-Feldt statistical analysis of statistically significant miRNAs differentially 
regulated following LPS.  Huynh-Feldt test was performed on normalised data, and 
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 Log2 fold change 
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Figure 5.11. Graphical representation of significantly regulated qPCR array 
miRNAs, to long term 1,25(OH)₂D3 (120hrs) 
qPCR array quantified expression changes in response to long term 1,25(OH)₂D3 for A) 
miR-10b-5p; B) miR-1-3p; C) miR-28-5p; D) miR-28-3p; E) miR-30e-3p; F) miR-32-3p; G) 
mir-340-3p; H) miR-374c-5p.  Individual donors (n=6) are shown. 1,25(OH)2D3 has been 
abbreviated to 1,25D.  Repeated-measures ANOVA for paired data was used to calculate 
statistical significance, and significance was taken as *p<0.05.   
















































































































































Figure 5.12. Graphical representation of significantly regulated qPCR array 
miRNAs, to short term 1,25(OH)₂D3 (24hrs) 
qPCR array quantified expression change in response to short term 1,25(OH)₂D3 for A) 
miR-125a-5p; B) miR-1284; C) miR-143-5p; D) miR-152-3p; E) miR-155-5p; F) miR-1914-
3p; G) mir-193a-5p; H) miR-200c-5p; I) miR-27b-5p; J) miR-296-3p; K) miR-377-5p; L) 
miR-432-5p; M) miR-506-3p.  Individual donors (n=6) are shown. 1,25(OH)2D3 has been 
abbreviated to 1,25D.  Repeated-measures ANOVA for paired data was used to calculate 
statistical significance, and significance was taken as *p<0.05.   

































































































































































































Figure 5.13. Graphical representation of significantly regulated qPCR array 
miRNAs, to LPS maturation (24hrs) 
qPCR array quantified expression changes in response to LPS maturation for A) miR-221-
5p; B) miR-155-5p.  Individual donors (n=6) are shown. 1,25(OH)2D3 has been 
abbreviated to 1,25D.  Repeated-measures ANOVA for paired data was used to calculate 
statistical significance, and significance was taken as *p<0.05.  






























    
 
 
miRNAs verified mRNA targets (miRTarBase) 
miR-1-3p MET TAGLN2 PTMA GJA1 EDN1 
miR-10b-5p HOXD10 KLF4 BCL2L11 HOXB3 PTEN 
miR-125a-5p CDKN1A TNFAIP3 CD34 TP53 ERBB2 
miR-1284 KCNK10 EIF4A1 KIF13A PMAIP1 TCTE1 
miR-143-5p COX2 GLCE RAB12 GINS4 ZNF460 
miR-152-3p HLA-G DNMT1 ADAM17 CD151 CD274 
miR-155-5p SOCS1 TAB2 PIK3R1 JARID2 APC 
miR-155-3p IRAK3 PTEN CREBRF ZNF460 UBE2K 
miR-1914-3p SEPT8 ZBTB46 SRM BARHL1 TXNIP 
miR-193a-5p TP73 ERBB2 RBBP6 PCSK9 FGF19 
miR-200c-5p C2orf72 POLR2F PKIA HPS4 ACTR1A 
miR-221-5p MBD2 YOD1 HES7 C18orf25 MUC17 
miR-27b-5p COX20 PPP4R1L G3BP1 DDX55 SNAP47 
miR-28-3p CTC1 VAV3 PER1 EIF4G2 MCTS1 
miR-28-5p CDKN1A MPL N4BP1 MAPK1 E2F6 
miR-296-3p KCNH1 FBXW7 GBA2 TFAP2A KMT2D 
miR-30e-3p NFKBIA KPNA2 EIF1 VAV3 MYC 
miR-32-3p ATAD5 COL23A1 VPS4A C5orf24 RBPJ 
miR-340-3p AGBL5 SYNJ2BP CNTN4 C18orf32 QTRT2 
miR-374c-5p E2F7 ANKRD33B ZNF850 KPNA6 CNBP 
miR-377-5p LYRM4 GDE1 TFDP2 TRIM66 ZNF573 
miR-432-5p MECP2 RCOR1 NES LRPPRC BLCAP 
miR-506-3p CD151 VIM CDK4 CDK6 YAP1   
Table 5.2. Summary of DC miRNAs significantly regulated by 1,25(OH)2D3 and their predicted mRNA targets 
Table of significantly regulated miRNAs in response to long term 1,25(OH)2D3, short term 1,25(OH)2D3 and LPS.  MiRNAs significantly 
regulated by each treatment is colour-coded accordingly.  Statistical significance is taken as p<0.05 by Huynh-Feldt analysis.  The top 5 
experimentally validated mRNA targets for each significant miRNA as predicted by miRTarBase are shown.  Only those with a target 


































Figure 5.14. Gene Ontology analysis of significantly regulated miRNA targets 
Cytoscape v3.6.1 gene prediction software was used in conjunction with ClueGo gene ontology software to identify experimentally validated 
gene targets of miRNAs and their biological functions.  Networks show validated gene targets of A) miR-155-5p; B) all significantly regulated 
miRNAs with functions in immune regulation; C) miRNAs significantly downregulated by long term 1,25(OH)₂D3; D) miRNAs significantly 
downregulated by short term 1,25(OH)₂D3; E) miRNAs significantly regulated by LPS.  For Cytoscape miRNA target prediction, all targets 
with a target prediction score below of 95% were excluded.  For ClueGo gene ontology (GO) analysis, statistical significance of genes with 
enriched biological functions was taken as p<0.05 calculated by Bonferroni step-down.  Where gene ontology is not shown, no statistically 
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Figure 5.15. Expression of genes associated with miRNA synthesis in different DC phenotypes  
Data for qRT-PCR analysis of mRNA represents an individual donor (n=4). Data is shown as: mean ± SD raw ΔCt values from qRT-PCR (left 
panels), and fold-change in mRNA expression (right panels) of: A) DROSHA; B) DICER1; C) AGO2; D) DGCR8; E) RAN; F) TARBP2; G) 
XPO5, in each of the 6 different DC phenotypes shown in Figure 5.3.   













































































































































































































































































The anti-inflammatory actions of 1,25(OH)2D3 have been well defined, with 
many studies showing a correlation between altered levels of 1,25(OH)2D3 and 
greater susceptibility to inflammatory disease via dysregulation of immune 
responses.  The key driver to this finding was the discovery of vitamin D activating 
enzyme CYP27B1 and the vitamin D receptor (VDR) present in other non-calcium 
processing related cells including immune cells  [563].  Thus immune cells that 
express the appropriate enzymes and receptors are capable of synthesising 
1,25(OH)2D3 in an extra-renal fashion, leading to immunomodulatory actions similar 
to that produced by local cytokines [564], by inducing activation on downstream T 
cells and mediating further release of cytokines.  Such cells capable of synthesising 
1,25(OH)2D3 include macrophages and DC.  Studies have shown 1,25(OH)2D3 to be 
capable of altering the function and morphology of DC to inhibit maturation [565] and 
induce tolerogenic status [524, 566].   
 
5.4.1 1,25(OH)2D3 on DC differentiation and maturation 
 
1,25(OH)2D3 has previously been shown to inhibit maturation of DC in vitro, as 
seen by down-regulation of CD80 and CD86 DC maturation marker expression [154, 
156, 567].  The current study showed immature DC (iDC) treated with 1,25(OH)2D3 
for 120hrs led to markedly down-regulated CD80 expression compared to untreated 
iDC (Figure 5.4A).  Interestingly, treatment with 1,25(OH)2D3 for 24hrs (mDC vs 
mDC+1,25(OH)2D3) did not produce such a significant effect on CD80 expression 
despite the fact mature DC have greater capacity for immunomodulation and 
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1,25(OH)2D3 response [481].  However, the lack of a significant reduction in CD80 
expression could be due to the short incubation time of 1,25(OH)2D3 in the current 
study (24hrs); this may not have been sufficient time for the establishment and up-
regulation of VDR to drive 1,25(OH)2D3-mediated responses.  Indeed, VDR 
expression was not significantly up-regulated following short term 1,25(OH)2D3 
treatment (Figure 5.5A), suggesting the immunomodulatory properties of 
1,25(OH)2D3 may be more apparent over a longer period of time.   
Penna and Adorini previously studied the inhibitory effect of 1,25(OH)2D3 on 
monocyte to iDC differentiation, and found that 1,25(OH)2D3 prevented the 
differentiation of monocytes into iDC, as seen by down-regulated CD14 monocyte 
marker expression [163].  The current study did not profile CD14 expression in 
monocytes as the study focus was on the phenotypic changes in DC, but did find that 
both long term and short term 1,25(OH)2D3 sustained expression of CD14 in iDC 
(Figure 5.4A).  This observation was supported by previous studies also finding 
CD14+ monocyte marker sustenance following 1,25(OH)2D3 exposure in iDC, 
suggesting the DC were promoted to differentiate away from the antigen presentation 
pathway [158, 568].  These studies found monocytes differentiated into iDC in the 
presence of 10nM 1,25(OH)2D3 in culture, the same concentration used in the 
current study, showed CD14 expression remained elevated compared to untreated 
cells, whilst co-stimulatory molecule CD86 was suppressed.  The current study also 
observed that LPS-induced DC maturation led to elevated expression of the DC 
activation markers CD83 and CD80, whereas subsequent addition of 1,25(OH)2D3 
resulted in the down-regulation of CD83 and CD80 expression; these findings were 
also observed in previous studies [157].  This inhibition of DC maturation by 
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1,25(OH)2D3 leads to reduced antigen presentation and acts to dampen the pro-
inflammatory immune response.  All of the above actions of 1,25(OH)2D3 act to 
maintain an immature DC phenotype, reduce antigen presentation and promote T 
cell hypo-responsiveness, thus leading to the strong anti-inflammatory properties of 
1,25(OH)2D3.   
 
5.4.2 1,25(OH)2D3 and the generation of tolerogenic DC 
 
1,25(OH)2D3 also promotes a tolerogenic DC status [158, 569].  This is 
possible due to the intracellular expression of the enzyme 1α-hydroxylase, allowing 
DC to establish and maintain a high local intracellular concentration of 1,25(OH)2D3 
required for immunomodulation [565].  CYP27B1 and VDR gene expression is up-
regulated as the DC undergoes maturation [459, 570].  Similarly, the current study 
also found a significant up-regulation of CYP27B1 and VDR expression upon 
maturing iDC with LPS (Figure 5.5).  Hewison et al. suggested the mechanism of up-
regulating CYP27B1 and VDR in mature DC phenotypes may be beneficial for 
inducing downstream T cell responses, due to overstimulation rendering the DC 
insensitive to further 1,25(OH)2D3.  In support of this mechanism, the current study 
found that CYP27B1 and VDR expression was down-regulated in mature DC 
phenotypes following long term 1,25(OH)2D3 treatment; this could be to prevent 
desensitisation to excess 1,25(OH)2D3 as part of the negative feedback mechanism 
of 1,25(OH)2D3 synthesis and regulation.  Another mechanism proposed for this 
regulation suggested that excessive 1,25(OH)2D3 limits 1α-hydroxylase activity by 
increasing FGF23 production [219] as well as self-regulation by inducing the 
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catabolic enzyme 24-hydroxylase [227], thus acting to maintain 1,25(OH)2D3 levels 
within a normal range.  Results from the current study appear to support this 
mechanism; consistent with down-regulated CYP27B1 and VDR expression following 
long term 1,25(OH)2D3, significant up-regulation of CYP24A1 expression was also 
observed (Figure 5.5B).  Other studies have shown 1,25(OH)2D3 to induce 
CYP24A1 expression and suppress CYP27B1 expression in DC [571, 572], which 
was also observed in the current study. In addition, 1,25(OH)2D3 is able to regulate 
the expression of its own receptor VDR in an autocrine fashion [573, 574].  The 
current accepted model for 1,25(OH)2D3 regulation shows 1,25(OH)2D3 to function in 
an autocrine or paracrine fashion in cells such as DC which express the 1α-
hydroxylase enzyme.  The 24-hydroxylase enzyme is also present in most cells 
expressing VDR.  In this way DC are capable of responding to 1,25(OH)2D3 to bring 
about molecular changes intracellularly, whilst regulating levels of 1,25(OH)2D3 
extracellularly to modulate downstream immune responses. 
 
5.4.3 1,25(OH)2D3 and immunomodulation by miRNAs in DC 
 
The process of immunomodulation is thought to involve post-transcriptional 
epigenetic regulation, in particular by miRNAs due to the regulatory roles they play in 
biological processes including immune regulation [575, 576].  Several miRNAs 
including miR-155 [577], let-7 [578] and miR-146a [464] have been shown to be 
selectively or highly expressed in immune cells, with potential roles in regulating 




5.4.3.1 1,25(OH)2D3 and miR-155 
 
The current study found that miR-155 expression was significantly up-
regulated in DC following maturation with LPS (Figure 5.6E).  Previous studies have 
also shown an association between miR-155 and DC maturation, where LPS 
induction of iDC leads to significantly up-regulated miR-155 expression [533, 535].  
These studies proposed that maturation-induced miR-155 up-regulation in DC were 
due to down-regulated expression of genes in the TIR/IL-1 pathway, of which genes 
are potential targets for miR-155.  In this way miR-155 acts in a negative feedback 
loop to target SOCS-1, leading to down-regulated inflammatory cytokine production 
following an immune challenge to prevent excessive inflammation [579].  MiRNA 
quantification data in the current study appear to support this mechanism of 
regulation, although surprisingly miR-155 expression was up-regulated by LPS-
induced maturation both in the presence and absence of 1,25(OH)2D3.  Given the 
anti-inflammatory nature of 1,25(OH)2D3, a down-regulation of miR-155 expression in 
mDC following 1,25(OH)2D3 treatment would have been expected, which was not the 
case in the current study.  Perhaps this finding further highlights the importance of 
the negative feedback loop in tightly regulating miR-155 expression within baseline 
and maximum levels in the cell to prevent autoimmune response.   
 
5.4.3.2 1,25(OH)2D3 and miR-146a 
 
Previous studies also found miR-146a expression to be up-regulated following 
LPS stimulus in DC [464].   The current study did not find such induction in LPS-
matured DC (Figure 5.6D); however this disparity could be explained by the different 
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sources of LPS used to stimulate DC between both studies.  Comparing the 
regulation of miR-146a expression in response to different sources of LPS stimulus in 
DC, purer forms of LPS such as those from E. coli as used to mature DC in the 
current study showed lower levels of miR-146a up-regulation compared to an 
alternative form of LPS as used by the previous study, which may explain why a 
significant induction of up-regulation of miR-146a in LPS-stimulated DC was not 
seen.  The current study also found let-7i expression to be regulated after LPS 
maturation (Figure 5.6G).  In DC, let-7i has been shown to be up-regulated in 
response to DC maturation [537, 538]; Kuppusamy et al. indicated that the let-7 
family of miRNAs may be important mediators of cell maturation.  Other studies 
support this idea; LPS-induced DC maturation was found to require the up-regulation 
of let-7i [539], where down-regulation of let-7i prevented DC maturation as shown by 
decreased expression of CD80 and CD86 mDC surface markers.  Similarly, the 
current study also saw an induction of let-7i expression upon maturation of DC with 
LPS, but this was only significant in the presence of 1,25(OH)2D3 (Figure 5.6G).   
 
5.4.3.3 1,25(OH)2D3 and LPS 
 
LPS stimulus, amongst other inflammatory stimuli such as cytokines, is able to 
induce the up-regulation or down-regulation of select miRNAs that control maturation 
processes and antigen presentation within DC, leading to modulations in the immune 
response [532, 580, 581].  Multiple studies have profiled miRNA expression changes 
before and after LPS-induced DC maturation, and found that miR-146a [582] and 
consistently miR-155 [535, 583, 584]  was up-regulated during DC maturation, 
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suggesting that these miRNAs contributed to a pro-inflammatory pathway.  Similarly, 
in the current study both candidate miRNA analyses and miRNA qPCR array 
analyses identified miR-155 expression as significantly up-regulated following LPS 
maturation in DC (Figure 5.6E; Figure 5.10B) however neither analysis identified 
miR-146a as being significantly regulated by LPS (Figure 5.6D; Figure 5.10B), in 
contrast to miR-146a up-regulation previously observed by Jin et al. [582].  This 
disparity could be due to a number of reasons.  Firstly, differences in culture 
methodology between studies could attribute to differences in miRNA expression; Jin 
et al. cultured monocytes from derived PBMC with GM-CSF and IL-4 for only 3 days, 
compared to the standard 5 day culture used in the current study.  The length of 
culture time is likely to affect miRNA expression as DC reach different levels of 
differentiation and maturity, with differential miRNA expression associated with each 
developmental stage.  Furthermore, Jin et al. profiled miRNA expression by only 
standard qPCR methodology and data analysis, whilst the current study and a 
number of others performed array analyses of multiple miRNA panels; for example 
Ceppi et al. performed an array analysis of multiple miRNAs and found miR-155 but 
not miR-146a to be up-regulated during DC maturation.  Likewise, in the current 
study let-7i expression by LPS maturation was originally identified as significantly up-
regulated in the single candidate qPCR experiments (Figure 5.6G), but this was not 
detected as significant in the qPCR arrays (Figure 5.10B).  This could be attributed 
to better detection and more advanced data analysis methods in array analyses 
compared to single qPCR miRNA analyses.  Additionally, the use of multiple 
endogenous controls in the arrays leads to better data normalisation, hence overall 
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array data is likely to be more reliable at detecting true changes in miRNA expression 
compared to single miRNA analysis. 
 
5.4.3.4 1,25(OH)2D3 and other miRNAs 
 
Following LPS maturation to DC in the current study, miR-221 down-regulation 
in DC was observed (Figure 5.10B); a previous study suggested that miR-221 was 
important for and contributed to the survival of iDC [539].  This study found 
decreased miR-221 in conjunction with up-regulated miR-155 expression following 
DC maturation correlated with the accumulation of p27 (kip1) expression and 
subsequent cell survival.  Therefore, this could explain why upon DC maturation in 
the current study, miR-221 expression was down-regulated as it was no longer 
required.  Based on these results it is possible that miR-221 and miR-155 are 
involved in regulation of apoptosis in DC.  An additional role of miR-155 in DC has 
been proposed; one study suggested miR-155 was necessary for the normal function 
of mDC to activate T cells [585].  However, this study found that despite knocking 
down miR-155 expression in mDC, these mDC did not show decreased CD86 
expression compared to mDC with functional miR-155, despite having impaired T cell 
activation.  In contrast, another study found that miR-155-deficient mDC had 
impaired T cell activation that correlated with significantly reduced expression of 
CD86 [533].  The current study did not profile miRNA expression in miR-155-
decficient DC but did find LPS maturation significantly up-regulated the expression of 
DC maturation markers including CD86.   
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Other miRNAs of interest with regard to DC differentiation, maturation and 
survival include miR-29, miR-148 and miR-451; all these miRNAs have previously 
been found to be up-regulated following DC maturation and play an anti-inflammatory 
role.  Increased miR-29 expression has been correlated with inhibited pro-
inflammatory cytokine secretion [586].  However, the vast majority of literature on 
candidate miRNA studies involves the role of miRNAs in DC function in BMDC, 
plasmacytoid DC or murine DC, thus were incomparable directly with the monocyte-
derived human DC in the present study.  There have been previous qPCR array 
analyses performed to quantify miRNA expression in human monocyte-derived DC; 
these studies identified miR-511 and miR-99b to be highly expressed in mDC [587], 
and inhibition of these miRNAs resulted in reduced CD80 and CD86 expression, 
suggesting these miRNAs are important for regulating the immune response.  The 
qPCR arrays performed in the current study was limited to 372 miRNAs most 
associated with inflammation.  Due to time and cost factors it was not feasible to 
profile the expression of all human miRNAs, and it is possible that other miRNAs with 
novel roles in immune regulation have yet to be identified.   
 
5.4.4 Global miRNA expression and the miRNA synthesis pathway 
 
It was interesting to observe the global down-regulation of miRNAs in DC 
following long term 1,25(OH)2D3, short term 1,25(OH)2D3 and LPS treatment.  The 
significance of this finding was debated with regard to whether the down-regulation of 
miRNA expression was truly due to a 1,25(OH)2D3 or LPS effect, or if there was 
another intrinsic mechanism more likely to be responsible for the global miRNA 
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down-regulation observed.  Since DROSHA and DICER1, amongst others, are 
crucial components of the pathway responsible for miRNA biogenesis, expression of 
the major miRNA synthesis genes was quantified in all DC phenotypes to identify any 
correlations between miRNA expression and these genes.  DROSHA, DICER1 and 
RAN expression were significantly down-regulated with short term 1,25(OH)2D3 
treatment (iDC to iDC+1,25(OH)2D3), and expression of DROSHA, RAN, TARBP2 
and XPO5 was also down-regulated following long term 1,25(OH)2D3 (iDC to itolDC) 
(Figure 5.15).  The down-regulation of these miRNA synthesis genes was originally 
thought to explain the majority of miRNAs similarly down-regulated with short term 
and long term 1,25(OH)2D3 in the qPCR arrays (Figures 5.8-5.10).  Interestingly, 
significant down-regulation of their counterpart genes DGCR8, XPO5 and TARBP2 
respectively was not observed, lending the possibility of these genes compensating 
for the diminished expression of their co-factors to maintain miRNA synthesis.  
Previous studies have shown the expression of DICER1 does not affect the function 
of its co-factor TARBP2 [588], but rather that TARBP2 is necessary for the 
recruitment of DICER1 and normal miRNA synthesis [589].  Additionally, AGO2, 
which is not associated with a co-functioning protein and acts at the end of the 
miRNA synthesis pathway, was not significantly regulated with long term 
1,25(OH)2D3, short term 1,25(OH)2D3 or LPS in the current study.  Hence the global 
down-regulation of miRNA expression observed is unlikely to be due to down-
regulated miRNA synthesis genes.  The importance of miRNAs for regulating DC 
differentiation has further been demonstrated by DICER1 knockdown studies, which 
observed that suppressed miRNA biogenesis led to the up-regulation of CD14 
marker in DC [590].  
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  However, in the case of LPS-induced DC maturation in the absence of 
1,25(OH)2D3 (iDC to mDC) and its effect on the expression of miRNA synthesis 
genes, DROSHA and RAN expression was significantly down-regulated along with 
their associated co-factors DGCR8 and XPO5.  Similarly, LPS-induced maturation in 
DC in the presence of long term 1,25(OH)2D3 (itolDC to mtolDC) also produced 
down-regulation of DGCR8 and RAN expression (Figure 5.15).  These findings 
would suggest a reduced synthesis of pre-miRNAs as well as reduced nuclear export 
of the pre-miRNA, leading to the overall down-regulated synthesis of mature miRNAs 
detected in DC.  Perhaps in this way LPS and other cell stressors function to down-
regulate the expression of miRNAs normally associated with preventing inappropriate 
immune activation [591].  Although many miRNAs in the current study were indeed 
down-regulated following LPS maturation in DC, miR-155 expression was up-
regulated.  If the global down-regulation of miRNAs was a result of reduced miRNA 
synthesis, one would expect all miRNAs to be down-regulated without exception.  In 
addition, miRNA biogenesis-mediated miRNA down-regulation would target both the 
5’ and 3’ end miRNA families for down-regulation, for example miR-155-5p and miR-
155-3p, however this was not the case in the current study.  Interestingly, further 
bioinformatics analysis identified genes encoding enzymes that hydrolyse the 5’ end 
miRNAs were down-regulated, but enzymes that attach to the 3’ end were 
unaffected, suggesting the global down-regulation of miRNAs was not linked miRNA 
synthesis machinery but rather involved select enzymatic targeting.  Under normal 
settings the 5’ region of a pre-miRNA is crucial for recognition and binding by DICER 
to synthesise the mature miRNA [592].    
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Additionally, the half-life of mature miRNAs in human immune cells can vary 
from 5 days to two weeks [593].  Relating this to miRNA biogenesis, even if 
expression of miRNA synthesis genes were down-regulated leading to reduced 
miRNA synthesis, it would take at least 5 days for the expression levels of miRNAs to 
fall by half and for significant changes to be detected, i.e. the time taken for the loss 
of DICER expression to take effect would most likely exceed the DC lifespan.  This is 
supported by a study which found that blocking the function of miRNA processing 
enzymes such as DICER1 took up to 3 days for the effects to be translated onto 
miRNAs [593].  Since DC in the current study were cultured for 6 days, it is very 
unlikely that during this time the miRNAs would become unstable and significantly 
down-regulated.  Instead, the current study proposes an alternative explanation for 
the global down-regulation of miRNAs observed, which suggests this effect may be 
independent of the DROSHA/DICER machinery.  Indeed a previous study suggested 
the availability of DROSHA and DICER did not affect miRNA synthesis, but instead it 
was the abundance of Argonaute proteins that controlled levels of mature miRNAs 
[594]. Genes including AGO2 which encodes the Argonaute proteins play a key post-
transcriptional role in elevating levels of mature miRNAs in the cellular environment. 
Further studies are required to elucidate the role of miRNA biogenesis genes alone, 
and determine whether the function of one gene affects that of others, and what 






5.4.5 MiRNA targets identified by bioinformatics analysis 
 
Bioinformatics coupled with gene ontology analysis of miRNA gene targets 
and functions in DC revealed that the majority of significantly regulated miRNAs 
targeted genes with roles in immune regulation.  MiR-155 targets many genes with 
new and established roles in immune regulation, including SOCS1, BCL6 and 
PIK3R1 (Table 5.2; Figure 5.14A).  Many of the miRNAs that were significantly 
regulated by both 1,25(OH)2D3 and LPS were shown to be over-represented for 
target genes with a role in immune regulation (Figure 5.14B).  In contrast, miRNAs 
significantly regulated by long term 1,25(OH)2D3 targeted genes with a much wider 
variety of functions from adipogenesis to cell hypertrophy (Figure 5.14C).  Some of 
these genes carry out more than one function, which makes it very difficult to identify 
a specific miRNA that targets each gene.  These bioinformatics tools are helpful to 
identify miRNA gene targets and biological functions of these genes, as a first step 





The mechanism of miRNA regulation with regard to DC differentiation and 
maturation remains unclear, but there is strong evidence to suggest that select 
miRNAs including miR-155 play key regulatory roles in the homeostasis and normal 
function of the innate immune system.  The immunomodulatory effects of 
1,25(OH)2D3 in DC bring about different phenotypical and functional changes 
depending on the stage of DC development, length of treatment time and the 
cytokine milieu.   
The expression of many genes is altered during these changes, and it remains 
likely that these changes are facilitated by the differential expression of a host of 
miRNAs.  In DC, miRNAs of particular interest with regard to inflammation and 
1,25(OH)2D3-mediated immune modulation include miR-146a, miR-155 and to an 
extent let-7i.  Furthermore, genes involved in the miRNA biogenesis pathway appear 
to be modulated by LPS-induced maturation, however the expression of these genes 
is unlikely to affect miRNA biogenesis in DC phenotypes.  LPS-mediated down-
regulation of these genes was not rescued by short term or long term 1,25(OH)2D3, 
suggesting the miRNA biogenesis machinery is stable and any immunomodulatory 
effects of 1,25(OH)2D3 are likely to act on mature miRNAs only.  Future studies 
should involve quantifying expression of pre-miRNAs and pri-miRNAs in DC, in 
conjunction with miRNA biogenesis gene expression analysis and 1,25(OH)2D3 
treatment, to elucidate the mechanism of 1,25(OH)2D3 on miRNA regulation.    
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CHAPTER 6.  VITAMIN D AND 























6.1.1 Introduction to T cells 
 
T lymphocytes (T cells) are responder cells that form part of the adaptive 
immune response.  They originate from bone marrow progenitor cells and migrate to 
the thymus where they mature and are exported to peripheral tissues.  Here they 
recognise foreign antigens presented by antigen presenting cells (APC) such as 
dendritic cells. In this way peripheral T cells become activated and can stimulate the 
production of a host of cytokines and chemokines to mediate inflammation.  The 
functional roles and mechanisms of T cells in vivo have largely been elucidated 
through mouse models [595, 596], however the interactions between T cells and 
pathogens that humans are exposed to in everyday life is thought to involve complex 
mechanisms [597].   
T cells are distinguished from other immune cells by the expression of Cluster 
of Differentiation (CD) CD3 on their cell surface.  Subsets of T cells are further 
classified by the expression of receptors on their cell surface; the two main classes 
are CD4+ and CD8+ T cells.  CD4+ T cells, or T helper (Th) cells, are distinguished 
by the abundant expression of CD4 receptor.  They coordinate immune responses by 
participating in cell-cell signalling to modulate the release of cytokines that go on to 
influence the behavior of downstream immune cells such as B cells.  On the other 
hand, CD8+ T cells, or cytotoxic killer T (Tc) cells, express CD8 receptor and are 
involved in killing infected cells.  In a healthy adult both CD4+ and CD8+ T cell 
subsets begin as naïve quiescent cells, and upon the detection of a foreign antigen 
presented by APC they become primed in secondary lymphoid tissues. 
Multiple sub-phenotypes of CD4+ and CD8+ T cells have been discovered, each with 
specific roles in the immune response.  CD4+ subsets include Th1, Th2, Th17 and T 
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regulatory (Treg) cells, each of which is associated with the production of a specific 
set of cytokines [598].  Th1 cells produce IFN-γ which creates an environment to 
activate CD8+ T cells, and Th1 cells are therefore associated with cellular immunity 
[599].  Th2 cells mainly secrete IL-4 and IL-10 which assists in the stimulation of 
antibody production by B cells, and Th2 cells are therefore associated with humoral 
immunity [599].  The Th17 subset is perhaps the most well documented with regards 
to inflammation, with the production of pro-inflammatory cytokines such as IL-17 and 
its interaction with IL-23 implicated in the basis of many autoimmune diseases 
including rheumatoid arthritis [600].  Finally, Tregs are characterised by the 
expression of CD4 and CD25 on their cell surface and FoxP3 intracellularly; these 
cells also secrete IL-10 as well as TGF-β and recognise self-antigens to prevent 
autoimmune responses [601].  Treg dysregulation has been implicated in 
malignancy, allergy and chronic infections.  CD8+ subsets include Tc1 and Tc2 
groups which are similar to Th1 and Th2 in terms of cytokine profile [602].  The 
subsets of T cells and their associated cytokines are summarised in Figure 6.1.    
In addition to Th (CD4+) and Tc (CD8+) subsets, both types of T cells can also 
be divided into naïve and memory T cells. Memory T cells are found in the periphery 
and maintain long term immunity, having a protective role against previously 
encountered antigens in order to elicit a faster immune response [603].  Memory T 
cells develop from effector T cells after exposure to an antigen, however their origins 
are still debated.  The focus of this chapter is on CD4+ T cells. Further details about 









Figure 6.1. Subsets of CD4+ T lymphocytes  
CD4+ T lymphocyte subsets include Th1, Th17, Th2 and Treg cells.  Each subset is 
associated with cytokines which play a role in the pro-inflammatory, anti-inflammatory and 
regulation of immune responses.  Following activation of naïve CD4+ T cells, these cells may 
differentiate into one of several lineages, defined by the cytokine signals in the environment.  
Th, T-helper; Treg, T-regulatory; IL, interleukin; TGF, transformation growth factor.   
 
6.1.2 Conventional CD4+ CD25- T cells 
Previously, the presence of cell surface CD25 was used to distinguish Treg 
cells from other classes of T cells, however activated effector T cells also express 
CD25.  A proportion of CD4+ CD25- cells known as conventional T cells possess 
regulatory properties similar to CD4+ CD25+ Tregs [604].  Now FoxP3 expression is 
used as the most definitive marker to distinguish between differentiated Tregs as 
they express FoxP3 in high quantities whereas conventional CD4+ CD25- T cells 
express it at very low levels.  A proportion of naïve CD4+ CD25- T cells expressing 
FoxP3 possess the capacity to convert to CD25+ Tregs after homeostatic expansion, 
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and can be selected for by IL-2 [605]. This process is thought to help maintain the 
Treg population in peripheral tissues [606].   
When naïve CD4+ CD25- T cells are subject to an immune challenge, they up-
regulate the expression of FoxP3 mediated by TGF-β, which promotes their transition 
to a Treg phenotype with immunosuppressive properties.  These ‘induced’ Tregs are 
unresponsive to further signals via the T cell receptor (TCR) [607].  Furthermore, 
when peripheral naïve CD4+ CD25- T cells are stimulated with anti-CD3 and anti-
CD28 and exposed to a Th17 cytokine cocktail of TGF-β, IL-6, IL-21 and IL-23, this 
encourages the generation of a pro-inflammatory Th17 lineage [608].  Th17 cells are 
a subset of CD4+ effector T cells that produce IL-17 and have a pro-inflammatory 
role; dysregulation in the form of over-activation of Th17 cells is a key feature of the 
pathogenesis of many autoimmune diseases such as rheumatoid arthritis (RA) [600].  
In contrast, the presence of TGF-β alone during peripheral CD4+ CD25- naïve T cell 
differentiation mediates the development of induced regulatory T (iTreg) cells which 
have immunosuppressive functions [609]. 
The relocation of CTLA-4 from intracellular vesicles to the cell surface is 
important for T cells to mediate suppressor function.  In naïve CD4+ CD25- T cells, 
CTLA-4 is localised in vesicles away from the cell surface, with no effect on T cell 
function.  Upon TCR-mediated T cell activation, internal CTLA-4 is released and 
signals at the cell surface to mediate T cell suppressor functions [610].  In this way 
the localisation of CTLA-4 is able to mediate immune response in T cells.  CTLA-4 at 
the cell surface is thought to be localised at the immune synapse, where it acts as a 
checkpoint control to determine whether a T cell responds to an antigen, and thus 
prevent autoimmune targeting of self-antigens [611].  Once CTLA-4 is internalised, it 
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can be recycled back to the plasma membrane or targeted for degradation by 
lysosomes.  Those that are targeted for degradation can capture its ligands on the 
way, so in this way CTLA-4 controls ligand availability for CD28 and suppresses T 
cell responses.   
        
6.1.3 Regulatory CD4+ CD25+ T cells 
 
Tregs are a subset of CD4+ CD25+ T cells that possess immunosuppressive 
functions.  This population was first discovered in mice by Asano and Sakaguchi, and 
was found to function in the maintenance of self-tolerance by down-regulating 
immune responses to self and non-self antigens [612, 613].  Initially they were 
identified in humans by their high expression of FoxP3 and CD25.  It is now known 
that activated effector T cells also express CD25, however in mice high CD25 
expression alone still remains a good cell surface discriminatory molecule for Tregs.  
Activated effector T cells also express many of the functional molecules of Tregs 
such as high CTLA-4 expression; hence it can be difficult to differentiate between the 
two T cell subtypes using these markers alone.  Activated T cells can also express 
FoxP3 although this transient expression only lasts for a few days.  
Tregs derived directly from the thymus are classed as natural Tregs, and T 
cells manipulated to differentiate into Tregs from peripheral cells are called 
induced/adaptive Tregs (iTreg) but possess the functions and characteristics of 
natural Tregs [606].  In vivo, TGF-β produced by natural Tregs is capable of inducing 
iTreg differentiation from naïve CD4+ T cells [614].  There are many classes of 
peripherally derived Tregs, of which some express FoxP3 and IL-10.  Tregs mainly 
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express CD4, CD25 and FoxP3, and may be derived from the same lineage as naïve 
CD4+ T cells.  Increased FoxP3 expression is a marker for naïve CD4+ T cell 
conversion to CD4+ Treg cell phenotype. Similarly, CTLA-4 is lowly expressed at rest 
and up-regulated during T cell activation/stimulation, with maximal expression at 48-
72hrs post-activation [615].  CTLA-4 expression is critical for the Treg to function and 
prevent autoimmunity, and its expression is dependent on the expression of FoxP3 
[616]; lack of CTLA-4 in Tregs leads to uncontrolled activation and expansion of 
naïve T cells [617-619].  The depletion of CD4+ CD25+ Tregs has been implicated in 
the development of many autoimmune diseases [613, 620, 621].  As a consequence, 
studies have focused on the effect of enhancing Treg numbers and function as a 
possible strategy for managing the pathogenesis of inflammation.   
In mice, stimulation of CD4+ CD25+ FoxP3+ Tregs prevents transplant 
rejection [622].  In humans, CD4+ CD25+ FoxP3+ Tregs are actively recruited to 
sites of infection [623].  It is thought Tregs exert these immunosuppressive functions 
mainly through the production of cytokines and occasionally through cell-cell contact 
[624, 625], or even via down-regulating CD80/CD86 expression on DC [626, 627].  
These studies summarise the critical role of Tregs in maintaining a healthy immune 
response.   
 
6.1.4 Th17 cells 
 
Th17 cells traditionally have roles in mediating responses to bacteria and fungi 
[628], however recently they have been implicated in the pathogenesis of 
autoimmune disease including inflammatory bowel disease and rheumatoid arthritis 
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[628].  In vitro, Th17 cells can be induced by first stimulating naïve CD4+ T cells with 
anti-CD3 and anti-CD28, followed by incubation in inflammatory Th17 cytokine 
cocktail consisting of IL-1β, IL-2, TGF-β, IL-6 and IL-23 [629, 630].  IL-4 and IFN-У 
cytokines released by Th1/Th2 subsets act to inhibit the differentiation of Th17 cells 
[631, 632], making the Th17 lineage distinct to that of Th1 and Th2.  In mice, Th17 
subsets can be induced by stimulating CD4+ T cells via the TCR, in the presence of 
TGF-β and IL-6.  The presence of TGF-β is critical to drive Th17 differentiation both 
in mice [633, 634] and in humans [635].   
The Th17 differentiation process involves three stages in humans: 1) 
differentiation stage mediated by TGF-β and IL-6; 2) self-amplification stage by IL-21; 
3) survival and expansion stage by IL-23.  Studies show TGF-β signalling is a critical 
driving force of CD4+ T cell commitment to Th17 lineage [634, 636]; the first study 
showed that TGF-β in the presence of IL-6 led to the generation of Th17 producing 
cells.  The latter study confirmed the role of TGF-β signaling in differentiation to Th17 
fate, and showed TGF-β up-regulated IL-23 receptor to enhance survival and further 
expansion of the lineage.  High concentrations of TGF-β alone in the CD4+ T cell 
differentiation stage mediates generation of Treg cells from peripheral CD4+ CD25- 
naïve T cells, via the up-regulation of FoxP3 transcription factor [607].  These 
induced Tregs have potent immunosuppressive properties [607].  In contrast, low 
concentrations of TGF-β synergizing with IL-6 induces Th17 differentiation to induce 
IL-23 receptor expression [634, 637], thus the decision between CD4+ T cells 
differentiating into a Treg or Th17 fate is dependent on the cytokine environment and 
regulatory expression of FoxP3.     
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The second stage of Th17 differentiation requires IL-21, produced by Th17 
cells, to act together with TGF-β to promote further Th17 differentiation in a self-
amplification fashion [638, 639].  The final stage is mediated by IL-23 produced by 
APC, to maintain the Th17 population [634, 640].  Together this shows the 
importance of maintaining the cytokine balance for appropriate T cell differentiation.  
Interestingly, previous studies have shown that in order for APC to direct Th cell 
differentiation, a third activation signal is required [641]; only APC directly activated 
by PAMPs are capable of inducing the third stimulatory signal for T cells, whereas 
APC indirectly activated by inflammatory mediators are capable of CD4+ T cell 
expansion but not Th cell differentiation.   
 
6.1.5 CD4+ T cell activation 
 
The activation of T cells serves several main purposes in the adaptive immune 
response: promoting inflammatory cytokine production (involves Th1 and Th17 
pathways); mediating B cell activation (involves Th2 cells); regulating 
immunosuppression (involves Tregs) and killing infected cells (involves cytotoxic T 
cells).   
CD4+ T cells which have never seen an immune stimulus are classed as 
naïve T cells.  Upon immune challenge they are activated and differentiate into 
different subtypes depending on the different cytokines present in the environment. 
Naïve CD4+ T cell activation requires a two-step process; the antigen-specific first 
step involves engagement of the highly variable T cell TCR with the peptide/MHC II 
(Major histocompatibility II) complex on APC, and the second step involves activation 
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of the CD28 receptor on naïve T cells with the co-stimulatory ligands CD80/CD86 on 
APC [642].  Following recognition and binding, in order for T cells to elicit a strong 
immune response, they also receive survival signals from inducible T cell co-
stimulator (ICOS) and CD134/OX40 ligands on APC, which bind to their respective 
receptors on T cells.  ICOS and OX40 ligands are only expressed by APC following 
pathogen recognition, to ensure inappropriate T cell activation does not occur.  In the 
absence of a co-stimulatory signal, TCR binding to the MHC II complex acts as an off 
switch for T cell activation.  The final stage to complete T cell activation, signal three, 
involves additional signals from cytokines.  This stage is critical to determine the T 
cell subset that will differentiate and is dependent on the cytokine milieu.  T cells will 
be pushed to differentiate into a Th1 fate in the presence of IL-12, Th2 fate in the 
presence of IL-4, and Th17 fate in the presence of IL-6 and IL-23.  Each cell subset 
has its unique role in downstream immune responses, as they migrate away from the 
site of infection.  Other factors such as chemokines and other cytokines at these sites 
will control the activation and proliferation of the newly differentiated T cell subset.  A 
simplified schematic of T cell activation by APC is depicted in Figure 6.2.      
CTLA-4 up-regulation is a marker of T cell activation; this receptor undergoes 
competitive binding with CD28 for the CD80/CD86 ligand on the surface of APC.  In 
this way CTLA-4 acts as a pivotal checkpoint regulator to control immune signals and 
prevent T cell over-activation.  A variety of mechanisms have been proposed for 
CTLA-4 mediated attenuation of T cell activation: 1) competitive binding of CTLA-4 to 
the CD80/CD86 co-stimulatory molecules on APC [643]; 2) selective recruitment of 
CTLA-4 in the immunological synapse [644]; 3) attenuation of TCR signalling by 
recruiting phosphatases [645, 646]; 4) reducing the contact period between T cells 
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and APC [647].  So far there is no definitive mechanism explaining CTLA-4 mediated 
inhibition of T cell signalling, although all the above theories are supported by strong 
experimental studies.   
CTLA-4 is located intracellularly and its relocation to the cell surface is 
required for negatively regulating T cell activation; this attenuation is possible since 
CTLA-4 has a twenty-fold higher affinity for CD80/CD86 ligands than CD28 does 
[648].  Thus, it is most likely that CTLA-4 mediates T cell signal inhibition by 
competing with CD28 for the common ligands CD80/CD86.  It has been reported 
that, following activation and translocation of CTLA-4 to the cell surface, CD4+ CD25- 
T cells see a rapid decline in surface CTLA-4 expression after just 4 hours, compared 
to much longer for memory T cells [649].  CTLA-4 therefore plays a critical role in the 
regulation of immune function but little is known about how its expression is 
controlled, although its expression appears to be modulated by 1,25(OH)2D3 [650, 







Figure 6.2. Schematic of T cell activation by APC 
Activation of T cells requires 2 signals; TCR binding to the MHC II, and CD28 binding to co-
stimulatory molecules CD80/CD86.  Conversely CTLA-4 translocating to the cell surface and 
competitively binding to CD80/CD86 prevents T cell over-activation.      
 
6.1.6 Immunological actions of 1,25(OH)2D3 on CD4+ T cells 
 
Evidence that CD4+ T cells express VDR [652, 653] led to the idea that T cells 
are able to participate in 1,25(OH)2D3-mediated signalling at sites of inflammation.  
Since then synthesis of 1,25(OH)2D3 has been observed for many cell types, notably 
those in the colon [523, 654], placenta [655] as well as APC [142], all of which are 
sites frequented by T cells.  Research in mice has shown that inhibition of 
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1,25(OH)2D3 production in immune cells led to reduced paracrine signalling to T cells 
and worsened autoimmune disease prognosis [656, 657].  In this way, paracrine 
signalling to T cells by 1,25(OH)2D3 produced by APC has become a widely 
accepted mechanism for 1,25(OH)2D3-mediated immune regulation [658].   
As key effector cells of autoimmune disease, the roles of CD4+ T cells in the 
pathogenesis of multiple autoimmune diseases have been studied in detail [659-661].  
In addition, the anti-inflammatory actions of 1,25(OH)2D3 on CD4+ T cells have been 
implicated in the pathogenesis of autoimmune diseases.  In the context of RA, 
impaired CD4+ T cell function has been found as a major cause of disease 
progression [662].  Previous studies have shown that in CD4+ CD25- T cells primed 
to differentiate into Th17 cells, 1,25(OH)2D3 impairs pro-inflammatory IL-17 
production [373, 663] and enhances CTLA-4 and FoxP3 expression which is 
associated with a more immunosuppressive Treg phenotype [650], underlining the 
immunoregulatory potential of 1,25(OH)2D3 in the adaptive immune system.  The 
potent immunosuppressive phenotype of these 1,25(OH)2D3-induced CD4+ CD25- 
FoxP3+ Tregs has been confirmed by multiple studies [91, 372, 373].  Hence CD4+ T 
cells are potential targets for the protective biological effects of 1,25(OH)2D3 via VDR 
signalling in both mice [664] and humans [665].  
The actions of 1,25(OH)2D3 on CD4+ CD25+ Tregs have also been studied in 
detail.  Previous studies have positively correlated CD4+ CD25+ Treg cell function 
with serum vitamin D (25(OH)D3) status in patients with autoimmune disease [666, 
667]; however this correlation was not found upon 1,25(OH)2D3 supplementation in 
humans [667].  In mice, CD4+ CD25+ Tregs treated with 1,25(OH)2D3 exhibited 
inhibited development of pro-inflammatory Th1 phenotype and promoted Th2 fate, 
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showing that Tregs can be direct targets of 1,25(OH)2D3 to enhance their 
suppressive ability [186, 668].   One theory is that 1,25(OH)2D3 acts as an on/off 
switch especially with regard to autoimmune disease prevention, however once T 
cells have matured and committed to a phenotype, 1,25(OH)2D3 is no longer able to 
modulate these immune responses.   
 
6.1.7 MiRNAs and CD4+ T cell activation, proliferation and function 
 
The role of miRNAs in the normal functioning and dysregulation of the immune 
response has been well studied.  Recent reports have suggested a role for select 
miRNAs in the development and function of CD4+ T cells, mediated by intracellular 
and extracellular signalling.  It is thought that miRNAs function post-transcriptionally 
to target genes involved in mediating T cell proliferation, differentiation and 
apoptosis.     
MiRNA expression during different T cell developmental stages can regulate 
the fate, function and development of CD4+ T cells [669].  Over-expression of miR-
181 inhibits T cell development by targeting CD69 [670, 671] whilst over-expression 
of let-7 in CD4+ T cells results in reduced IL-10 levels which may have an anti-
inflammatory effect [672].  T cell activation in healthy individuals has been associated 
with the induced expression of miR-21, miR-146a and miR-155, and the reduced 
expression of miR-31 [673]; up-regulated miR-155 expression occurred early after 
activation and miR-146a was up-regulated later.  MiR-146a silences its target gene 
STAT1, which helps to maintain the immunosuppressive function of CD4+ FoxP3+ 
Tregs [674].  MiR-155 co-functioning with miR-221 is predicted to target PIK3R1 to 
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inhibit excess CD4+ T cell proliferation and cytokine production [675].  MiR-21, 
induced by TCR activation, is thought to negatively modulate T cell activation by 
targeting genes involved in signal transduction [676] and supporting the survival of 
memory T cells [677], thereby helping to maintain an appropriate level of immune 
response.  Regulation of CD4+ T cell apoptosis is another process mediated by 
miRNA targeted gene silencing; miR-15a and miR-16-1 targets BCL2 which 
regulates the BCL-2/BIM apoptosis pathway [678, 679].  Previous global microarray 
analysis [680] and candidate miRNA analysis [681, 682] observed significant down-
regulation of miR-16, miR-142, miR-150, miR-15 and let-7 expression following naïve 
CD4+ T cell activation, suggesting these miRNAs may target genes necessary for 
mediating the shift from naïve to activated T cells.    
On the other hand, up-regulated expression of miRNAs has also been 
implicated in facilitating the inflammatory response.  Induction of miR-214, a target of 
PTEN, leads to increased T cell proliferation [683].  IL-2 induces the expression of 
miR-182, a target of FOXO1, and the silencing of this gene acts as a switch for the 
conversion of resting state T cells to Th cell clonal expansion [684]. In Th1 cells, miR-
17 and miR-19 function as a cluster to target CREB1 and PTEN respectively, to 
enhance T cell proliferation, survival and cytokine production, and to prevent 
inducible Treg differentiation in humans [685, 686] and mice [687].  In CD4+ Tregs, 
the induction of miR-210, miR-24, miR-95 and miR-145 is necessary for immune 
homeostasis, with miR-95 regulating FOXP3 indirectly and miR-145 regulating CTLA-
4 [688].  The immunoregulatory functions of Tregs may also be dependent on the 
high expression of miR-10a, which is induced by TGF-β and retinoic acid and targets 
BCL-6 [689].  In this way miR-10a discourages the conversion from Treg to 
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inflammatory Th17 cell phenotype.  In stimulated Tregs, the predicted miR-155 target 
FOXOa3 is down-regulated, reducing T cell action via the AKT pathway [690].    
The differential expression of these miRNAs at different stages of 
development may be in part due to the efficiency of T cell responses at each stage.  
More so it suggests that strict miRNA regulation at different developmental stages of 
T cells is important to maintain an appropriate level of immune response, and 
aberrant over-expression or down-regulation of their expression can have 
consequences on inappropriate gene expression.   
 
6.2 Chapter outline 
 
Lineage-specific differentiation of T cells is dependent on many factors 
including the cytokine milieu of the microenvironment [691], strength of TCR signals 
[692], and epigenetic modifications [693].  These factors must be tightly regulated; 
over-activation of T cells can lead to many problems including autoimmune diseases 
[694].   
Previously, Jeffery et al. [650] showed that naïve CD4+ CD25- T cells 
stimulated in the presence of 1,25(OH)2D3 and Th17 polarising conditions are able to 
inhibit the production of pro-inflammatory cytokines such as IFN-У, IL-17 and IL-21, 
as well as up-regulating expression of CTLA-4 and FoxP3 [373].  The authors utilised 
these conditions to generate cells for RNA sequencing to observe genome-wide 
changes in mRNA expression and found multiple patterns of gene regulation at early 
and late time points for incubation with 1,25(OH)2D3 (unpublished data). However, in 
addition to transcriptomic changes, multiple miRNAs are known to be involved in the 
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activation and differentiation of immune cells. In the current thesis, this has been 
demonstrated for the effects of 1,25(OH)2D3 on DC from the innate immune system 
(see Chapter 5). We therefore hypothesised that changes in miRNAs also play an 
important role in maintaining immune responses to 1,25(OH)2D3 in the adaptive 
immune system.  Due to the role that Th17 cells play in the pathogenesis of 
autoimmune disease, studies in the current chapter sought to profile changes in gene 
and miRNA expression during T cell activation under Th17 inflammatory conditions, 
and how these changes may be differentially regulated in the presence of 
1,25(OH)2D3.  Work described in this chapter aims to investigate the role of miRNAs 
in mediating CD4+ CD25- T cell responses to 1,25(OH)2D3.   
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6.3 Results  
6.3.1 Preliminary gene analysis in CD4+ T cell subsets 
 
Preliminary studies to explore the effect of T cell activation and 1,25(OH)2D3 
treatment on gene expression were performed by qPCR in Th0, Th1, Th17 and Treg 
cell subsets.  These Th cell subsets were generated from naïve CD4+ cells under 
culture with different cytokines.  Th0 populations were generated by incubating naïve 
CD4+ cells with IL-4 for 3 days.  Th1 populations were generated by culturing CD4+ 
cells in Human Th1 differentiation media containing IL-12 (R&D Systems) on an anti-
CD3 coated plate for 3 days.  Tregs were isolated and expanded using Dynal CD4+ 
CD25+ Treg Kit (Thermo Fisher) with IL-2 for 5 days.  The expression of VDR, IL-10 
and IL-21 in these subsets and treatment groups was quantified and compared.  
VDR was expressed in all CD4+ T cell populations and following activation, 
expression was slightly increased but this was not statistically significant.  The 
addition of 1,25(OH)2D3 did not significantly affect VDR expression (Figure 6.3A).  
IL-10 expression was significantly up-regulated following T cell activation for all CD4+ 
T cell subtypes (Figure 6.3B), but only Th17 cells and Treg cells saw a further 
significant up-regulation of IL-10 expression following 1,25(OH)2D3 treatment 
(p=0.0052).  Although Th17 and Treg cells both showed a response to 1,25(OH)2D3, 
only Treg cells are sensitive to modulation by 1,25(OH)2D3.  IL-21 expression was 
also significantly up-regulated in Th0 (p=0.0007), Th1 (p=0.0245), Th17 (p=0.0246) 
and Treg (p=0.043) cell subsets after activation (Figure 6.3C) however IL-21 was not 
significantly regulated by 1,25(OH)2D3 in any of the subsets.  These results showed 
that Th17 and Treg cells show a significant response to 1,25(OH)2D3 in the form of 
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increased IL-10 expression, hence subsequent studies were carried out using one of 
these T cell phenotypes: Th17 cells.   
 
6.3.2 CD4+ T cell model of cytokine activation and 1,25(OH)2D3 response 
 
Previous literature has shown that for CD4+ T cells activated under Th17 
inflammatory conditions, the addition of 1,25(OH)2D3 promoted up-regulation of cell 
markers associated with an anti-inflammatory Treg phenotype [650].  Therefore, to 
explore if these changes were associated with gene regulation at specific time points 
following 1,25(OH)2D3 treatment, a CD4+ T cell time course model for T cell 
activation and 1,25(OH)2D3 treatment was utilised for gene and miRNA studies in 
this chapter.   
Naïve CD4+ CD25- T cells from healthy donors were stimulated with plate-
coated anti-CD3 and anti-CD28, then activated for 20 hours with a Th17 pro-
inflammatory cytokine cocktail consisting of IL-2, TBG-β, IL-1β, IL-6 and IL-23 to 
encourage Th17 polarisation.  The resulting activated Th17 cells were then incubated 
with 1,25(OH)2D3 for up to 72 hours, and cells were harvested at regular time points 
for flow cytometric phenotype analysis and extraction of RNA for gene and miRNA 
expression studies.  The model for induction and treatment of CD4+ Th17 cells is 
shown in Figure 6.4. 
 
6.3.3 Flow cytometry analysis of CD4+ T cell purity  
 
In order to validate the purity and functionality of the Th17 CD4+ T cell model 
shown in Figure 6.4, flow cytometry was used to quantify changes in T cell marker 
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expression.  Naïve CD4+ CD25- T cells were isolated from PBMC and stained for 
CTLA-4, FoxP3, CD4 and the IL-7 receptor CD127.  As expected low expression of 
the Treg markers CTLA-4 (MFI 15.0) and FoxP3 (MFI 33.9) were observed in resting 
naïve T cells, with levels of CTLA-4 being similar to PBMC controls (MFI 15.1) 
(Figure 6.5A), By contrast high expression of CD4 (MFI 100) and CD127 (MFI 150) 
compared to PBMC (MFI 18.3 and 17.9 respectively), distinguished the isolated T 
cells from PBMC mixed populations.   
 
6.3.4 Flow cytometry analysis of CD4+ T cell activation and 1,25(OH)2D3 
response 
 
Following activation of naïve CD4+ T cells with the Th17 cytokine cocktail, cell 
surface expression of CTLA-4 (MFI 28), FoxP3 (MFI 11.9) and IFN-γ (MFI 48.4) was 
up-regulated compared to the naïve T cells (CTLA-4 MFI 2.82; FoxP3 MFI 3.53; IFN-
γ MFI 6.8).  Treatment with 1,25(OH)2D3 for 72 hours decreased IFN-γ (MFI 26.1) 
and increased CTLA-4 (MFI 262) expression, compared to activated vehicle-treated 
cells (IFN-γ MFI 48.4; CTLA-4 MFI 28) (Figure 6.5B).  FoxP3 expression was also 
up-regulated following T cell activation (MFI 11.9) compared to naïve T cells (MFI 
3.53), with 1,25(OH)2D3 treatment resulting in only a modest further up-regulation of 
FoxP3 (MFI 14.7).  Activation of CD4+ T cells also induced the expression of CD25 
(MFI 40.9 compared to 1.91 in the unstimulated naïve population), showing that 
these previously CD4+ CD25- T cells now possessed a more anti-inflammatory 
phenotype.  This is also shown in FACS plot format (Figure 6.5C); unstimulated 
naïve CD4+ T cells were mostly negative for FoxP3 and CTLA-4 as shown by the 
majority of cells stained in the lower left quadrant Q4 (left plot, 99.9%).  Following 
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stimulation of CD4+ naïve T cells with a Th17 inflammatory cytokine cocktail, there 
was strong up-regulation of CTLA-4 compared to unstimulated T cells (central plot, 
population expressing CTLA-4 increased from 0.15% to 69.4% in Q1). Naïve T cell 
stimulation also mildly up-regulated the expression of FoxP3 (central plot, population 
expressing FoxP3 increased from ~0% to 1.27% in Q3).  Stimulated cells were also 
analysed following 1,25(OH)2D3 treatment for 72 hours, and these cells showed up-
regulation of both FoxP3 and CTLA-4, as shown by the increase in double-positive 
stained cells in the top right quadrant Q2 (right plot, 5.96% T cells + vehicle to 8.36% 
T cells +1,25(OH)2D3).   
To further characterise the effect of 1,25(OH)2D3 on activated T cells in an 
inflammatory setting, cytokine secretion was also analysed (Figure 6.5D).  Treatment 
with 1,25(OH)2D3 treatment up-regulated CD25 (MFI 9978) and IL-10 (MFI 184) 
compared to vehicle controls (CD25 MFI 3437; IL-10 MFI 169).  1,25(OH)2D3 also 
down-regulated IL-17 (MFI 6054), IFN-γ (MFI 133), IL-21 (MFI 7934) and IL-2 (MIF 
6.73) compared to vehicle controls.         
Collectively these results confirmed that the CD4+ T cell model was 
responsive to Th17 activation and treatment with 1,25(OH)2D3, and also suggested 
that 1,25(OH)2D3 stimulated CD4+ T cells to overcome the Th17 inflammatory 
polarisation by up-regulating CTLA-4 expression and thus promote a Treg 
phenotype, despite the presence of the Th17 inflammatory cocktail.  These 
observations further highlight the immunosuppressive properties of 1,25(OH)2D3 in 




6.3.5 Effect of 1,25(OH)2D3 on candidate gene expression in CD4+ T cells  
 
To assess gene expression changes in activated CD4+ T cells in response to 
1,25(OH)2D3, a time course study was performed to profile mRNA expression at 0hr, 
2hrs, 10hrs, 24hrs, 48hrs and 72hrs post-1,25(OH)2D3 treatment.  qPCR analysis 
was performed on two candidate genes associated with T cell inflammation.  Firstly, 
CTLA-4 expression did not significantly change in the vehicle-treated cells at different 
time points, compared to cells at the 0hr time point.  IFN-γ expression was 
significantly up-regulated at the 24hr time point in the vehicle compared to 
unstimulated control (p=0.0425) (Figure 6.6B).     
In response to 1,25(OH)2D3, CTLA-4 expression was significantly up-
regulated at 2hrs, 24hrs, 48hrs and 72hrs following 1,25(OH)2D3 treatment, 
compared to the vehicle-treated T cells at the same time points (Figure 6.7A).  IFN-γ 
expression was only significantly down-regulated after 72 hours treatment with 
1,25(OH)2D3 (Figure 6.7B), although earlier time points showed a downward trend in 
expression.  These results confirmed the anti-inflammatory effects of 1,25(OH)2D3 on 
CD4+ CD25- T cells.  
 
6.3.6 Effect of 1,25(OH)2D3 on candidate miRNA expression in CD4+ T cells  
 
To determine if the anti-inflammatory effects of 1,25(OH)2D3 on CD4+ T cells 
shown in Figure 6.7 were associated with regulation of miRNA expression, further 
qRT-PCR was performed for 7 candidate miRNAs (miR-21, miR-29a, miR-145, miR-
146a, miR-155, miR-627 and let-7i) closely related to immune cell function and 
inflammation according to previous literature [556-562].  The unstimulated control at 
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the 0hr time point was compared to vehicle cells at each time point, to determine any 
miRNA expression changes in the absence of 1,25(OH)2D3.  Only miR-155 
expression was significantly up-regulated at the 48hr and 72hr time points, in vehicle 
compared to unstimulated control cells (p=0.04) (Figure 6.8E).   
Following the addition of 1,25(OH)2D3, significant expression changes in 
expression were observed for 2 miRNAs; miR-155 (p=0.048) (Figure 6.9E) and miR-
627 (p=0.02) (Figure 6.9F), which were significantly down-regulated by 1,25(OH)2D3 
at 2hrs treatment, compared to the vehicle-treated T cells at the same time point.  
These results indicated that although the candidate miRNAs have been linked to 
inflammatory immune function, they are not strongly responsive to 1,25(OH)2D3 in 
CD4+ T cells. Further studies were therefore required for an unbiased analysis of 
miRNAs in these cells. 
 
6.3.7 miRNA qPCR array response to 1,25(OH)2D3 
 
To identify other miRNAs potentially responding to 1,25(OH)2D3, qPCR arrays 
were performed to profile expression of 372 human miRNAs closely linked to immune 
function and inflammation.  Early (24hr) and late (72hr) time points for T cells treated 
with 1,25(OH)2D3 were chosen to compare possible temporal effects of 1,25(OH)2D3 
on T cell miRNA expression.  Based on the gene and candidate miRNA expression 
data obtained earlier in this study, it was predicted that these time points were the 
most likely to have significantly regulated miRNA expression in response to 




6.3.7.1 Effect of CD4+ T cell activation on miRNA expression 
 
In the first instance, experiments were carried out to determine changes 
following activation of T cells to induce a Th17 inflammatory phenotype. After 
incubating naïve CD4+ T cells with the cytokine cocktail of IL-2, TGF-β, IL-1β, IL-6 
and IL-23 for 20 hours, CTLA-4 and IFN-γ gene expression was quantified by qPCR 
to assess changes in T cell phenotype (Figure 6.10). The T cell activation marker 
CTLA-4 (p=0.0103; 95% confidence interval 3.444-0.997; SD 0.7688) and 
inflammatory cytokine IFN-γ (p=0.0023; 95% confidence interval 8.039-4.076; SD 
1.245) were both significantly up-regulated following stimulation, confirming that the 
previously naïve CD4+ T cells had been activated to an inflammatory phenotype.   
Following on from this, further qPCR quantification of 7 candidate miRNAs was 
performed to determine possible effects of T cell stimulation on miRNA expression.  
Of the candidate miRNAs quantified, only miR-155 expression was significantly up-
regulated (p=0.0199; 95% confidence interval 8.263-1.459; SD 2.138) following 
cytokine stimulation (Figure 6.11).   
Further studies were therefore carried out to produce an unbiased analysis of 
altered miRNA expression following T cell activation. Preliminary qPCR data were 
analysed using SABiosciences PCR Array Data Analysis software (SABiosciences) 
recommended for the arrays, and data visualized in heat maps and scatter plots.  
Only miRNAs with a fold change >2 were included in the preliminary analysis.  Of the 
372 miRNAs included in the qPCR array panel, 16 miRNAs were down-regulated and 
128 up-regulated in response to cytokine stimulation of the T cells (>2-fold change 
based on mean of n=4 separate donor samples) (Figure 6.12B).  Huynh-Feldt 
statistical analysis revealed that of the miRNAs showing > 2-fold change, 9 were 
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significantly down-regulated and 24 significantly up-regulated, with miR-155 amongst 
the latter (Figure 6.12C).  All Huynh-Feldt significantly regulated miRNAs in response 
to T cell activation are shown in full graphical format in Figure 6.13.   
 
6.3.7.2 Effects of short-term treatment with 1,25(OH)2D3 (24hrs) on miRNA 
expression 
 
Preliminary heat map and scatter plot visualisation data showed that of the 
372 miRNAs screened following short term (24hr) culture of cytokine-stimulated T 
cells with 1,25(OH)2D3, 6 miRNAs were up-regulated (>2-fold change) and 2 down-
regulated (Figure 6.14B).  Statistical analysis by Huynh-Feldt testing was then 
performed on all miRNAs to identify statistically significant changes to miRNA 
expression in response to short term 1,25(OH)2D3.  Further Huynh-Feldt analysis 
identified only 2 miRNAs that were significantly regulated by short term 1,25(OH)2D3; 
miR-16-5p (p=0.004) and miR-212-3p (p=0.004) were both up-regulated (Figure 
6.14C).  Full details of the results for short term treatment of activated T cells with 
1,25(OH)2D3 are shown in Figure 6.15.   
 
6.3.7.3 Effects of long-term treatment with 1,25(OH)2D3 (72hrs) on CD4+ T 
cell miRNA expression 
 
Preliminary data showed that of the 372 miRNAs analysed following long term 
(72hr) culture with 1,25(OH)2D3, 16 miRNAs were up-regulated (>2-fold change) and 
6 down-regulated (Figure 6.16B).  Huynh-Feldt testing was then performed on all 
372 miRNAs to identify statistically significant changes to miRNA expression in 
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response to long term 1,25(OH)2D3.  Further Huynh-Feldt statistical analysis 
revealed 9 miRNAs were significantly up-regulated (p<0.05) and 1 miRNA down-
regulated, with that being miR-335-3p (p=0.008) (Figure 6.16C).  All Huynh-Feldt 
significantly regulated miRNAs for long term 1,25(OH)2D3 are shown in full graphical 
format in Figure 6.17.   
 
6.3.8 Predicted targets for miRNAs: a bioinformatics approach 
 
A full list of T cell miRNAs significantly regulated in response to cytokine 
activation or 24 or 72 hour treatment with 1,25(OH)2D3, as calculated by Huynh-Feldt 
analysis is shown in Table 6.1.  Following the identification of these miRNAs from the 
qPCR array analysis, a bioinformatics approach was carried out to identify potential 
target genes for each miRNA.  The MiRTarBase database was initially used to 
identify predicted gene targets for all significantly regulated miRNAs.  All gene targets 
on miRTarBase have been experimentally validated and ranked according to 
published research results verifying the targets, then given a target prediction score 
out of 100.  The top 5 target genes for each miRNA identified in Figures 6.12-6.17 
were then ranked and listed (Table 6.1B); target genes were ranked from most to 
least validated, and the established cut-off target prediction score was set at 95 and 
above to exclude experimentally ‘weak’ targets.   
To further analyse and validate the functionality of select miRNA gene targets, 
bioinformatic strategies were used to identify predicted gene targets for each of the 
miRNAs shown to be significantly regulated in the current study.  MiRBase miRNA 
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database was combined with Cytoscape software to produce a list of significant 
(p<0.05) experimentally validated gene targets of miRNAs.  By combining Cytoscape 
analysis with ClueGo gene ontology (GO) analysis, target genes were grouped 
according to enriched biological functions.  This approach was used to analyse the 
expression of miR-132-3p, miR-132-5p, miR-147a, miR-424-3p, miR-424-5p, miR-
212-3p and miR-155-5p which were selected from the miRNA list in Table 6.1A as 
they were regulated by more than one treatment i.e. a combination of short term 
1,25(OH)2D3, long term 1,25(OH)2D3 and stimulation.   
Using MiRBase, miR-132-3p was shown to target 14 genes (Figure 6.18). 
Gene ontology analysis showed that these genes were associated with cell 
processes related to cell proliferation and vesicle transportation, with CDKN1A being 
a common gene for all these biological processes.  MiR-132-5p, miR-147a and miR-
424-3p targeted a much smaller collection of genes (Figure 6.19) and none of these 
effects were significantly enriched in specific biological processes so, unlike miR-132-
3p, we were unable to produce a gene ontology analysis for these miRNAs.  MiR-
212-3p and miR-424-5p targeted genes that were mainly associated with cell cycle 
regulation and apoptotic processes (Figures 6.20-6.21).  Gene targets of miR-155-
5p were of special interest due to the differential regulation of miR-155 expression in 
response to LPS and 1,25(OH)2D3 in DC described in Chapter 5, and the 
implications of miR-155 as a master regulator of inflammation.  Indeed miR-155 was 
found to target many genes which are involved in a plethora of enriched biological 
processes, indicating the widespread systemic role of miR-155 from regulation of the 
cell cycle to haematopoiesis (Figure 6.22).  This network was simplified in order to 
focus on genes with functions in immune regulation; this identified well-studied genes 
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such as SOCS1, and lesser studied genes such as CD68.  Overall, this 
bioinformatics analysis was a useful tool to identify miRNA gene targets from an 
experimentally validated database, and to identify genes linked to immune functions.  
These data were compared to previous unpublished data by other Birmingham group 
members, where CD4+ T cells polarised with Th17 cocktail was treated with 
1,25(OH)2D3.  The genes significantly regulated with long term (72hr) 1,25(OH)2D3 















Figure 6.3. Gene expression analysis in CD4+ T cell subsets 
qPCR gene expression analysis to study the effect of T cell activation and 1,25(OH)2D3 
treatment on gene expression in Th0, Th1, Th17 and Treg cell subsets.  Genes quantified 
were A) VDR; B) IL-10; C) IL-21. Data is shown as delta Ct (ΔCt) so a higher value 
reflects a lower expression. Bars are shown as mean expression ± SD for n=3 individual 
samples.  RM one-way ANOVA for paired values was performed for analysis of 
significance, and Tukey’s multiple comparisons test was performed to identify differences 















Figure 6.4. Induction of CD4+ CD25- T cells with cytokine cocktail and 1,25(OH)2D3 
T cell unstim – unstimulated naïve CD4+ CD25- T cell; T cell stim – CD4+ T cell activated 
with Th17 cytokine cocktail; T cell –activated vehicle CD4+ T cell; T cell +1,25(OH)2D3 – 
activated CD4+ T cell+1,25(OH)2D3 (10nM).  CD4+ CD25- T cells were isolated from 
PBMC derived from whole blood leukocyte cones of healthy donors (n=4).  Anti-CD3 and 
anti-CD28 antibodies were coated onto an empty culture plate for 2 hours at 37ᴼC, prior to 
addition of T cells and cytokines for stimulation.  Th17 cytokine cocktail was added to 
promote CD4+ T cell differentiation into a pro-inflammatory Th17 phenotype.  
1,25(OH)2D3 or vehicle (Ethanol) was added at a final concentration of 10nM per well.  T 
cells were harvested at the following time points after 1,25(OH)2D3 treatment: 0hr 






































 Figure 6.5. Flow cytometry validation of CD4+ T cell purity, activation and response to 1,25(OH)2D3 
CD4+ CD25- T cells were stained for intracellular and surface markers.  FACS plots show A) intracellular expression of CTLA-4 and FoxP3 
and surface expression of CD4 and CD127 in freshly isolated CD4+ CD25- naïve T cells; B) surface expression of CTLA-4, CD25, FoxP3 
and IFN-γ in activated CD4+ T cells in the presence and absence of 1,25(OH)2D3 after 72hrs, compared to unstimulated naïve T cells; C) 
Surface expression of CTLA-4 vs FoxP3 in unstimulated, vehicle and treated T cells after 72hrs; D) Median fluorescence intensity (MFI) 
values for 5 day CD4+ T cell cytokine expression. IgG Isotype stain conjugated to the matching fluorophores was used as the experimental 





Figure 6.6. Gene expression time course for CD4+ T cell response over time 
qPCR time course graphs showing T cell gene expression at 0hr, 2hrs, 10hrs, 
24hrs, 48hrs and 72hrs in vehicle cells compared to the unstimulated control, for the 
genes A) CTLA-4; B) IFN-У.  Y-axis shows delta Ct (ΔCt) values of vehicle 
compared to unstimulated cells at each time point, so a higher ΔCt reflects a lower 
expression. Results for each time point are shown as individual response for n=4 
individual samples.  2-way ANOVA with Sidak’s multiple analysis test for paired 
values was performed for each time point.  Statistical significance is taken as 

















Figure 6.7. Gene expression time course for CD4+ T cell response to 
1,25(OH)2D3 by qRT-PCR 
qPCR time course graphs showing T cell gene expression at 0hr, 2hrs, 10hrs, 
24hrs, 48hrs and 72hrs post incubation with 1,25(OH)2D3 (10nM), for the genes A) 
CTLA-4; B) IFN- У.  Y-axis shows delta Ct (ΔCt) values of vehicle compared to 
treated cells at each time point, so a higher ΔCt reflects a lower expression. Results 
for each time point are shown as individual response for n=4 individual samples.  
0hr time point refers to 20hrs after T cell activation, but 0hr after 1,25(OH)2D3 
treatment.  2-way ANOVA with Sidak’s multiple analysis test for paired values was 
performed for each time point.  Statistical significance is taken as *p<0.05 and 





Figure 6.8. miRNA expression time course for CD4+ T cell response over time 
qPCR time course graphs showing T cell miRNA expression at 0hr, 2hrs, 10hrs, 24hrs, 
48hrs and 72hrs in vehicle cells compared to the unstimulated control, for the miRNAs A) 
miR-21; B) miR-29a; C) miR-145; D) miR-146a; E) miR-155; F) miR-627; G) let-7i. Y-axis 
shows delta Ct (ΔCt) values of vehicle compared to unstimulated cells at each time point, 
so a higher ΔCt reflects a lower expression. Results for each time point are shown as 
individual response for n=4 individual samples.  2-way ANOVA with Sidak’s multiple 
analysis test for paired values was performed for each time point. Statistical significance 






























Figure 6.9. miRNA expression time course for CD4+ T cell response to 1,25(OH)2D3 
by qRT-PCR 
qPCR time course showing miRNA expression in T cells at 0hr, 2hrs, 10hrs, 24hrs, 48hrs 
and 72hrs post incubation with 1,25(OH)2D3 (10nM), for the miRNAs A) miR-21; B) miR-
29a; C) miR-145; D) miR-146a; E) miR-155; F) miR-627; G) let-7i. Y-axis shows delta Ct 
(ΔCt) values of vehicle compared to treated cells at each time point, so a higher ΔCt 
reflects a lower expression. Results for each time point are shown as individual response 
for n=4 individual samples.  0hr time point refers to 20hrs after T cell activation, but 0hr 
after 1,25(OH)2D3 treatment. 2-way ANOVA with Sidak’s multiple analysis test for paired 
values was performed for each time point. Statistical significance is taken as *p<0.05 and 







   
 
  
Figure 6.10. qPCR gene expression for CD4+ CD25- T cell response to Th17 
cytokine cocktail stimulation (20hrs) 
qPCR detected gene expression between unstimulated and Th17 cytokine cocktail 
stimulated (vehicle) T cells (n=4), for A) CTLA-4; B) IFN-У.  Stimulation was 
performed for 20hrs in the presence of pro-inflammatory Th17 cytokine cocktail: 
TGF-β, IL-1β, IL-2, IL-6, IL-23.  Data is shown as mean normalised Ct, so a lower 
value corresponds to higher expression. Significance was calculated using paired 



















Figure 6.11. Candidate qPCR miRNA expression for CD4+ CD25- T cell response to Th17 cytokine cocktail stimulation 
qPCR detected candidate miRNA expression between unstimulated and Th17 cytokine cocktail stimulated (vehicle) T cells (n=4), for A) miR-
21; B) miR-29a; C) miR-145; D) miR-146a; E) miR-155; F) miR-627; G) let-7i.  Stimulation was performed for 20hrs in the presence of pro-
inflammatory Th17 cytokine cocktail: TGF-β, IL-1β, IL-2, IL-6, IL-23.  Data is shown as mean normalised Ct, so a lower value corresponds to 
higher expression. Significance was calculated using paired two-tailed t-test, and significance taken as *p<0.05.  Data is shown as mean ± 







Figure 6.12. qPCR array of miRNA expression in response to cytokine stimulation   
A) Naïve CD4+ T cell activation with Th17 cytokine cocktail (20hrs) schematic; B) Scatter 
plot showing expression change of miRNAs following 20hrs stimulation with pro-
inflammatory Th17 cytokine cocktail in CD4+CD25- T cells.  Green and red represent 
downregulation and up-regulation of miRNA expression respectively, calculated as log₂ 
fold change; C) Huynh-Feldt statistical analysis of statistically significant miRNAs 
differentially regulated following T cell activation.  Huynh-Feldt test for sphericity was 











Figure 6.13. Graphical representation of significantly regulated qPCR array 
miRNAs, to Th17 cytokine cocktail stimulation (20hrs) 
qPCR array quantified expression change in response to Th17 cytokine cocktail 
stimulation for A) miR-155-5p; B) miR-106a-3p; C) miR-103a-3p; D) miR-106b-5p; E) 
miR-107; F) miR-185-5p; G) mir-221-5p; H) miR-330-3p; I) miR-20b-5p; J) miR-340-5p; K) 
miR-378a-3p; L) miR-423-3p; M) miR-7-5p; N) miR-744-5p; O) miR-505-3p; P) miR-93-
5p; Q) miR-96-5p; R) miR-98-5p; S) miR-10a-5p; T) miR-10b-5p; U) miR-125b-5p; V) 
miR-138-5p; W) miR-196b-5p; X) miR-342-3p; Y) miR-431-5p.  UNSTIM, unstimulated 
naïve T cells; vehicle, stimulated T cells; 1,25D, stimulated T cells + 1,25D.  Individual 
donors (n=4) are shown.  Repeated-measures ANOVA for paired data was used to 
calculate statistical significance, and significance was taken as *p<0.05.  Data is shown 





































Figure 6.14. qPCR array of miRNA expression in response to short term 1,25(OH)2D3 (10nM) 
A) Short term 1,25(OH)2D3 (24hrs) schematic; B) Scatter plot showing miRNA expression change following short term 1,25(OH)2D3 (24hrs) 
in activated CD4+ CD25- T cell populations.  Green and red represent downregulation and up-regulation of miRNA expression respectively, 
calculated as log₂ fold change; C) Huynh-Feldt statistical analysis of statistically significant miRNAs differentially regulated following short 









Figure 6.15. Graphical representation of significantly regulated qPCR array 
miRNAs, to short term 1,25(OH)2D3 (24hrs) 
qPCR array quantified expression changes in response to short term 1,25(OH)2D3 
for A) miR-16-5p; B) miR-212-3p.  UNSTIM, unstimulated naïve T cells; vehicle, 
stimulated T cells; 1,25D, stimulated T cells + 1,25D.  Individual donors (n=4) are 
shown.  Repeated-measures ANOVA for paired data was used to calculate 
statistical significance, and significance was taken as *p<0.05.  Data is shown as 







Figure 6.16. qPCR array of miRNA expression in response to long term 1,25(OH)2D3 (10nM) 
A) Long term 1,25(OH)2D3 (72hrs) schematic; B) Scatter plot showing miRNA expression change following long term 1,25(OH)2D3 (72hrs) in 
activated CD4+ CD25- T cell populations.  Green and red represent downregulation and up-regulation of miRNA expression respectively, 
calculated as log₂ fold change; C) Huynh-Feldt statistical analysis of statistically significant miRNAs differentially regulated following long 



















Figure 6.17. Graphical representation of significantly regulated qPCR array miRNAs, to long term 1,25(OH)2D3 (72hrs) 
qPCR array quantified expression changes in activated CD4+ T cells in response to long term 1,25(OH)2D3 for A) miR-129-1-3p; B) 
miR-129-2-3p; C) miR-137; D) miR-335-3p; E) miR-132-5p; F) miR-132-3p; G) mir-147a; H) miR-212-3p; I) miR-424-5p; J) miR-424-
3p. UNSTIM, unstimulated naïve T cells; vehicle, stimulated T cells; 1,25D, stimulated T cells + 1,25D.  Individual donors (n=4) are 
shown.  Repeated-measures ANOVA for paired data was used to calculate statistical significance, and significance was taken as 




Table 6.1. Summary of all significantly regulated miRNAs  
A) Table of significantly regulated miRNAs in response to long term 1,25(OH)2D3 (72hrs), 
short term 1,25(OH)2D3 (24hrs) and Th17 cytokine cocktail stimulation (20hrs).  
Significance taken as p<0.05 by Huynh-Feldt analysis.  B) Top 5 experimentally validated 
gene targets for each significant miRNA, as predicted by miRTarBase.  Only those with a 

























Figure 6.18. Gene Ontology analysis of significantly regulated miRNA targets (miR-
132-3p) 
Cytoscape v3.6.1 gene prediction software was used in conjunction with ClueGo to 
identify experimentally validated gene targets of miRNAs and their cellular functions.  
Validated gene targets and functional gene links of miR-132-3p is shown.  For Cytoscape 
miRNA target prediction, all targets with a target prediction score below of 95% were 
excluded.  For ClueGo gene ontology (GO) analysis, statistical significance of genes with 
enriched biological functions was taken as p<0.05 calculated by Bonferroni step-down.  
Colours and distance of nodes do not correspond to level of significance, and are for 





Figure 6.19. Gene Ontology analysis of significantly regulated miRNA targets (miR-132-5p, miR-147a, miR-424-3p) 
Cytoscape v3.6.1 gene prediction software was used in conjunction with ClueGo to identify experimentally validated gene targets of miRNAs 
and their cellular functions.  Validated gene targets of A) miR-132-5p; B) miR-147a; C) miR-424-3p.  For Cytoscape miRNA target prediction, 
all targets with a target prediction score below of 95% were excluded.  Where gene ontology is not shown, no statistically significant links 


























Figure 6.20. Gene Ontology analysis of significantly regulated miRNA targets (miR-
212-3p) 
Cytoscape v3.6.1 gene prediction software was used in conjunction with ClueGo to 
identify experimentally validated gene targets of miRNAs and their cellular functions.  
Validated gene targets and functional gene links of miR-212-3p is shown.  For Cytoscape 
miRNA target prediction, all targets with a target prediction score below of 95% were 
excluded.  For ClueGo gene ontology (GO) analysis, statistical significance of genes with 
enriched biological functions was taken as p<0.05 calculated by Bonferroni step-down.  
Colours and distance of nodes do not correspond to level of significance, and are for 














Figure 6.21. Gene Ontology analysis of significantly regulated miRNA targets (miR-424-5p) 
Cytoscape v3.6.1 gene prediction software was used in conjunction with ClueGo to identify experimentally validated gene targets of miRNAs 
and their cellular functions.  Validated gene targets and functional gene links of miR-424-5p is shown.  For Cytoscape miRNA target 
prediction, all targets with a target prediction score below of 95% were excluded.  For ClueGo gene ontology (GO) analysis, statistical 
significance of genes with enriched biological functions was taken as p<0.05 calculated by Bonferroni step-down.  Colours and distance of 
nodes do not correspond to level of significance, and are for display purposes only.  
 
  
Figure 6.22. Gene Ontology analysis of significantly regulated miRNA targets (miR-155-5p) 
Cytoscape v3.6.1 gene prediction software was used in conjunction with ClueGo to identify experimentally validated gene targets of miRNAs 
and their cellular functions.  Validated gene targets and functional gene links of miR-155-5p is shown.  For Cytoscape miRNA target 
prediction, all targets with a target prediction score below of 95% were excluded.  For ClueGo gene ontology (GO) analysis, statistical 
significance of genes with enriched biological functions was taken as p<0.05 calculated by Bonferroni step-down.  Colours and distance of 




Genes regulated by long term (72hr) 1,25(OH)2D3 
ABCA1 CTSB IFNG PLK3 TRIM56 
ADGRE1 CXCR6 IL10RA PLXNB2 TSPAN2 
ADGRE5 CYTH4 IL23R PLXNC1 UCP2 
AGFG2 DDX26B IL26 POU2AF1 VAV1 
AHR DENND1B IL7R PPFIBP1 VPS37B 
ALOX5 DENND6B IL9 PTPRJ YWHAQ 
APOL3 DMD INPP5D PTRF ZC3H12C 
ARHGAP5 DUSP2 IRAK2 RARRES3 ZFP36 
ARHGEF1 DUSP5 IRF2BPL RGS16 ZHX2 
ARHGEF2 ECE1 ISG20 RGS3 ZSWIM6 
BACH2 EFTUD1 ITGAM SDR42E1 
 BEND5 EHBP1L1 ITGAX SERPINA1 
 BTBD11 ELF4 JHDM1D-AS1 SERPINB1 
 BTLA EML2 JUNB SERPINB6 
 C18orf54 EPAS1 KDM1B SERPINB9 
 CA2 EPS8 KDM7A SFT2D1 
 CARD11 ETS1 LAG3 SH3TC1 
 CCR7 EVI2B LINC00649 SLC16A2 
 CD200 EVL LRP12 SLC2A3 
 CD28 FAM53B LRRC32 SLC5A3 
 CD38 FAM89B LRRC8A SNN 
 CD59 FBLN7 MALT1 SPECC1 
 CDCA7L FNBP1L MAP4K4 ST3GAL1 
 CHST3 FOSL2 NA TAGAP 
 CLMN FYCO1 NAMPT TIMP1 
 COL6A3 G0S2 NAPSA TMC6 
 CRTAP GADD45A NFKBIA TNFRSF8 
 CSF1 GIT1 NKG7 TNFSF14 
 CSRNP1 GPCPD1 NRIP1 TRAK1 




Table 6.2. Transcriptomics genes regulated by long term 1,25(OH)2D3 (72hrs) 
Unpublished data from University of Birmingham lab group showing list of genes 
significantly regulated by long term 1,25(OH)2D3 (72hrs) in CD4+ T cells stimulated with 








It is well established that CD4+ T cells play a critical role in the regulation of 
the immune system, by mediating a number of processes including pro- versus anti-
inflammatory cytokine production, downstream (B cell) antibody secretion and Treg 
maintenance.  These processes all require the complex regulation of gene 
expression at different stages of T cell development and function.  Dysregulation in 
gene expression can lead to aberrant T cell signalling which has been implicated in 
many autoimmune diseases.  The anti-inflammatory actions of 1,25(OH)2D3 are 
thought to act potently at specific stages of T cell development [191, 695].  These T 
cell effects of 1,25(OH)2D3 are primarily mediated via changes in VDR target gene 
expression.  The transcriptomic effect of 1,25(OH)2D3 on T cells is clear [696, 697].  
However, it is now clear that epigenetic mechanisms may also contribute to the 
actions of 1,25(OH)2D3, and the aim of this chapter of the thesis was to investigate 
the role of one particular epigenetic pathway, namely miRNAs.   
 
6.4.2 CD4+ T cell subtypes and cytokine production with regards to activation 
and 1,25(OH)2D3 
 
Activation of naïve CD4+ T cells has been associated with an up-regulation of 
IL-21, a pro-inflammatory cytokine which promotes T cell survival and is a 
contributing factor in the onset of autoimmune disease [698, 699].  IL-10 is also a key 
regulatory cytokine involved in the T cell immune response, and it is up-regulated in 
activated CD4+ T cells and acts to inhibit their proliferation [700-702].  In this way an 
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abundance of IL-10 maintains immune homeostasis by preventing excessive 
inflammation, hence IL-10 has an important role in T cell immunosuppression.  In the 
current study, IL-10 expression in naïve CD4+ T cells in response to activation 
showed an increase in all CD4+ T cell subtypes (Th0, Th1, Th17, Treg), although the 
expression of IL-10 was further increased upon 1,25(OH)2D3 treatment in Th17 and 
Treg cell subtypes only (Figure 6.3).  Previous studies also found increased gene 
expression and secretion of IL-10 in Treg cells after 1,25(OH)2D3 treatment [159, 
703].  IL-10 is known to inhibit further CD4+ T cell proliferation [700, 704] by selective 
inhibition of the CD28 pathway [705], suggesting that Treg cell function is likely to be 
regulated by 1,25(OH)2D3-mediated cytokine secretion.   
Similarly, in the current study CD4+ T cell activation led to an up-regulation in 
IL-21 expression.  There was also a trend for the down-regulation of IL-21 expression 
in response to 1,25(OH)2D3, however unlike observations from previous studies [651, 
706, 707] this was not statistically significant.  Due to the well-established effects of 
1,25(OH)2D3 on IL-21 secretion [159, 373], it is possible that a significant reduction in 
IL-21 expression would have been observed with larger sample numbers. However, 
this observation also highlights the limited information gained from simply studying 
established T cell marker genes as targets for 1,25(OH)2D3.  To address this, 
unpublished studies by other Birmingham group members have characterised 
genome-wide changes in mRNA expression in the same 1,25(OH)2D3-treated 
activated Th17 cell model described in this thesis.  These transcriptomic data 
indicated that IL-21 was not amongst the genes regulated by early or late 
1,25(OH)2D3 treatment in this particular T cell model.     
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The current proposed mechanism for 1,25(OH)2D3-mediated gene regulation 
in T cells is via 1,25(OH)2D3 binding to VDR and translocation of the 1,25(OH)2D3-
VDR complex to target gene VDRE and regulation of gene expression. In the current 
study, VDR expression was not significantly up-regulated in response to 
1,25(OH)2D3 treatment in Tregs.  Consistent with this, activated, but not resting T 
cells, express VDR [652], and this was confirmed in the current study by the 
approximate 50-fold higher levels of VDR mRNA observed for all different types of T 
cells following activation, with this response being unaffected by the addition of 
1,25(OH)2D3.  An induction in VDR mRNA expression is not required to obtain a 
response to 1,25(OH)2D3, since the VDR is already present.   
The VDR has been demonstrated as essential for the regulation and control of 
IL-10 secretion by 1,25(OH)2D3 [708], and in turn 1,25(OH)2D3 has been shown to 
decrease STAT3 phosphorylation in autoimmune models [709].  Interestingly, IL-10 
acts primarily through the STAT3 pathway to induce anti-inflammatory effects [710], 
however the STAT3 pathway is also used by IL-6 which promotes a pro-inflammatory 
Th17 fate.  The ability of IL-10 to mimic IL-6 signalling in the presence of excess IL-
10 receptor suggests this signaling pathway is highly modulatory, and pro- versus 
anti-inflammatory outcomes are dependent on receptor expression rather than 
cytokine availability [711].  Hence 1,25(OH)2D3 may act to reprogram T cells via 
controlling STAT3 pathway activation.  Future studies may explore the mechanism of 





6.4.3 CD4+ CD25- T cells and cytokine production with regards to activation 
and 1,25(OH)2D3 
 
Activation of naïve CD4+ T cells is associated with the increased production of 
pro-inflammatory cytokines including IFN-У, IL-17 and IL-21.  It has been shown that 
naïve CD4+ T cells activated in the presence of 1,25(OH)2D3 are able to inhibit the 
production of these cytokines as well as up-regulate the expression of intracellular 
CTLA-4 and FoxP3 [159, 373], where CTLA-4 is later translocated to the cell surface 
to mediate immunosuppression.  Flow cytometry data in the current study showed 
the up-regulated expression of intracellular CTLA-4 and FoxP3 in response to CD4+ 
T cell activation, and a further up-regulation in cell surface CTLA-4 expression in 
response to long term 1,25(OH)2D3 treatment (Figure 6.5).  This result supports the 
current mechanism of CTLA-4 mediated immunoregulation, where CTLA-4 is thought 
to exert its actions once it has translocated to the cell surface where it directly 
competes with the CD28 ligand to attenuate signalling.  1,25(OH)2D3 is thought to 
then enhance the up-regulation of CTLA-4 to mediate further immunosuppression, 
underlining the immunoregulatory potential of 1,25(OH)2D3 in the adaptive immune 
system.   
In naïve CD4+ CD25- T cells, the intracellular expression of CTLA-4 and 
FoxP3 was very low before stimulation, and the process of activation led to the up-
regulation of both markers.  Multiple other studies have found intracellular CTLA-4 to 
be constitutively expressed at low levels in resting T cells, and up-regulated in 
response to cytokine stimulation with maximal effects around 48-72 hours post-
activation [649, 712, 713].  The current study did not measure CTLA-4 expression on 
the cell surface immediately following T cell activation due to expression being 
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undetectable in many previous studies [714-716], however one study found that 
naïve CD4+ T cells exhibited up-regulated CTLA-4 surface expression after just 2 
hours post-stimulation [649], whereas previously only CTLA-4 mRNA was found so 
soon after activation [717].  Perhaps the presence of CTLA-4 protein on the cell 
surface so early suggests a role for CTLA-4 in rapidly preventing inappropriate 
activation in the first instance, with later CTLA-4 expression helping to maintain this 
response [718].      
Activation of CD4+ T cells has also been associated with the up-regulation of 
FoxP3 and CD25, both considered Treg cell markers [719].  In the current study, a 
proportion of activated CD4+ T cells would have been expected to express FoxP3 
albeit at very low levels.  The reason that FoxP3 expression was not observed as 
highly as expected following T cell stimulation may be due in part to the strength of 
the stimulation factors.  The stimulation may not have been sufficiently strong 
through the CD28 receptor and therefore did not produce a sufficient amount of IL-2.  
IL-2 in the thymus promotes naïve T cell to Treg differentiation to prevent 
autoimmune response; in this way IL-2 enhances FoxP3 expression.  Additionally, 
using anti-CD3 and anti-CD28 beads for stimulation may have been able to produce 
much stronger T cell stimulatory signals compared to anti-CD3/anti-CD28 plate-
bound antibodies used in the current study, leading to more FoxP3 expression.   
Alternatively, culturing naïve T cells in a higher dose of IL-2 (200 IU/mL) would have 
produced more FoxP3 induction, and in theory could induce FoxP3 expression to 





6.4.4 CD4+ CD25- T cell stimulation with Th17 cocktail is able to overcome 
inflammatory phenotype 
 
The rationale for stimulating naïve CD4+ T cells with the Th17 inflammatory 
cytokines was to gain a further understanding of cytokine production and gene 
regulation during inflammation versus regulation.  In the current study, the naïve 
CD4+ CD25- T cells were stimulated under pro-inflammatory conditions with Th17 
cytokine cocktail consisting of IL-2, IL-1β, TGF-β, IL-6 and IL-23, to promote 
differentiation into a pro-inflammatory Th17 fate.  Interestingly, it was found that 
under these inflammatory conditions the CD4+ regulatory phenotype was able to 
overcome the inflammatory Th17 phenotype, as shown by the strong induction of 
CTLA-4 expression and mild FoxP3 up-regulation, which are both associated with an 
immunosuppressive Treg phenotype (Figure 6.5).  The induction of Treg phenotypes 
under pro-inflammatory conditions have also been reported in previous studies; 
CD4+ T cells stimulated with Th17 cocktail containing IL-2 in the presence of 
1,25(OH)2D3 produced the highest levels of CTLA-4 and FoxP3 [651], as well as up-
regulated IL-10 and suppression of inflammatory cytokines IL-17 and IFN-γ, 
underlining the potential for 1,25(OH)2D3 to suppress inflammation.  Similarly, in the 
current study the addition of 1,25(OH)2D3 following T cell activation further enhanced 
the regulatory phenotype as shown by increased CTLA-4 and FoxP3 expression 
compared to activated vehicle T cells (Figure 6.5C).  Results from the current study 
suggest that the Treg regulatory phenotype was ‘strong’ enough to overcome the 
Th17 polarising conditions.  Since the dysregulation of Th17 lymphocytes are 
strongly implicated in the onset and pathogenesis of autoimmune disease like 
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rheumatoid arthritis [600, 720], this brings potential for 1,25(OH)2D3-enhanced, Treg-
mediated immunosuppression in health and disease.     
 
6.4.5 1,25(OH)2D3 exerts anti-inflammatory effects on Th17 cells over time 
 
Previous studies found that 1,25(OH)2D3 in T cell culture acts to regulate 
CD4+ differentiation and promote a Treg phenotype, as well as induce CTLA-4 
expression [721, 722].  In the current study, the expression of CTLA-4 in activated T 
cells cultured under Th17 inflammatory conditions was significantly up-regulated in 
the presence of 1,25(OH)2D3 compared to untreated T cells (Figure 6.7A).  This 
difference was observed throughout the time course of 1,25(OH)2D3 treatment, and 
was most apparent at 72 hours post-1,25(OH)2D3.   
Also in the current study, IFN-γ expression was most significantly down-
regulated at the 72 hour post-1,25(OH)2D3 time point in T cells (Figure 6.7B).  This 
observation has been well established in previous studies showing that 1,25(OH)2D3 
down-regulates the production of IFN-γ in activated T cells [723-725], although no 
studies to date have looked at the 1,25(OH)2D3-mediated regulation of IFN-γ over 
time.  In the current study, the delayed down-regulation of IFN-γ after 1,25(OH)2D3 
treatment may be explained by the role of IFN-γ in mediating an early antimicrobial 
response.  Following an immune challenge to T cells, the presence of 1,25(OH)2D3 
induces the release of IFN-γ, which up-regulates the production of antimicrobial 
cathelicidin to overcome pathogens [726].  This process occurs rapidly and only after 
the removal of pathogens does 1,25(OH)2D3 mediate the down-regulation of INF-γ to 
prevent excess inflammatory responses.  Another explanation for the delayed 
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response of IFN-γ to 1,25(OH)2D3 may be to provide the T cells with ample time to 
establish VDR responses.  Activated T cells express the CYP27B1 enzyme and are 
able to convert 25(OH)D3 in the local environment to 1,25(OH)2D3 [721], hence they 
are also responsive to extracellular 1,25(OH)2D3 responses via binding to the VDR.  
The current mechanism for 1,25(OH)2D3-mediated INF-γ down-regulation involves 
the binding of 1,25(OH)2D3 to VDR and RXR to inhibit production of the Th1 
polarising cytokine IL-12 [727].  Normally IL-12 activates the STAT4 signaling 
pathway for IFN-γ production.  In this way VDR acts as a transcriptional modulator of 
the IFN-γ gene [728], with 1,25(OH)2D3 able to control its expression and mediate 
inflammatory responses.   These findings confirm the immunosuppressive and anti-
inflammatory role of 1,25(OH)2D3 in Th17 cells over time.      
 
6.4.6 CTLA-4 and IFN-y expression is up-regulated by T cell activation 
 
The constitutive expression of the immune suppressor protein CTLA-4 is 
required for the normal function of Tregs [650].  Following T cell activation, the 
majority of CTLA-4 molecules are transported to the cell surface via AP-2 mediated 
clathrin-coated pits and is thought to act at the immunological synapse for TCR 
engagement [729, 730].  In the current study, both CTLA-4 and IFN-γ mRNA 
expression was up-regulated following T cell activation (Figure 6.10). Similarly, 
previous studies found that stimulation of naïve CD4+ T cells led to the up-regulation 
of inflammatory cytokines such as IFN-γ [731].  Previous studies also found that the 
expression of CTLA-4 mRNA was detectable in naïve T cells following activation after 
just 1 hour [717], however surface CTLA-4 protein expression was not significantly 
283 
 
detectable until 48-72hrs post-activation [732], possibly to provide ample time for 
CTLA-4 localization and TCR engagement.  This is necessary to prevent NF-AT 
translocation to the nucleus in order to inhibit transcription of the IL-2 gene [733].  In 
this way CTLA-4 is thought to exert its immunosuppressive effects upon the immune 
response.  Importantly, the presence of 1,25(OH)2D3 is able to enhance CTLA-4 
expression even under Th17 inflammatory conditions [373] (see Figure 6.5), 
suggesting a role for 1,25(OH)2D3-mediated regulation of anti-inflammatory gene 
expression in T cells.  This effect was most significant after 72 hours of 1,25(OH)2D3.  
However, one limitation in the current study is the interpretation of CTLA-4 
expression by flow cytometry on a whole population level. Single cell analysis is 
thought be a more sensitive detection method, particularly during early time points 
when surface expression of CTLA-4 is very low.  Since only a small percentage of 
newly activated T cells express surface CTLA-4 expression [734], perhaps these are 
the T cells that form the most potent immune responses and are capable of 
modulation by 1,25(OH)2D3.  Future studies could utilise analysis of CTLA-4 
expression on newly activated T cells to study individual cell responses to activation, 
in order to identify such cells.  Further improvements to the current study could 
involve quantifying the expression of AP-2 to study its relationship between 
intracellular and cell surface CTLA-4 expression and validating its role in CTLA-4 





6.4.7 Candidate miRNAs miR-155 and miR-627 expression is down-regulated 
by 1,25(OH)2D3  
 
Intrinsic changes to gene expression are likely to be mediated by differential 
miRNA expression, as different miRNA expression profiles have been associated 
with different stages of CD4+ T cell development.  Thus, any dysregulation of 
miRNAs that attenuate expression of target genes involved in T cell differentiation, 
proliferation and survival is likely to impact upon the normal function of these T cells 
at different time points.  Taken together with changes to gene expression in response 
to T cell activation and 1,25(OH)2D3 as shown earlier in this chapter, the aim of 
further studies in Chapter 6 was to characterise the effects of 1,25(OH)2D3 on T cell 
miRNA expression at different time points. 
Candidate miRNA analyses of 1,25(OH)2D3 effects on T cell miRNA 
expression showed that miR-155 and miR-627 were significantly down-regulated 
within 2 hours following 1,25(OH)2D3 treatment (Figure 6.9).  This down-regulation 
was not significant at later time points, and none of the other candidate miRNAs 
showed significant changes in response to 1,25(OH)2D3 over time.  Previous studies 
have implicated the role for miRNA-mediated gene regulation in controlling immune 
responses in T cells. Some studies have also suggested a role for 1,25(OH)2D3 in 
further mediating epigenetic changes via the regulation of miRNA expression in T 
cells [98, 735, 736], sometimes in a negative feedback fashion such as the 
relationship between 1,25(OH)2D3 and miR-155 [240].  These studies have shown 
that miRNAs can be up-regulated or down-regulated in response to 1,25(OH)2D3, 
reflecting the complex regulatory roles of miRNAs in immune cells.  In the present 
study we also expected to see an up-regulation of miR-627 expression following 
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1,25(OH)2D3 in T cells, due to the proposed role of miR-627 to target JMJD1A, 
whose down-regulation leads to suppressed cell proliferation factors [737].  Indeed, 
the authors of that study found that 1,25(OH)2D3 down-regulated miR-627 
expression [737, 738] whereas the present study did not find this.  However, studies 
on miR-627 are still relatively limited and its role is not fully understood, with 
contradicting studies reporting elevated levels of miR-627 in various disease 
compared to healthy controls, from cancer [739] to Parkinson’s disease [740].  Thus 
it is likely that miR-627 targets other genes in addition to JMJD1A, and further studies 
are needed to elucidate the role of miR-627 in immune regulation and identify any 
other important gene targets.  Perhaps future studies involving larger sample 
numbers will observe significant changes to this miRNA in response to 1,25(OH)2D3.   
 
6.4.8 MiR-212-3p and miR-16 is up-regulated by 1,25(OH)2D3, and may be 
therapeutic targets in disease 
 
Further unbiased array analysis of T cell miRNA expression identified more 
miRNAs were up-regulated in response to long term (72hr) 1,25(OH)2D3 compared 
to short term (24hr) 1,25(OH)2D3 treatment (Figure 6.16; Figure 6.14), with miR-
212-3p being the only miRNA up-regulated by both long and short term 1,25(OH)2D3.  
Interestingly, miR-212-3p which was significantly up-regulated by 1,25(OH)2D3 was 
also significantly up-regulated by T cell activation (p=0.002).  There are no studies to 
date on the regulation of this miRNA with respect to T cells and 1,25(OH)2D3, 
however low miR-212-3p expression has been linked to increased risks of colorectal 
cancer [741] and rheumatoid arthritis [742], both diseases which are linked to excess 
pro-inflammatory cytokine release. The role of miR-212-3p in disease may be an 
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important area of research for future studies. Of the up-regulated miRNAs following 
short term 1,25(OH)2D3 (24hrs), 6 of these miRNAs were also up-regulated in 
response to cytokine stimulation. These results suggest that select miRNAs are very 
responsive to modulation during CD4+ T cell activation, and 1,25(OH)2D3 appeared 
to enhance this up-regulation. Of these miRNAs significantly up-regulated, it is likely 
that some may also be involved in the inflammatory process. 
MiR-16 up-regulation following short term 1,25(OH)2D3 was also observed in 
the present study.  Previous studies have detailed the link between suppressed miR-
16 expression and B cell lymphocytic leukemia [743, 744].  The importance of this 
miRNA in immune health is further validated by its role in inducing apoptosis by 
targeting BCL2 [745, 746], to promote malignant B cell death.  Thus it is possible that 
sufficient miR-16 expression also plays an important role in mediating T cell 
apoptosis, and the role of 1,25(OH)2D3 in up-regulating its expression reinforces the 
immunomodulatory role of 1,25(OH)2D3. 
Another miRNA of interest is miR-146a.  No published studies to date have 
found down-regulated miR-146a expression after 1,25(OH)2D3 treatment specifically 
in CD4+ T cells, which the current study aimed to address. MiR-146a is an 
inflammation-associated miRNA consistently up-regulated following immune 
challenge [261, 747-749] and down-regulated following 1,25(OH)2D3 treatment in 
disease states [238, 750].  Despite these promising studies, the current study did not 
observe a significant down-regulation of miR-146a in CD4+ T cells after 1,25(OH)2D3 




6.4.9 MiR-155 is induced by T cell activation but not by 1,25(OH)2D3 
 
As expected, activation of naïve CD4+ T cells induced the expression of miR-
155 when profiled by both candidate qPCR and array qPCR (Figure 6.11; Figure 
6.12), due to the established role of miR-155 in systemic inflammation [751-753].  
Surprisingly, miR-155 expression was not significantly regulated following long term 
(72hr) or short term (24hr) 1,25(OH)2D3 treatment.  The work on DC described in 
Chapter 5 along with previous literature [240, 754] found that in DC, miR-155 was 
down-regulated after 1,25(OH)2D3, thus the same may be expected of miR-155 in T 
cells.  There may be several explanations as to why the current study did not find 
miR-155 down-regulation with long term or short term 1,25(OH)2D3 treatment.  Whilst 
down-regulation of miR-155 expression after 1,25(OH)2D3 was observed in 
candidate miRNA analysis (Figure 6.11E), that was only at a very early time point of 
2 hours after 1,25(OH)2D3 treatment.  Therefore, perhaps 1,25(OH)2D3-mediated 
regulation of miR-155 expression occurs very early in T cells, thus changes were not 
detected in the ‘early’ 24 hour array time point.  The early regulation of miR-155 
expression could be important for its mechanism of action; miR-155 normally targets 
SOCS1 to mediate inflammation [240].  Perhaps rapid 1,25(OH)2D3-induced down-
regulation of miR-155 is needed to induce effects on SOCS1 which in turn blocks the 
JAK/STAT signalling pathway of pro-inflammatory cytokines, leading to immediate 
anti-inflammatory responses.  Secondly, it is plausible that 1,25(OH)2D3 may not 
affect miR-155 expression depending on the cytokine milieu present during T cell 
differentiation.  This theory has been suggested by a recent study which found 
1,25(OH)2D3 was able to suppress Th17 subtype differentiation with no effects on 
miRNA expression including miR-155 [755].   
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6.4.10  Gene ontology analysis reveals miRNAs with roles in immune regulation 
 
Bioinformatics coupled with gene ontology analysis of miRNA gene targets 
and functions in T cells revealed the majority of significantly regulated miRNAs 
targeted genes with roles in cell proliferation and metabolism.  MiR-155 targets many 
genes with new and established roles in immune regulation, such as SOCS1, BCL6 
and PIK3R1 to name a few (see Figure 6.22).  Some of these genes carry out more 
than one function, which makes it very difficult to identify a specific miRNA that 
targets each gene.  These bioinformatics tools are helpful to identify miRNA gene 
targets and biological functions of these genes, as a first step for any future studies 
delineating the mechanistic actions of these miRNAs.   
Previous unpublished transcriptomic data from other Birmingham group 
members showed genes significantly regulated by long term (72 hour) and short term 
(4 hour) 1,25(OH)2D3 treatment in CD4+ T cells polarised with the same T17 
cocktail.  There were 130 genes regulated by long term 1,25(OH)2D3, with CTLA-4 
amongst them. We compared these genes with those targeted by the miRNAs 
regulated by 1,25(OH)2D3 and found no common genes.  The list of unpublished 
genes regulated by long term 1,25(OH)2D3 is shown in Table 6.2.  We attempted to 
relate some of the anticipated transcriptome changes that may arise as a result of 
reported changes in miRNA expression with corresponding transcriptome changes 
within the RNAseq dataset.  However limitations that complicate this potential 
approach is largely due to the broad array of genes targeted by each miRNA.  As a 







The studies reported in this chapter have firstly confirmed the CTLA-4 
mediated immunoregulation in CD4+ T cells, demonstrated by the up-regulated 
expression of intracellular CTLA-4 and FoxP3 in response to T cell activation.  
1,25(OH)2D3 further enhanced the up-regulation of CTLA-4, underlining the 
immunoregulatory potential of 1,25(OH)2D3 in the adaptive immune system.  Naïve 
CD4+ CD25- T cells stimulated under Th17 polarising conditions were able to 
overcome the inflammatory Th17 phenotype in the presence of 1,25(OH)2D3, as 
shown by the strong induction of CTLA-4 in these cells.  This suggested that the Treg 
regulatory phenotype was strong enough to exert its immunosuppressive effects on 
these T cells even under pro-inflammatory conditions.  The expression of CTLA-4 
was further up-regulated after 72 hours incubation with 1,25(OH)2D3 compared to 
untreated T cells, with a simultaneous down-regulation of IFN-γ expression.  The 
above results demonstrate that 1,25(OH)2D3 is able to exert immunosuppressive 
actions upon CD4+ T cells polarised under Th17 conditions.   
It was proposed that miRNAs could be mediating these changes due to their 
established regulatory roles in literature.  Results showed that miR-155 was up-
regulated following T cell activation but was not significantly down-regulated following 
1,25(OH)2D3 treatment, most likely due to the rapid actions of miR-155 that occurred 
too early to detect in the arrays.  Interestingly, long term 1,25(OH)2D3, short term 
1,25(OH)2D3 and T cell activation all up-regulated miR-212-3p expression.  When 
interpreted with gene ontology analysis identifying gene targets of miR-212-3p with 
roles in cell proliferation and metabolism, it is likely that this miRNA has important 
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regulatory roles in and beyond the immune system.  Similarly, targets of miR-155 
included genes with new and established roles in the immune response.  Taken 
together, miR-212-3p and miR-155 provide a useful starting point to identify other 
miRNAs with key regulatory roles in the adaptive immune system.         
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Vitamin D deficiency has been implicated in a wide range of diseases from 
cancer [74, 756] to autoimmune conditions [96, 757], although whether vitamin D 
deficiency is causal or simply associated with these diseases is still unclear.  What is 
clear is that vitamin D exerts potent anti-inflammatory actions upon cells including 
those in the innate and adaptive immune system such as dendritic cells (DC) and T 
cells [758].  This is thought to occur via epigenetic regulation by modulating the 
expression of miRNAs in these cells, leading to altered gene expression and 
downstream effects.  Vitamin D has thus been proposed to be a modulator of miRNA 
expression.  This thesis aimed to address the relationship between vitamin D and 
miRNA expression in cells of the human innate and adaptive immune system, from 
both a healthy and inflammatory disease perspective.   
The principle aims of this thesis were to firstly investigate the relationship 
between vitamin D metabolites and miRNAs with respect to RA disease activity, as 
discussed in Chapter 4.  Current analyses of vitamin D status relies on measuring 
inactive serum 25(O)D3 levels, thus another aim of this study was to identify if other 
vitamin D metabolites including 1,25(OH)₂D3 could be used as a better indicator of 
RA disease status.  Interestingly, the actual levels of 1,25(OH)2D3 generated locally 
within the SF appeared to be very low or undetectable.  This suggests that any 
1,25(OH)2D3 generated within the synovial microenvironment may be restricted to 
the cells involved in immunoregulation within this tissue.  Additionally, the current 
study showed up-regulated expression of the inflammation-associated miRNAs miR-
146a and miR-155 in RA SF compared to serum, however since there was a lack of 
correlation between miRNA expression and RA disease markers in serum or SF, it is 
unlikely that these miRNAs are actively mediating gene silencing to cause 
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inflammation within the local environment; it is possible they are maintained as a 
reserve of miRNAs not associated with their target gene [478].  Hence the role of 
miR-146a and miR-155 in the pathogenesis of RA remains unclear, although future 
work on the contribution of miRNAs to various aspects of RA pathogenesis is 
required and holds great potential.  There is scope for future studies to include the 
metabolite analysis of healthy control SF, in order to better establish whether the low 
1,25(OH)2D3 observed in SF compared to serum is a cause or simply a result of 
disease aetiology.  We did have access to limited SF from a healthy cohort of 
pregnant women, however due to the complex hormonal changes that occur in 
pregnancy we decided that this may interfere with 1,25(OH)2D3 readings.  Hence any 
future recruitment of healthy controls should contain a mix of genders and ages.  
Overall, the role of vitamin D metabolites, especially active 1,25(OH)2D3, in the 
synovium of RA patients is still far from clear and the link between 1,25(OH)2D3 and 
miRNAs was further investigated in the rest of the thesis.   
Studies in Chapter 5 and Chapter 6 investigated the role of miRNAs as 
mediators of the immunomodulatory effects of 1,25(OH)₂D3 on the innate and 
adaptive immune system, respectively.  The work undertaken in these chapters of 
the thesis have provided detailed insights into the role of 1,25(OH)₂D3 on miRNA 
expression in monocyte-derived dendritic cells (DC) of the innate immune system 
and CD4+ T cells of the adaptive immune system, by profiling the expression of 372 
miRNAs most closely related to inflammation and the regulation of their expression 
with regard to vitamin D treatment.  The expression of many genes is altered during 
these changes, and it remains likely that these changes are facilitated by the 
differential expression of a host of miRNAs.    
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In DC, analysis of these data identified 8 miRNAs that were significantly down-
regulated by long term (72hr) vitamin D treatment, and 14 miRNAs down-regulated 
by short term (24hr) vitamin D treatment.  DC maturation by LPS saw the up-
regulation of miR-155-5p and down-regulation of miR-221-5p.  The mechanism of 
miRNA regulation with regard to DC differentiation and maturation remains unclear, 
but there is strong evidence to suggest that select miRNAs including miR-155 play 
key regulatory roles in the homeostasis and normal function of the innate immune 
system. Overall the array profiling data showed a global down-regulation of miRNAs 
following vitamin D treatment.  Down-regulation of these genes were not rescued by 
short term or long term 1,25(OH)2D3, suggesting the miRNA biogenesis machinery 
was stable and any immunomodulatory effects of 1,25(OH)2D3 are likely to act on 
mature miRNAs only.  The immunomodulatory effects of 1,25(OH)2D3 in DC bring 
about different phenotypical and functional changes depending on the stage of DC 
development, length of treatment time and the cytokine milieu.  Future studies may 
involve quantifying expression of pre-miRNAs and pri-miRNAs in DC, in conjunction 
with miRNA biogenesis gene expression analysis and 1,25(OH)2D3 treatment, to 
elucidate the mechanism of 1,25(OH)2D3 on miRNA regulation.  In addition it may be 
prudent to validate the gene targets of any miRNAs that were significantly regulated 
by 1,25(OH)2D3.  This can be achieved by miRNA over-expression or knock-down 
studies in the DC phenotypes, which will induce or silence target gene expression.  
Using further qPCR or western blotting to validate gene and protein expression will 
allow us to identify any genes specifically targeted by these miRNAs, and the effect 
that 1,25(OH)2D3 may have in modulating their expression.   
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In T cells, studies have firstly confirmed CTLA-4 mediated immunoregulation 
in CD4+ T cells, which was further enhanced by 1,25(OH)2D3, demonstrating the 
immunosuppressive role of 1,25(OH)2D3 in the adaptive immune system.  
Furthermore, naïve T cells stimulated under Th17 polarising conditions were able to 
overcome the pro-inflammatory Th17 phenotype, suggesting that the Treg regulatory 
phenotype was strong enough to exert its immunosuppressive effects despite 
inflammatory conditions.  Similar to DC, it was proposed that miRNAs could be 
mediating these changes.  Results showed that miR-155 was up-regulated following 
T cell activation but was not significantly down-regulated following 1,25(OH)2D3 
treatment, most likely due to the rapid actions of miR-155 that occurred too early for 
detection.  Interestingly, long term 1,25(OH)2D3, short term 1,25(OH)2D3 and T cell 
activation all up-regulated miR-212-3p expression.  When interpreted with gene 
ontology analyses identifying gene targets of miR-212-3p with roles in cell 
proliferation and metabolism, it is likely that this miRNA has important regulatory 
roles in and beyond the immune system.  Similarly, targets of miR-155 included 
genes with new and established roles in the immune response.  Importantly, T cells 
treated with vitamin D did not display global down-regulation of miRNAs as 
previously observed with DC, suggesting this miRNA down-regulation was not likely 
due to mechanisms such as decreased miRNA synthesis and was likely to be 
mediated by 1,25(OH)2D3.  Taken together, miR-212-3p and miR-155 provide a 
useful starting point to identify other miRNAs with key regulatory roles in the adaptive 
immune system.  Similar to Chapter 5, future studies should include further validation 
of miRNA gene targets, and how 1,25(OH)2D3 may modulate their expression.            
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In summary, the work in this thesis has demonstrated that vitamin D has a 
broad range of genetic and epigenetic effects on cells of the immune system.  In RA, 
other metabolites aside from 25(OH)D may be better markers of disease activity.  In 
healthy immune cells, miRNAs appear as likely targets for the immunomodulatory 
actions of 1,25(OH)2D3, with effects on both the innate and adaptive immune system.  
Bioinformatics tools have identified predicted targets of significantly modulated 
miRNAs, some of which have roles in immune function.  Despite the current data 
depicting an association between 1,25(OH)2D3 exposure and changes in miRNA 
expression associated with immune-function related gene targets, further studies are 
needed to provide definitive proof that the immunomodulatory effects of 1,25(OH)2D3 
are truly mediated through these miRNAs.  To do so would require additional 
experimental studies, for example using miRNA over-expression to silence the gene 
of interest to study the effect this has on immune cell function, phenotype and 
response to 1,25(OH)2D3.       
Nonetheless, the focus of this thesis was to provide a theoretical overview of 
the complex roles of miRNAs in immune modulation, and how 1,25(OH)2D3 further 
modulates their expression.  Data arising from this thesis has provided strong 
indications that the immunomodulatory effects of 1,25(OH)2D3 are mediated by 
miRNAs, as shown by significant miRNA expression changes in DC of the innate 
immune system and T cells of the adaptive immune system in response to 
1,25(OH)2D3.  Future studies may also focus on elucidating the mechanism of 
1,25(OH)2D3-mediated miRNA modulation in other immune cells, to further 
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Figure 4.20. Relationship between serum vitamin D metabolites and patient sex 
Serum vitamin D metabolites 25(OH)D3, 3-epi-25(OH)D3, 25(OH)D2, 24,25(OH)₂D3 (all ng/mL) and 1,25(OH)₂D3 (pg/mL) concentrations 
compared to patient sex.  Unpaired t-test for non-parametric data was performed between male and females from the same cohort.  
Unpaired non-parametric Kolmogorov-Smirnov test was performed between sex-matched HC and RA patients.  Significance taken as 
*p<0.05.      
  

















































































































Figure 4.21. Relationship between serum and SF vitamin D metabolites and patient 
age 
Serum and SF vitamin D metabolites 25(OH)D3, 3-epi-25(OH)D3, 25(OH)D2, 
24,25(OH)₂D3 (all ng/mL) and 1,25(OH)₂D3 (pg/mL) concentrations correlated to patient 
age. Linear regression was performed by best-fit values ± SD. Coefficient of 
determination (r
2




Figure 4.22. Relationship between serum and SF vitamin D metabolites and RA 
disease duration 
Serum and SF vitamin D metabolites 25(OH)D3, 3-epi-25(OH)D3, 25(OH)D2, 
24,25(OH)₂D3 (all ng/mL) and 1,25(OH)₂D3 (pg/mL) concentrations correlated to RA 
patient disease duration (months). Linear regression was performed by best-fit values ± 
SD. Coefficient of determination (r
2
) values are shown for correlations that were 
statistically significant, *p<0.05.  
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Figure 4.23. RA disease activity markers in male vs female RA 
Comparisons between RA activity markers CRP, ESR, SJC and TJC in male vs 
female RA patients.  Kolmogorov-Smirnov unpaired test for non-parametric data was 
performed between male and females. Significance taken as *p<0.05.      
  




Figure 4.24.  Vitamin D metabolite correlations in RA and HC 
Correlation between 25(OH)D3 and other vitamin D metabolites in serum and 
synovial fluid (SF) from persistent rheumatoid arthritis (RA) patients.  25(OH)D3 vs 
A) 3-epi-25(OH)D3; B) 25(OH)D2; C) 24,25(OH)2D3 (all ng/mL); D) 1,25(OH)2D3 
(pg/mL); E) linear correlation between 24,25(OH)2D3  and 1,25(OH)2D3  in RA; F) 
linear correlation between 24,25(OH)2D3  and 1,25(OH)2D3 in HC .  Significance is 
taken as *p<0.05. Linear regression graphs performed by best-fit values ± SD. P 
and r2 significance values shown where significance is determined.     
  




Figure 4.25. Total vs free vs bioavailable 25(OH)D3 in RA and ReA serum and SF 
Calculations of free (not bound to DBP or albumin) and bioavailable (not bound to DBP) 25(OH)D3 based on total 25(O)D3 concentrations, 
DBP and albumin, in RA and ReA serum and SF.  DBP and albumin expressed as uM; total, free and bioavailable 25(OH)D3 expressed as 
nM.  RA=blue (n=20); ReA=green (n=7)   
Patient DBP (uM) Albumin (uM) Total 25(OH)D3 (nM) free 25(OH)D3 (nM) Bioavailable 25(OH)D3 (nM) Total 25(OH)D3 (nM) free 25(OH)D3 (nM) Bioavailable 25(OH)D3 (nM)
M 0.96 249.04 37.59 0.02 2.64 32.46 0.04 6.07
F 0.75 301.50 51.28 0.02 4.13 37.29 0.05 9.85
M 0.13 202.61 32.07 0.02 3.68 10.89 0.05 6.39
F 0.66 372.85 47.50 0.03 3.90 40.17 0.06 13.50
F 0.11 192.39 21.16 0.01 2.80 6.06 0.03 3.63
F 0.54 207.73 74.16 0.03 6.26 45.38 0.09 11.80
F 0.83 197.50 59.96 0.08 26.10 39.29 0.06 6.94
M 0.49 192.39 23.92 0.02 2.81 18.34 0.04 4.71
F 0.75 254.25 10.83 0.01 1.43 7.29 0.01 1.66
F 1.03 275.16 30.76 0.02 3.42 32.81 0.04 6.26
F 0.40 228.32 64.26 0.05 13.37 42.25 0.11 14.50
F 1.38 182.21 93.74 0.08 15.94 54.14 0.05 5.73
M 0.43 254.25 20.66 0.02 2.56 23.79 0.05 8.20
M n/a n/a n/a n/a n/a n/a n/a n/a
F 0.72 187.30 55.35 0.06 8.91 17.33 0.03 3.22
F 0.44 202.61 20.72 0.01 2.83 10.13 0.02 2.91
F 0.63 207.73 85.97 0.04 12.79 40.00 0.07 9.24
M 0.91 192.39 41.73 0.02 3.25 33.86 0.05 5.38
F 1.59 207.73 80.23 0.03 5.74 63.51 0.05 6.66
F 0.30 192.39 58.71 0.04 6.44 31.81 0.10 11.70
M 0.92 360.29 75.48 0.07 11.81 56.98 0.07 14.90
M 0.90 269.91 29.34 0.02 5.00 15.59 0.02 3.23
M 0.26 238.66 18.75 0.01 1.96 2.29 0.01 1.01
M 0.74 249.04 13.33 0.01 1.80 10.98 0.02 2.49
M 1.33 243.85 24.64 0.02 3.31 17.16 0.02 2.37
M 0.87 233.48 86.91 0.06 23.92 64.02 0.09 12.60




Figure 4.26A. Free 25(OH)D3 and RA disease activity markers  
Correlations between free 25(OH)D3 and RA disease activity markers CRP, ESR, SJC and TJC.  Linear regression was performed by best-
fit values ± SD. Coefficient of determination (r
2
) values are only shown for correlations that were statistically significant, *p<0.05.  





Figure 4.26B. Bioavailable 25(OH)D3 and RA disease activity markers  
Correlations between bioavailable 25(OH)D3 with RA disease activity markers CRP, ESR, SJC and TJC.  Linear regression was performed 
by best-fit values ± SD. Coefficient of determination (r
2
) values are only shown for correlations that were statistically significant, *p<0.05.  
   
 
